Back grey_arrow_rt.gif
 
Recent articles on HIV. Check out articles on HIV related Bone Issues and HIV and Aging.
 
null.gif
 
 
  1. IAC: Vienna Intl AIDS Conference Thoughts from Jules Levin, NATAP - (07/23/10)
     
  2. Is It Safe to Discontinue Primary Pneumocystis jiroveci Pneumonia Prophylaxis in Patients with Virologically Suppressed HIV Infection and a CD4 Cell Count <200 Cells/µL? - (08/30/10)
     
  3. High Rates of Asymptomatic Neurocognitive Impairment in Vertically Acquired HIV-1-Infected Adolescents Surviving to Adulthood - (08/29/10)
     
  4. High prevalence of reduced bone mineral density in primary HIV-1-infected men - (08/29/10)
     
  5. CD4 Predicts acute renal failure: Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure - (08/29/10)
     
  6. Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses - (08/29/10)
     
  7. Opioid Use & Bone Loss: Prospective study of bone mineral density changes in aging men with or at risk for HIV infection - (08/29/10)
     
  8. IAC: Webcast Complications Plenary at IAC Vienna: The Double-Edged Sword: Long-Term Complications of ART and HIV - (08/29/10)
     
  9. Neurologic disease burden in treated HIV/AIDS predicts survival A population-based study - (08/26/10)
     
  10. Identification of a gp41 Core-Binding Molecule with Homologous Sequence of Human TNNI3K-Like Protein as a Novel Human Immunodeficiency Virus Type 1 Entry Inhibitor - published pdf attached - (08/25/10)
     
  11. Potential HIV Drug Keeps Virus out of Cells: "PIE12-trimer is an entry-inhibitor, has the potential to work as a microbicide to prevent people from contracting HIV and as a treatment for HIV infected people." published study pdf attached - (08/25/10)
     
  12. Development of National and Multiagency HIV Care Quality Measures - (08/19/10)
     
  13. Quality of Care for Patients Infected with HIV - EDITORIAL COMMENTARY - (08/19/10)
     
  14. IAC: IAC Summary on New Drugs and New Combinations - How will They Change What We Do? - Written by Joe Eron, Univ of North Carolina - (08/16/10)
     
  15. IAC: A Pilot Study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-Naïve HIV-1 Infected Subjects: 48 Week Results - (08/15/10)
     
  16. IAC: Transmission of Integrase Strand-Transfer Inhibitor Multi-drug Resistant HIV: Case Report and Natural History of Response to Raltegravir-containing Antiretroviral Therapy - (08/15/10)
     
  17. IAC: Abacavir/Lamivudine with Fosamprenavir/Ritonavir or Efavirenz in Underrepresented, Antiretroviral-Naïve, HIV-Infected Subjects (SUPPORT): Tolerability, Safety, and Efficacy after 24 Weeks - (08/15/10)
     
  18. HIV and Low CD4 Increases Risk for Heart Disease - (08/13/10)
     
  19. After CAPRISA 004: time to re-evaluate the HIV lexicon - 'oral PrEP has greater likelihood for success' - (08/13/10)
     
  20. Cardiovascular effects of marine omega-3 fatty acids - Review - publication pdf attached - (08/13/10)
     
  21. Cognitive Decline Biomarkers-HIV Studies Needed !!!! - (08/13/10)
     
  22. Plasma β-Amyloid and Cognitive Decline - publication pdf attached - (08/12/10)
     
  23. Raltegravir Intensification Did Not Reduce Residual Viremia PLoS Medicine published - (08/11/10)
     
  24. IAC: SWITCH-EE Study (Swiss-Cohort): A Randomized Cross-over Study to Compare Etravirine and Efavirenz treatment - (08/10/10)
     
  25. IAC: The SENSE Trial: Etravirine (ETR) shows fewer Neuropsychiatric Adverse Events than Efavirenz (EFV) in Treatment-naïve HIV-1 Infected Patients - (08/10/10)
     
  26. Persistent Microbial Translocation and Immune Activation in HIV-1-Infected South Africans Receiving Combination Antiretroviral Therapy - (08/10/10)
     
  27. Can HIV be cured with stem cell therapy? commentary - (08/10/10)
     
  28. IAC: Efficacy of NGX-4010 (QUTENZA), an 8% capsaicin patch, in patients with HIV-associated distal sensory polyneuropathy: results of integrated analyses - (08/10/10)
     
  29. IAC: The SENSE trial: etravirine (ETR) QD shows fewer neuropsychiatric adverse events than efavirenz (EFV) in treatment-naïve HIV-1 infected patients - (08/10/10)
     
  30. IAC: Abacavir/lamivudine (ABC/3TC) with fosamprenavir/ritonavir (FPV/r) or efavirenz (EFV) in underrepresented, antiretroviral (ARV) naïve, HIV-infected subjects (SUPPORT): tolerability, safety, and efficacy after 24 weeks - (08/10/10)
     
  31. IAC: A pilot study of abacavir/lamivudine (ABC/3TC) and raltegravir (RAL) in antiretroviral naive HIV-1 infected subjects: 48-week results - (08/10/10)
     
  32. IAC: HBV related complications in HIV positive patients during HAART therapy - LAM resistance and high serum HBV-DNA & advancd liver disease - (08/10/10)
     
  33. IAC: Vienna Declaration: 'decriminalize illicit drug use as an HIV prevention measure' - (08/10/10)
     
  34. High prevalence of reduced bone mineral density in primary HIV-1-infected men - publication pdf attached - (08/08/10)
     
  35. C-Reactive Protein Levels Increase During HIV-1 Disease Progression in Rakai, Uganda, Despite the Absence of Microbial Translocation - publication pdf attached - (08/07/10)
     
  36. HPV-associated head and neck cancer: a virus-related cancer epidemic Review - pdf attached - (08/07/10)
     
  37. Immune Exhaustion Occurs Concomitantly With Immune Activation and Decrease in Regulatory T Cells in Viremic Chronically HIV-1-Infected Patients - publication pdf attached - (08/07/10)
     
  38. Lopinavir Tablet Pharmacokinetics With an Increased Dose During Pregnancy - publication pdf attached - (08/07/10)
     
  39. IAC: Highlights of the Vienna International AIDS Conference by Pablo Tebas, MD, University of Pennsylvania. - (08/07/10)
     
  40. IAC: High Prevalence of Bone Demineralization in a Cohort of HIV-Infected Postmenopausal Women - (08/06/10)
     
  41. Albuminuria and Estimated Glomerular Filtration Rate Independently Associate with Acute Kidney Injury - (08/04/10)
     
  42. Heart Disease in HIV: 64-slice multidetector row computed tomography coronary angiography predicts outcome, are we evaluating risk for heart disease in HIV correctly? - (08/04/10)
     
  43. Failing Heart Linked to Failing Brain - attached are both pdfs, the article & a commentary from the Jnl of the Am Heart Ass Epub - (08/04/10)
     
  44. Following is a statement by the National Osteoporosis Foundation on Bone Mineral Density Testing - (08/04/10)
     
  45. Kidney function and the risk of cardiovascular events in HIV-1-infected patients - (08/04/10)
     
  46. IAC: Bioequivalence of the Co-Formulation of Emtricitabine/Rilpivirine/Tenofovir DF - (08/04/10)
     
  47. IAC: Pharmacokinetic interaction study between TMC278, a next-generation NNRTI, and methadone - (08/04/10)
     
  48. IAC: Switching from Kivexa [ABC/3TC ]+Kaletra [LPV/r] to Truvada [TDF/FTC]+Kaletra [LPV/r] Reduces High Cholesterol: Results of a 12 Week Randomized, Controlled Study (ROCKET II) - (08/04/10)
     
  49. IAC: Switching to Atripla (EFV/FTC/TDF) from ABC/3TC FDC (Kivexa/Epzicom) + Efavirenz (EFV) Improves Lipid Levels Towards NCEP Recommendations: Primary Endpoint Results of a 24-week Randomised Study - (08/04/10)
     
  50. IAC: The impact of switching to etravirine on efavirenz-related CNS toxicity - (08/04/10)
     
  51. IAC: Meta-analysis Shows Abacavir Has No Effect on Cardiovascular Adverse Events: Presented at AIDS 2010 - (08/04/10)
     
  52. IAC: Use of genotypic and maraviroc (MVC) clinical trial data to develop statistical models for predicting response to a MVC-containing regimen in a treatment-experienced (TE) population - (08/04/10)
     
  53. IAC: Low Risk of Malignancy With Maraviroc in Treatment-Experienced and Treatment-Naïve Patients Across the Maraviroc Clinical Development Program - (08/04/10)
     
  54. IAC: Significant enhancement in survival with early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis: "34% Reduction in Mortality in Early Arm" - (08/04/10)
     
  55. IAC: Abacavir Use and Cardiovascular Disease Events: A Meta-Analysis of Published & Unpublished Data - (08/04/10)
     
  56. IAC: Darunavir/Ritonavir Monotherapy Fails Primary Noninferiority Test at MONET Week 96 - written by Mark Mascolini - (07/29/10)
     
  57. IAC: HIV Prevention at AIDS 2010 Vienna - written by Jared Baeten, MD PhD and Connie Celum, MD MPH University of Washington (07/29/10)
     
  58. Impact of Individual Antiretroviral Drugs on the Risk of Myocardial Infarction in Human Immunodeficiency Virus-Infected Patients - full text pdf attached - (07/27/10)
     
  59. IAC: Viral Control and Switch/Stop Rates Similar With ABC/3TC and TDF/FTC in Canada - written by Mark Mascolini - (07/27/10)
     
  60. IAC: Resistance and Bilirubin Derail Twice-Daily Raltegravir/Atazanavir - written by Mark Mascolini - (07/27/10)
     
  61. IAC: Tenofivir Once-Daily PrEP in MSM Friday Late Breaker - (07/27/10)
     
  62. IAC: The Monet Trial 96 Weeks: drunavir Monotherapy vs darunavir + 2 NRTIs inpatients with HIV RNA < 50 copies/ml at baseline - (07/27/10)
     
  63. IAC: Abacavir vs Tenofovir - Similar times to virologic suppression and switching or stopping for abacavir/3TC and tenofovir/FTC in naives in Canadian Observational Cohort Collaboration - (07/27/10)
     
  64. IAC: Coronary CT Sees Blockage in Half of HIV Group With No Heart Disease Symptoms - written by Mark Mascolini - (07/27/10)
     
  65. IAC: Small Study Suggests Once-Daily MVC Plus ATV/r as Viable First Regimen - written by Mark Mascolini - (07/26/10)
     
  66. IAC: Metabolic Marker Changes Similar After 12 Weeks of Darunavir and Atazanavir - written by Mark Mascolini - (07/26/10)
     
  67. IAC: HIV Infection Tied to Lower Risk of Vitamin D Deficiency in US Women's Study - (07/26/10)
     
  68. IAC: Individual Antiretrovirals Not Tied to Vitamin D Deficiency in London HIV Clinic - (average age 48, 50% vit D low/deficient, 40% osteopenia, 13% oseoporosis) - (07/26/10)
     
  69. IAC: Infection With Resistant Virus More Than Doubles Risk of Virologic Failure - (07/26/10)
     
  70. IAC: HCV Co-infection is Associated with a High Risk of Osteoporotic Fractures Among HIV Patients - (07/26/10)
     
  71. IAC: 80% Prevalence of hypovitaminosis D and factors associated in a sample of HIV patients in Italy - (07/26/10)
     
  72. IAC: Oral Poster discussion: Shining Light on Vitamin D deficiency - (07/26/10)
     
  73. IOF position statement: vitamin D recommendations for older adults - Position Paper - (07/23/10)
     
  74. IAC: Benefits and Risks of Stepdown to Atazanavir/Ritonavir Plus Lamivudine - (07/23/10)
     
  75. IAC: HIV Raises Heart Disease Risk 60% in People Over 49 - (07/23/10)
     
  76. IAC: HAART Initiation and Clinical Outcomes: insights from the CASCADE Cohort on 'When To Start' - (07/23/10)
     
  77. IAC: Gardasil Effective in Preventing AIN and Anal Cancer Related to HPV: 'Quadrivalent HPV Vaccine Efficacy against HPV 6/11/16/18 Infection and Disease in Men' - (07/23/10)
     
  78. IAC: Association of Antiretroviral Therapy, Immunologic and Virologic Factors with Myocardial Infarction Rates in a U.S. Health Care System - (07/23/10)
     
  79. IAC: Nadir CD4 is a Predictor of HIV Neurocognitive Impairment (NCI) in the era of Combination Antiretroviral Therapy (CART): Results from the CHARTER Study - (07/23/10)
     
  80. IAC: Increased Rate of HIV Neurocognitive Impairment (NCI) among non-AIDS Cases in the Post-CART versus Pre-CART era - (07/23/10)
     
  81. IAC: Gardasil Effective in Preventing AIN and Anal Cancer Related to HPV: 'Quadrivalent HPV Vaccine Efficacy against HPV 6/11/16/18 Infection and Disease in Men' - (07/23/10)
     
  82. Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats - pdf attached - (07/22/10)
     
  83. IAC: HPV Vaccine Prevents HPV Lesions and Infection in Men - written by Mark Mascolini - (07/22/10)
     
  84. IAC: Cognitive Impairment Rate Rising in HIV+ Without AIDS: CHARTER - written by Mark Mascolini - (07/22/10)
     
  85. IAC: Comparison of 48 week efficacy and safety of 400mg QD nevirapine (NVP) extended release formulation (Viramune XR) versus 200mg BID nevirapine immediate release formulation (Viramune IR) in combination with emtricitabine/tenofovir in antiretroviral (ARV) naïve HIV-1 infected patients (VERxVE) - (07/22/10)
     
  86. IAC: Once-Daily Maraviroc (MVC) + Atazanavir/Ritonavir(ATV/r) vs. Emtricitabine/Tenofovir(TDF/FTC) + ATV/r in Treatment Naïve Patients: A Week 24 Planned Interim Analysis - (07/22/10)
     
  87. IAC: The SPARTAN Study: A Pilot Study to Assess the Safety and Efficacy of an Investigational NRTI- and RTV-Sparing Regimen of Atazanavir (ATV) Experimental Dose of 300mg BID plus Raltegravir (RAL) 400mg BID (ATV+RAL) in Treatment-Naïve HIV-Infected Subjects - (07/22/10)
     
  88. IAC:VERxVE study demonstrates efficacy and safety of 400mg once daily nevirapine (Viramune) extended release (NVP XR) formulation - BI press release - (07/22/10)
     
  89. IAC: Pooled Week 48 efficacy and safety results from ECHO and THRIVE, two double-blind, randomised, Phase III trials comparing TMC278 versus efavirenz in treatment-naïve, HIV-1-infected patients - (07/22/10)
     
  90. IAC: TMC278 Noninferior to Efavirenz in Naive But With More Virologic Failures - written by Mark Mascolini - (07/22/10)
     
  91. IAC: Once-Daily S/GSK1349572 as Part of Combination Therapy in Antiretroviral Naïve Adults: Rapid and Potent Antiviral Responses in the interim 16-Week Analysis from SPRING-1 (ING112276) - (07/22/10)
     
  92. IAC: S/GSK1349572 Works Fast in Phase 2 Study of Treatment Naive - written by Mark Mascolini - (07/22/10)
     
  93. IAC: Nadir CD4 Count Strongly Predicts Neurocognitive Impairment in CHARTER - written by Mark Mascolini - (07/22/10)
     
  94. IAC: Two to Three Times Higher Hodgkin Risk in First Months of ART - written by Mark Mascolini - (07/22/10)
     
  95. IAC: Five Times Higher Risk of Intracranial Hemorrhage With HIV - written by Mark Mascolini - (07/22/10)
     
  96. IAC: Types of Kidney Problems May Be Changing as HAART Era Matures - written by Mark Mascolini - (07/22/10)
     
  97. IAC: Effects of Randomized Regimen and Nucleoside Reverse Transcriptase Inhibitor (NRTI) Selection on 96 Week Bone Mineral Density (BMD): Results from ACTG 5142 - (07/22/10)
     
  98. IAC: Concomitant nevirapine therapy is associated with higher efficacy of pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients - (07/22/10)
     
  99. IAC: METABOLIK (Metabolic Evaluation in Treatment-naïves Assessing the impact of two BOosted protease inhibitors on LIpids and other marKers): Comparison of the Metabolic Effects of Darunavir/ritonavir versus Atazanavir/ritonavir over 12Weeks - (07/22/10)
     
  100. IAC: Lipodystrophy and Inflammation Predict Grip Strength in HIV-Infected Men: the MACS Body Composition Sub-study - (07/22/10)
     
  101. IAC: New, Deadly, but Rare Encephalitis Described in 14 French HIV Patients - written by Mark Mascolini - (07/21/10)
     
  102. Tesamorelin FDA Briefing Document pdf attached - (07/21/10)
     
  103. IAC: Low CD4s Trump Other MI Risk Factors in 6500-Person US Analysis - written by Mark Mascolini - (07/21/10)
     
  104. IAC: CDC Study Confirms Rising Non-AIDS Cancer Rate in With HIV - written by Mark Mascolini - (07/21/10)
     
  105. IAC: Cancer Rates in HIV+ in Atlanta: 'Non-AIDS Cancers Found 10 to 15 Years Earlier in People With HIV' - written by Mark Mascolini - (07/21/10)
     
  106. IAC: A Year of ART Does Not Ease Anal Cancer Harbingers in Men - written by Mark Mascolini - (07/21/10)
     
  107. IAC: Higher CD4 Count at Lung Cancer Diagnosis Predicts Survival - written by Mark Mascolini - (07/21/10)
     
  108. IAC: HCV SVR Rate Higher With Nevirapine Than Lopinavir in Multicenter Study - written by Mark Mascolini - (07/21/10)
     
  109. IAC: Congresswoman Barbara Lee Calls for $6 Billion for Global Fund - (07/21/10)
     
  110. IAC: S/GSK1265744: A Next Generation Integrase Inhibitor (INI) with Activity Against Raltegravir-Resistant Clinical Isolates - (07/21/10)
     
  111. IAC: Activity of the Next Generation Integrase Inhibitor S/GSK1349572 and Two First Generation Inhibitors Across a Broad Panel of HIV Subtype Isolates in PBMCs and MDMs - (07/21/10)
     
  112. IAC: HIV Integrase Genotypic and Phenotypic Changes Between Day 1 and Day 11 in Subjects with Raltegravir Resistant HIV Treated with S/GSK1349572: Results of VIKING Study - (07/21/10)
     
  113. IAC: 'Start HIV Therapy Earlier, IAS-USA Panel Recommends' - (07/20/10)
     
  114. IAC: Bill Clinton on HIV/AIDS: Much More Needs to be Done - (07/20/10)
     
  115. IAC: Bill Clinton, Gates: Fight AIDS more efficiently - (07/20/10)
     
  116. IAC: Tenofovir AIDS gel protects women in study - (07/20/10)
     
  117. IAC: Tenofovir Gel found to reduce AIDS risk in women - (07/20/10)
     
  118. IAC: New Tenofovir Gel Cuts Risk of HIV Infection for Women in Study - WSJ Report - (07/20/10)
     
  119. IAC: New Tenofovir Gel Cuts Risk of HIV Infection for Women in Study - WSJ Report - (07/20/10)
     
  120. IAC: Number Globally of HIV-positive in treatment rose by a quarter last year - (07/20/10)
     
  121. IAC: Gays With Well-Controlled HIV Not Protected From Lymphogranuloma Venereum - written by Mark Mascolini - (07/20/10)
     
  122. IAC: Long-Term Nonprogression Rare and Transient in Large CASCADE Cohort Study - written by Mark Mascolini - (07/20/10)
     
  123. IAC: Liver Death Rate in Spain Similar With and Without HIV, But Only in HCV-Negative - written by Mark Mascolini - (07/20/10)
     
  124. IAC: Death Rate Has Not Dropped in Certain Disadvantaged HIV+ US Groups - written by Mark Mascolini - (07/20/10)
     
  125. IAC: Fatal Liver Failure Still 8 Times More Common With HIV in Large US Cohort - written by Mark Mascolini - (07/20/10)
     
  126. IAC: HCV in HIV-Positives Raises Osteoporotic Fracture Risk Over 40% - written by Mark Mascolini - (07/20/10)
     
  127. IAC: Once- Versus Twice-Daily Raltegravir When Switching From a PI - written by Mark Mascolini - (07/19/10)
     
  128. IAC: Antioxidants With ART Boost CD4s, Ease Mitochondrial Damage in 8-Week Trial - written by Mark Mascolini - (07/19/10)
     
  129. IAC: Trading a Ritonavir-Boosted PI for Twice-Daily Raltegravir in SPIRAL - written by Mark Mascolini - (07/19/10)
     
  130. IAC: Abbott's PROGRESS Study of Kaletra and Isentress Compared with a Standard HIV Regimen Meets the Pre-Specified Primary Efficacy Endpoint - Abbott Press Release - (07/19/10)
     
  131. IAC: Impact of prior NRTI failure in the ODIS trial, a study conducted in HIV+ patients with undetectable viremia on protease inhibitors who switched to raltegravir qd versus bid - (07/19/10)
     
  132. IAC: TBR-652, a Potent Dual CCR5/CCR2 Antagonist in Phase 2 Development for Treatment of HIV Infection - Inflammation - (07/19/10)
     
  133. IAC: Tenofovir Gel Reduced HIV Transmission - pdf of Science Mag publication attached - (07/19/10)
     
  134. IAC: First-Line Lopinavir/r/Raltegravir (With No NRTIs) in Treatment Naive - written by Mark Mascolini - (07/19/10)
     
  135. IAC: Activity of Next Generation Integrase Inhibitor (INI) S/GSK1349572 in Subjects with HIV Exhibiting Raltegravir Resistance: Initial Results of VIKING Study (ING112961) - (07/19/10)
     
  136. IAC: Lopinavir/ritonavir (LPV/r) Combined with Raltegravir (RAL) Demonstrated Similar Antiviral Efficacy and Safety as LPV/r Combined with Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in Treatment-Naïve HIV-1-Infected Subjects: PROGRESS 48 week results (07/19/10)
     
  137. IAC: Raltegravir Resistance Pattern Critical in Early Response to S/GSK1349572 - written by Mark Mascolini - (07/19/10)
     
  138. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection - Editorial Review - (07/19/10)
     
  139. Untreated HIV: harmful even at high CD4 cell counts - Editorial - 'When To Begin HAART' - (07/19/10)
     
  140. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per µL in Europe and North America: a pooled cohort observational study - (07/19/10)
     
  141. IAC: New Guidelines Urge Earlier Therapy for HIV Patients - (07/19/10)
     
  142. IAC: Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study - (07/19/10)
     
  143. IAC: AIDS group fears annual HIV costs may hit $35 bln - (07/19/10)
     
  144. IAC: HIV/AIDS numbers from around the world - (07/19/10)
     
  145. IAC: CDC Study Reports Poverty Among Minorities Doubles HIV Infection Rate - (07/19/10)
     
  146. IAC: Julio Montaner AIDS Conference Chief Lashes Out At World Leaders for Not Funding Global HIV - (07/19/10)
     
  147. IAC: 18th Int'l AIDS Conference opens in Vienna - (07/19/10)
     
  148. IAC: World AIDS Conference (IAC) Opens -to hear progress on drugs, money worries - (07/19/10)
     
  149. Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes - (07/15/10)
     
  150. Early vs Standard HAART Start in Haiti Randomized Study NEJM - pdf attached - (07/15/10)
     
  151. Alzheimer disease and HIV A tangled story - Editorial - (07/15/10)
     
  152. Geron Provides Update on Telomerase Anti-Aging Therapy Activation Program - (07/15/10)
     
  153. HIV & Alzheimers: are HIV+ At Greater Risk for Alzheimers - pdf full text attached - (07/14/10)
     
  154. HIV/Aging & Antiaging Therapy - (07/12/10)
     
  155. CD4 Predicts Cardiovascular Disease (CVD), nadir cd4 too perhaps - (07/12/10)
     
  156. Model Forecasting Test & Treat Impact - CID August 2010 - pdf attached - (07/12/10)
     
  157. Proton Pump Inhibitors and Histamine-2 Receptor Antagonists Are Associated With Hip Fractures Among At-Risk Patients - pdf of full text attached - (07/12/10)
     
  158. Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: A meta-analysis of the risk factors - (07/10/10)
     
  159. NIH-Led Scientists Find Antibodies that Prevent Most HIV Strains from Infecting Human Cells - 2 pdfs attaced of both Science mag published reports - (07/10/10)
     
  160. HIV Persistence and the Prospect of Long-Term Drug-Free Remissions for HIV-Infected Individuals - Review - pdf attached - (07/10/10)
     
  161. Advance in Quest for HIV Vaccine - (07/10/10)
     
  162. Inflammation Predicts Mortality in FRAM - (07/08/10)
     
  163. Telomere Length and Risk of Incident Cancer and Cancer Mortality - (07/08/10)
     
  164. Sexually Transmitted Diseases Among Users of Erectile Dysfunction Drugs: Analysis of Claims Data - (07/07/10)
     
  165. Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment - (07/07/10)
     
  166. Depressive symptoms and risk of dementia - The Framingham Heart Study - (07/07/10)
     
  167. New Gene Therapy Zinc Fingers Research Published: 'doctors may someday control HIV virus using stem cells without using anti-retroviral drugs' - (07/07/10)
     
  168. Raltegravir Switch from PI Effective - Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study - pdf attached - (07/05/10)
     
  169. Long-term use of anabolic steroids associated with reduced LV ejection fraction - (07/04/10)
     
  170. Neurological Symptoms-HIV ART Drug Resistance & Discordant CNS & Plasma Viral Load, Patients Suppressed on ART - pdf attached - (07/04/10)
     
  171. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication - pdf of publication attached - (07/02/10)
     
  172. Steady increase in cellular HIV-1 load during the asymptomatic phase of untreated infection despite stable plasma viremia - (07/01/10)
     
  173. Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study - (06/30/10)
     
  174. Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy - (06/30/10)
     
  175. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients - (06/30/10)
     
  176. Immunosenescence and Vaccination - Commentary - (06/29/10)
     
  177. Mechanisms of immunosenescence Short report - (06/29/10)
     
  178. New Inhaled Insulin for Diabetes 2 - (06/25/10)
     
  179. Hypertension Strongest Predictor of Stroke: and includes waist-to-hip ratio, regular exercise, smoking, diabetes, depression, stress - (06/23/10)
     
  180. Diabetes & Liver Disease: does diabetes cause liver disease - pdf of article attached - (06/23/10)
     
  181. Immunosenescence comes of age. Symposium on Aging Research in Immunology: The Impact of Genomics - (06/23/10)
     
  182. Is human immunosenescence clinically relevant? Looking for 'immunological risk phenotypes' - (06/23/10)
     
  183. Premature immunosenescence in HIV-infected patients on highly active antiretroviral therapy with low-level CD4 T cell repopulation - (06/23/10)
     
  184. Diabetes & Liver Disease: does diabetes cause liver disease - pdf of article attached - (06/22/10)
     
  185. HIV-associated lipodystrophy: from fat injury to premature aging - Review - pdf of article attached - (06/22/10)
     
  186. Mitochondrial Dysfunction in HIV+ CNS/Muscular Organ Systems Disorders in HIV+ Children, and perhaps related to accelerated aging in older HIV+ adults - (06/20/10)
     
  187. ResisWksp: Clinical, Virological, and Immunological Characteristics of Patients With Discordant Phenotypic and Genotypic (Ultra-Deep Sequencing) Tropism Test Results: Analysis of Tropism Calls in MOTIVATE and 1029 - poster - (06/18/10)
     
  188. ResisWksp: Analysis of the HIV-1 gp120 V3 Loop at Screening for Treatment-Experienced Patients in the MOTIVATE Studies With CCR5-Tropic Virologic Failure - poster - (06/18/10)
     
  189. ResisWksp: Genotypic Analysis of V3 in Patients Experiencing Virologic Failure on Maraviroc-containing Regimens and Correlation with Pre-treatment "Deep" Sequencing Results - poster - (06/18/10)
     
  190. ResisWksp: Long-Term Outcome of Individuals Experiencing a Phenotypic Switch in HIV-1 Co-receptor Use in the Merit Study - (06/18/10)
     
  191. Predictors and treatment strategies of HIV-related fatigue in the combined antiretroviral therapy era - (06/16/10)
     
  192. ResisWksp: Intl Resistance Workshop Report by Mark Wainberg, PhD, McGill University, Montreal - (06/16/10)
     
  193. Immunologic and Virologic Events in Early HIV Infection Predict Subsequent Rate of Progression - MAJOR ARTICLE - (06/11/10)
     
  194. Host and Viral Genetic Correlates of Clinical Definitions of HIV-1 Disease Progression - (06/11/10)
     
  195. EACS: New EACS (European AIDS Clinical Society) HIV Guidelines: HIV treatment, comorbidities (prevention and management of metabolic diseases), management and treatment of chronic hepatitis B and C coinfection in HIV+
     
  196. (Test & Treat) HIV Prevention, Diagnosis and Treatment A Best Practices Symposium at Albert Einstein School of Medicine, Bronx, NY -pdf attached
     
  197. ResisWksp: Strong Inhibition of Wild-Type and Integrase Inhibitor (INI)-Resistant HIV Integrase (IN) Strand Transfer Reaction by the Novel INI S/GSK1349572 - (06/15/10)
     
  198. ResisWksp: Strong Inhibition of Wild-type and Integrase Inhibitor (INI)-Resistant HIV Integrase (IN) Strand Transfer Reaction by the Novel INI S/GSK1349572, poster report: "S/GSK1349572 had stronger and faster binding to mutant IN than RAL" - (06/15/10)
     
  199. ResisWksp: S/GSK1349572 Demonstrates Significantly Slower Dissociation Rates than Raltegravir when Comparing Wild Type and Raltegravir Resistant Integrase Protein - (06/15/10)
     
  200. ResisWksp: HIV Integrase Resistance Profiles and S/GSK1349572 Baseline Phenotypic Susceptibility for Subjects Experiencing Virologic Failure on Raltegravir (RAL) in the VIKING Study (ING112961) - (06/15/10)
     
  201. ResisWksp: S/GSK1349572 Demonstrates Significantly Slower Dissociation Rates than Raltegravir When Comparing Wild Type and Raltegravir Resistant Integrase Protein - (06/15/10)
     
  202. ResisWksp: Structural Models of HIV-1 Integrase and DNA in Complex with S/GSK1349572, Raltegravir and Elvitegravir: Structure-based Rationale for INI Resistance Profiles - (06/15/10)
     
  203. Study reveals promise for New/Improved HIV testing & Reporting Results on Internet - (06/15/10)
     
  204. Common genetic determinants of vitamin D insufficiency: a genome-wide association study - (06/15/10)
     
  205. A Finite Course of ART during Early HIV-1 Infection Modestly Delays Need for Subsequent ART Initiation: ACTG A5217, the SETPOINT Study - (06/12/10)
     
  206. ResisWksp: Only Two Major PI Mutations (But No Resistance) in Darunavir Monotherapy Trial - written by Mark Mascolini - (06/12/10)
     
  207. ResisWksp: US/Canadian HIV Transmission Clusters Largely Male, White, and Gay - written by Mark Mascolini - (06/12/10)
     
  208. ResisWksp: Infection With 3TC/FTC Mutant Virus Favors Lower Pretreatment Viral Load - written by Mark Mascolini - (06/12/10)
     
  209. ResisWksp: Treatment Success Rates High, Resistance Rates Lower, in France in 2009, but integrase resistance is present among failures - written by Mark Mascolini - (06/12/10)
     
  210. ResisWksp: HIV CSF/Plasma Ratio and Genetic Distance in People With Neurologic Disorders - written by Mark Mascolini - (06/12/10)
     
  211. ResisWksp: Genotypic Analysis of V3 in Patients Experiencing Virologic Failure on Maraviroc-containing Regimens and Correlation with Pre-treatment Deep Sequencing Results - (06/11/10)
     
  212. ResisWksp: Clinical, Virological, and Immunological Characteristics of Patients With Discordant Phenotypic and Genotypic (Ultra-Deep Sequencing) Tropism Test Results: Analysis of Tropism Calls in MOTIVATE and 1029 - (06/11/10)
     
  213. ResisWksp: Use of the Enhanced Sensitivity Tropism Assay (ESTA) to Predict On-Treatment Detection of CXCR4-using Virus and Impact on Virologic Outcomes in a Vicriviroc (VCV) Phase 2 Treatment Experienced Study (VICTOR-E1) - (06/11/10)
     
  214. ResisWksp: Mutation Rate in Antiretroviral-Naive Falling in One US Patient Population (GSK studies in USA) - written by Mark Mascolini - (06/11/10)
     
  215. ResisWksp: Are Single Transmitted Mutants the Tip of a Resistance Iceberg? - written by Mark Mascolini - (06/11/10)
     
  216. ResisWksp: New Mutations Found in 43% of People With Low But Detectable Viral Loads - written by Mark Mascolini - (06/11/10)
     
  217. ResisWksp: Study Clarifies Risk of Switch to Raltegravir From Suppressive PI - written by Mark Mascolini - (06/11/10)
     
  218. ResisWksp: Truvada Protects Macaques From Rectal Exposure to FTC-Resistant Virus - written by Mark Mascolini - (06/11/10)
     
  219. ResisWksp: Transmitted Resistance Imperils First-Line Response in 10,000-Person Study - written by Mark Mascolini - (06/11/10)
     
  220. ResisWksp: "Deep" Sequencing Finds X4 Virus in Screening Samples of Maraviroc Failures - written by Mark Mascolini - (06/10/10)
     
  221. ResisWksp: Pairwise Comparison of genotypic tropism prediction between one reference center and 10 European laboratories - (06/10/10)
     
  222. ResisWksp: Better Etravirine Response Predicted After Efavirenz Than Nevirapine - written by Mark Mascolini - (06/10/10)
     
  223. ResisWksp: Over Half of European Raltegravir Failures Without Apparent Integrase Mutations - written by Mark Mascolini - (06/10/10)
     
  224. ResisWksp: GSK Integrase Following Raltergavir Use: When Is It Risky to Use S/GSK1349572 After Raltegravir? - written by Mark Mascolini - (06/10/10)
     
  225. ResisWksp: Debate Follows Data on Genotypic Predictions of HIV Tropism - written by Mark Mascolini - (06/10/10)
     
  226. Similar Safety and Efficacy of Once- and Twice-Daily Lopinavir/Ritonavir Tablets in Treatment-Experienced HIV-1-Infected Subjects at 48 Weeks - (06/10/10)
     
  227. The Effects of Opiate Use and Hepatitis C Virus Infection on Risk of Diabetes Mellitus in the Women's Interagency HIV Study: history of opiate use & HCV both increase risk for diabetes - (06/10/10)
     
  228. Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials - (06/10/10)
     
  229. ResisWksp: Resistance Emergence With Raltegravir Versus Efavirenz in Treatment Naive - written by Mark Mascolini - (06/10/10)
     
  230. ResisWksp: Temporal Order of Resistance Emergence for Lamivudine/Emtricitabine, Efavirenz, and Raltegravir in Treatment-Naïve Patients - (06/10/10)
     
  231. ResisWksp: Differing Integrase Dissociation Rates With S/GSK1349572 and Raltegravir - written by Mark Mascolini - (06/10/10)
     
  232. Beyond Hemoglobin A1c-Need for Additional Markers of Risk for Diabetic Microvascular Complications - commentary - (06/08/10)
     
  233. Does Lipoatrophy Persist ? - Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy - pdf attached (I suggest reading the pdf closely) - (06/07/10)
     
  234. Phase 1 Study of Anti-CTGF Monoclonal Antibody in Patients with Diabetes and Microalbuminuria - pdf full text attached - (06/07/10)
     
  235. Circulating mitochondrial DAMPs cause inflammatory responses to injury - (06/07/10)
     
  236. "mitochondria.....might initiate inflammation....mitochondria are probably released in patients with infectious disease" - (06/07/10)
     
  237. Immunology & Mitochondria - Clinical immunology: Culprits with evolutionary ties - (06/07/10)
     
  238. The Mitochondrion - A Trojan Horse That Kicks Off Inflammation? - (06/07/10)
     
  239. Anti-inflammatory treatment with pentoxifylline improves HIV-related endothelial dysfunction: a pilot study - (06/03/10)
     
  240. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia - (06/03/10)
     
  241. HIV-associated neurocognitive disorders: is there a hidden epidemic? - Editorial Comment - (06/03/10)
     
  242. The role of cytology (Pap tests) and human papillomavirus testing in anal cancer screening - (06/03/10)
     
  243. Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens - (06/03/10)
     
  244. Tibotec Therapeutics Debuts Innovative Web Portal for HIV/AIDS Front-Line Service Providers Free, Centralized Resource Designed to Help Overcome Some Barriers to Supportive Care - (05/30/10)
     
  245. Late Presentation for Human Immunodeficiency Virus Care in the United States and Canada - (05/30/10)
     
  246. The Gap between Human Immunodeficiency Virus (HIV) Infection and Advances in HIV Treatment - EDITORIAL - (05/30/10)
     
  247. HPV and Therapeutic Vaccines: Where are We in 2010? - pdf attached - (05/29/10)
     
  248. M2010: Press briefings at International Microbicides Conference, May 22-25 - (05/28/10)
     
  249. M2010: Using ARVs to Prevent HIV Could Result in Drug Resistance if Routine Screening is Not Done New Research Presented at International Microbicides Conference - (05/28/10)
     
  250. M2010: Researchers Searching For New Ways (micobicides: tablets, gel, film, vaginal rings) To Protect Women Against HIV - (05/28/10)
     
  251. M2010: Lubricant Use May Raise HIV Infection Risk During Anal Sex - (05/28/10)
     
  252. M2010: Vaginal gel with integrase inhibitor shows promise in monkeys; Darunavir/Maraviroc/NNRTis/Fusion - (05/28/10)
     
  253. M2010: New ARTs Research Takes The Lead: HIV Microbicides Conference Report - (05/28/10)
     
  254. In this analysis of almost 3400 HIV-1 serodiscordant heterosexual couples from seven African countries, ART use by the infected person was accompanied by a 92% reduction in risk of HIV-1 transmission to their partner - (05/28/10)
     
  255. HIV drugs for treatment, and for prevention Editorial - (05/28/10)
     
  256. Tesamorelin & IGF-1 Levels - (05/28/10)
     
  257. Tesamorelin Reduces VAT: FDA Hearing - (05/28/10)
     
  258. VOTE: 16-0 to recommend approval for tesamorelin - 'benefit outweighs risk' - (05/28/10)
     
  259. FDA: Possible Fracture Risk with High Dose, Long-term Use of Proton Pump Inhibitors - (05/26/10)
     
  260. New CVD Anti-Inflammation Drug: Treatment With 5-Lipoxygenase Inhibitor VIA-2291 (Atreleuton) in Patients With Recent Acute Coronary Syndrome - pdf full text attached - (05/26/10)
     
  261. People with AIDS more likely to develop cancers, research says - (05/26/10)
     
  262. Tesamorelin FDA Briefing Document pdf attached - (05/26/10)
     
  263. Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation - pdf attached - (05/25/10)
     
  264. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals - (05/25/10)
     
  265. Cholesterol Crystals Incite Inflammation in Coronary Arteries, Research Finds - (05/25/10)
     
  266. Cholesterol crystals incite inflammation in coronary arteries - (05/25/10)
     
  267. 11th Wrkshp Adverse Drug Reactions Omega-3 fatty acids supplementation may improve inflammation and endothelial activation in HIV-infected adults on stable antiretroviral therapy - (05/24/10)
     
  268. 11th Wrkshp Adverse Drug Reactions Vitamin D and Efavirenz - (05/24/10)
     
  269. 11th Wrkshp Adverse Drug ReactionsAssociation between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D - (05/24/10)
     
  270. Study pinpoints how a normally defensive immune response can help HIV - journal commentary included - (05/24/10)
     
  271. New Aging/HIV Study-blocking inflammation: Tryptophan Catabolism by Indoleamine 2,3-Dioxygenase 1 Alters the Balance of TH17 to Regulatory T Cells in HIV Disease - (05/24/10)
     
  272. Visceral fat is associated with lower brain volume in healthy middle-aged adults - (05/20/10)
     
  273. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis - (05/18/10)
     
  274. Low Vitamin D Levels Associated with Genotype 1, Fibrosis, Inflammation, with SVR, with waist circumference, Low HDL - (05/18/10)
     
  275. High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men - (05/17/10)
     
  276. "A higher 25(OH)D (vit D) was associated with better dietary quality, lower %BF (body fat, central obesity), and lower number of MetD (metabolic disturbances including CRP, glucose)"...dairy in diet helped vit D levels - pdf attached - (05/13/10)
     
  277. Denosumab Inhibits Bone Loss in RA - (05/13/10)
     
  278. High Dose Vitamin D Increased Fall & Fracture Rate - (05/13/10)
     
  279. High-Dose Vitamin D Supplementation, Too Much of a Good Thing? - (05/12/10)
     
  280. Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model - (05/12/10)
     
  281. HPV, Genital wart virus may raise men's risk of HIV - link to free full text JID article - (05/12/10)
     
  282. Markers of Inflammation, Coagulation, and Renal Function Are Elevated in Adults with HIV Infection - (05/07/10)
     
  283. Inflammation and Complications of HIV Disease - EDITORIAL COMMENTARY - (05/07/10)
     
  284. Pre-HAART Immune Activation Associated with Developing Cancers & Death - (05/07/10)
     
  285. Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection (and HCV) - (05/07/10)
     
  286. Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy - (05/05/10)
     
  287. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations - (05/05/10)
     
  288. Experimental NYC HIV Anal Cancer Screening Clinic - (05/05/10)
     
  289. An aged T cell phenotype: A prognostic indicator in liver transplant recipients? Editorial - (05/03/10)
     
  290. Features of immune senescence in liver transplant recipients with established grafts - (05/03/10)
     
  291. ACCORD Glycemia (intensive control <6% A1C) Results Continue to Puzzle Editorial - (05/03/10)
     
  292. Intensive Sugar Control HbA1C <6% Is Beneficial; Unsuccessful intensive therapy the culprit in ACCORD - (05/03/10)
     
  293. (Low A1C <6% Reduces Death) Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial - (05/03/10)
     
  294. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients - (04/29/10)
     
  295. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis - (04/29/10)
     
  296. PK Workshop: 11th International Workshop on Clinical Pharmacology of HIV Therapy (April 2010) Report - written by Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center - (04/27/10)
     
  297. Rosuvastatin for Primary Prevention in Older Persons With Elevated C-Reactive Protein and Low to Average Low-Density Lipoprotein Cholesterol Levels: Exploratory Analysis of a Randomized Trial - (04/26/10)
     
  298. Statins for Primary Prevention in Older Adults: Who Is High Risk, Who Is Old, and What Denotes Primary Prevention? Editorial - (04/26/10)
     
  299. PK Workshop: Evaluation of Ritonavir-boosted Elvitegravir PK upon Co-administration with a Second Potent CYP3A inhibitor, Ketoconazole - (04/23/10)
     
  300. PK Workshop: Metabolism and Excretion in Humans of the Pharmacoenhancer GS-9350 - (04/22/10)
     
  301. Anti-HIV-1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140, a CCR5 Monoclonal Antibody - (04/22/10)
     
  302. PK Workshop: Relative Bioavailability and Pharmacokinetics of Darunavir when boosted with the Pharmacoenhancer GS-9350 versus Ritonavir - (04/21/10)
     
  303. Sequential Acquisition of Human Papillomavirus (HPV) Infection of the Anus and Cervix: The Hawaii HPV Cohort Study. - (04/13/10)
     
  304. HAART Reduces HPV - Influence of Adherent and Effective Antiretroviral Therapy Use on Human Papillomavirus Infection and Squamous Intraepithelial Lesions in Human Immunodeficiency Virus-Positive Women - (04/13/10)
     
  305. The role of secondary lymphatic tissue in immune deficiency of HIV infection, and aging - (04/13/10)
     
  306. HIV Drug Resistance over the Long Haul - EDITORIAL COMMENTARY - (04/13/10)
     
  307. PK Workshop: GRACE PK Study: Median (range) AUC12h and C0h were similar between women and men, and across black, Hispanic and white patients; Pharmacokinetic results from GRACE demonstrated no clinically relevant differences in exposure to DRV across a range of covariates, including sex, race/ethnicity, use of ETR, use of TDF, age, body weight and hepatitis B co-infection status - (04/13/10)
     
  308. PK Workshop: Pharmacokinetic interaction study between TMC278, a next-generation NNRTI, and methadone - (04/13/10)
     
  309. PK Workshop: Higher Darunavir and Raltegravir Levels in Small Study of People With Liver Disease - written by Mark Mascolini - (04/13/10)
     
  310. PK Workshop: Limited Risk of Serious Interaction Between TMC278 and Methadone - written by Mark Mascolini - (04/13/10)
     
  311. PK Workshop: More Than Half in Barcelona HIV Clinic Use Alternative Therapies - written by Mark Mascolini - (04/13/10)
     
  312. PK Workshop: Cell Levels of Once-Daily Raltegravir Adequate in Pilot Study - written by Mark Mascolini - (04/13/10)
     
  313. PK Workshop: Older Age Impairs Kidney Function During Tenofovir Therapy - written by Mark Mascolini - (04/13/10)
     
  314. PK Workshop: Etravirine Lowers Levels of S/GSK Integrase Inhibitor, But PIs Counter Effect - written by Mark Mascolini - (04/13/10)
     
  315. PK Workshop: Darunavir Boosting with GS-9350 (Cobicistat) or Ritonavir in Healthy Volunteers - written by Mark Mascolini - (04/13/10)
     
  316. PK Workshop: Extra CYP3A Inhibitor Has Modest Impact on Already-Boosted Elvitegravir - written by Mark Mascolini - (04/13/10)
     
  317. PK Workshop: What Will It Take To Replace Ritonavir as the Prime PK Booster? ...Debate Ritonavir v GS9350 - written by Mark Mascolini - (04/13/10)
     
  318. PK Workshop: Higher Atazanavir Levels Sync With Higher Raltegravir Levels in Dual Combo - written by Mark Mascolini - (04/13/10)
     
  319. PK Workshop: The Effect of Food Intake on Reyataz Blood Levels - written by Mark Mascolini - (04/13/10)
     
  320. PK Workshop: Darunavir Levels Not Tied to Detectable HIV RNA in MONET Monotherapy Trial - written by Mark Mascolini - (04/13/10)
     
  321. PK Workshop: Darunavir Levels Not Affected by Gender, Race, or Age in GRACE Trial - written by Mark Mascolini - (04/13/10)
     
  322. PK Workshop: Impact of Pravastatin on Raltegravir Levels in Healthy Volunteers - written by Mark Mascolini - (04/13/10)
     
  323. PK Workshop: Efavirenz Troughs Higher in People Over 50 Years Old - written by Mark Mascolini - (04/13/10)
     
  324. PK Workshop: Women With Tight HIV Control Have Higher Antiretroviral Troughs Than General Population - written by Mark Mascolini - (04/13/10)
     
  325. Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials - (04/06/10)
     
  326. Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management - (04/06/10)
     
  327. Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients - (04/06/10)
     
  328. Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy - (04/06/10)
     
  329. Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience - (04/06/10)
     
  330. CROI: HAART Reduces New Infections - Decreases in Community Viral Load Are Associated with a Reduction in New HIV Diagnoses in San Francisco (CROI) - (04/05/10)
     
  331. Conspiracy Beliefs About HIV Are Related to Antiretroviral Treatment Nonadherence Among African American Men With HIV - (04/05/10)
     
  332. 45% of Eligible Patients Receive HIV Drug Resistance Testing - (04/05/10)
     
  333. The Impact of Transmitted Drug-Resistance on Treatment Selection and Outcome of First-Line Highly Active Antiretroviral Therapy (HAART) - (04/05/10)
     
  334. Efficacy, Safety, and Tolerability of Etravirine With and Without Darunavir/Ritonavir or Raltegravir in Treatment-Experienced Patients: Analysis of the Etravirine Early Access Program in the United States - (04/05/10)
     
  335. CROI: Prolonged Control of Viremia After Transfer of Autologous CD4 T Cells Genetically Modified with a Lentiviral Vector Expressing Long Antisense to HIV env (VRX496) - (04/04/10)
     
  336. Serum C-reactive protein is linked to cerebral microstructural integrity and cognitive function - (04/03/10)
     
  337. Inflammation, CRP & new test (DTI, difussion tensor imaging) - Are white matter signal abnormalities clinically relevant? Editorial - (04/03/10)
     
  338. Raltegravir Is a Potent Inhibitor of XMRV, a Virus Implicated in Prostate Cancer and Chronic Fatigue Syndrome - (04/03/10)
     
  339. Effect of Osteoporosis Treatment on Mortality: A Meta-Analysis - (03/28/10)
     
  340. Proton-Pump Inhibitor Use Is Not Associated With Osteoporosis or Accelerated Bone Mineral Density Loss - (03/28/10)
     
  341. Evolving Data about Subtrochanteric Fractures and Bisphosphonates-EDITORIAL - (03/25/10)
     
  342. Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur - (03/25/10)
     
  343. NYS Guidelines recommendations on anal pap smears - (03/25/10)
     
  344. CROI: HIV Persistence, Raltegravir/Maravoric Intensification, Immunology: Some Impressions from San Francisco: CROI 2010 - written by David Margolis MD University of North Carolina - (03/24/10)
     
  345. MRSA Risk 6-Fold Higher in HIV+: Community-Associated Methicillin-Resistant Staphylococcus aureus and HIV: Intersecting Epidemics - (03/24/10)
     
  346. CROI: Management of Treatment-Experienced Patients: darunavir, raltegravir, raltegravir intensification, maraviroc, vicriviroc - written by Rafael E. Campo, MD Professor of Clinical Medicine Division of Infectious Diseases University of Miami Leonard M. Miller School of Medicine Miami, Florida - (03/23/10)
     
  347. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects - pdf attached - (03/22//10)
     
  348. Short-Course Raltegravir Intensification Does Not Reduce Persistent Low-Level Viremia in Patients with HIV-1 Suppression during Receipt of Combination Antiretroviral Therapy - (03/22/10)
     
  349. Benefit or Toxicity from Neurologically Targeted Antiretroviral Therapy? EDITORIAL COMMENTARY - (03/22/10)
     
  350. Does Choice of Combination Antiretroviral Therapy (cART) Alter Changes in Cerebral Function Testing after 48 Weeks in Treatment-Naive, HIV-1-Infected Individuals Commencing cART? A Randomized, Controlled Study - (03/22/10)
     
  351. CROI: Antiviral and Immunological Effects of Intensification of Suppressive ART with Maraviroc, a CCR5 Antagonist - (03/22/10)
     
  352. CROI: Antiviral and Immunological Effects of Intensification of Suppressive ART with Maraviroc, a CCR5 Antagonist - (03/22/10)
     
  353. CROI: No Evolution of HIV-1 Total DNA and 2-LTR Circles after 48 Weeks of Raltegravir-containing Therapy in Patients with Controlled Viremia: A Sub-study of the Randomized EASIER-ANRS 138 Trial - (03/22/10)
     
  354. CROI: Effect of the Intensification with a CCR5 Antagonist on the Decay of the HIV-1 Latent Reservoir and Residual Viremia - (03/22/10)
     
  355. CROI: No Decrease in Intrathecal Immunoactivation or Residual CSF Viremiaduring Treatment Intensification in Patients on Stable ART - (03/22/10)
     
  356. CROI: Quantification of Persistent Viremia in Cerebrospinal Fluid and Plasma: Initial Experience in a Raltegravir Intensification Study - (03/22/10)
     
  357. CROI: Differences in HIV Burden throughout the Gut of Patients on Suppressive ART: Implications for HIV Persistence - (03/21/10)
     
  358. CROI: HIV-1 Replication and Immune Dynamics Are Impacted by Raltegravir Intensification of HAART-suppressed Patients - (03/21/10)
     
  359. CROI: Raltegravir Intensification in Antiretroviral-treated Patients Exhibiting a Suboptimal CD4+ T Cell Response - (03/21/10)
     
  360. Test & Treat-what is the impact? Can antiretroviral therapy eliminate HIV transmission? The lancet 2009 - (03/20//10)
     
  361. Intermittent Prophylaxis with Oral Truvada Protects Macaques from Rectal SHIV Infection - (03/19//10)
     
  362. CROI: Efficacy of Intermittent Prophylaxis with Tenofovir and Emtricitabine against Rectal SHIV Transmission in Macaques and Relationship to Systemic and Mucosal Drug Levels - (03/19/10)
     
  363. CROI: Protection of Rhesus Macaques from Vaginal Infection by Maraviroc (solution), an Inhibitor of HIV-1 Entry via the CCR5 Co-receptor - (03/19/10)
     
  364. CROI: Clinical Pharmacology at CROI 2010: Advances in Antiretroviral Discovery, Drug Interactions, Compartmental Penetration, and Adverse Reactions - written by Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center- (03/14/10)
     
  365. CROI: CROI: Inflammation/activation linked to diseases of organ systems (heart, kidney, liver) & death in USA and now reported as well in Africa - HIV accelerated aging will be bigger problem in undeveloped countries - (03/18/10)
     
  366. CROI: INFLAMMATORY MARKERS DURING TREATMENT OF OIs ARE PREDICTIVE OF LATE VIROLOGIC AND IMMUNOLOGIC RESPONSES: Sub-study of A5164 - (03/16/10)
     
  367. CROI:Prevalence of hypovitaminosis D among HIV+ patients enrolled in a large italian cohort - (03/15/10)
     
  368. CROI: Bone/Osteoporosis/Vitamin D CROI 2010 Update - written by Michael Yin, MD MS Assistant Professor of Clinical Medicine Columbia University Medical Center New York, NY- (03/14/10)
     
  369. Long-Term Efficacy and Safety of the HIV Integrase Inhibitor Raltegravir in Patients With Limited Treatment Options in a Phase II Study - (03/11/10)
     
  370. CROI: Longitudinal Analysis of Bone Mineral Density in Aging Men With or at Risk for HIV Infection: heroin causes bone loss; accelerated bone loss progressed over 3 years in HIV+ - (03/10/10)
     
  371. CROI: Changes in Bone Mineral Density: two-years follow-up of the ANRS CO3 Aquitaine Cohort - Bone Metabolism Evolves- in 11% from osteopenia to osteoporosis and to osteopenia, bone markers worsen in 41% - (03/10/10)
     
  372. Atypical Fractures of the Femoral Diaphysis in Postmenopausal Women Taking Alendronate - (03/09/10)
     
  373. Severely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy - (03/09/10)
     
  374. CROI: Non-AIDS-defining Events among HAART-treated Adults in an Urban US vs an Urban Sub-Saharan African Setting: 'high non-AIDS events rate in Africa' - (03/09/10)
     
  375. CROI: Low CD4 Cell Count and Impaired Renal Function (eGFR) Are Independent Risk Factors for ARF (acute renal failure) in HIV-infected Patients - (03/09/10)
     
  376. CROI: Prevalence of Hepatitis Coinfection among HIV-Infected Nigerian Children in the Harvard PEPFAR ART Program - (03/09/10)
     
  377. CROI: Persistent Low-level Viremia Is Associated with Increased Risk of Virologic Failure and Mortality - (03/09/10)
     
  378. CROI: Association of IL28B Haplotypes with Chronic HCV Infection in HIV/HCV Co-infected Individuals - (03/09/10)
     
  379. CROI: Genetic Variation in IL28B and Treatment-induced Clearance of HCV in HCV/HIV Co-infected Patients - (03/09/10)
     
  380. CROI: Sustained Virological Response to Interferon plus Ribavirin Reduces HIV Progression and Non-liver-related Mortality in Patients Co-infected with HIV and HCV - (03/09/10)
     
  381. CROI: HIV Prevention at CROI 2010 - written by Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (03/07/10)
     
  382. CROI: 5-Year Tenofovir Therapy Is Associated with Maintained HBV Response and Renal Toxicity in HIV/HBV Co-infected Patients - (03/06/10)
     
  383. CROI: Determinants of Incident Chronic Kidney Disease in a Cohort of HIV-infected Patients with Free Access to Care - (03/06/10)
     
  384. CROI: Predictors for Change in Estimated Glomerular Filtration Rate in HIV-infected Individuals with or without cART: The Swiss HIV Cohort Study - (03/06/10)
     
  385. CROI: Improved Correlation of Coronary Atherosclerosis with Estimated Glomerular Filtration Rate Assessed with Chronic Kidney Disease Epidemiology Collaboration Equation than with MDRD and Cockcroft-Gault in HIV-infected Patients - (03/06/10)
     
  386. CROI: HAART Is Associated with Improved Kidney Function in Patients with Impaired Kidney Function at Baseline but Was Associated with Slight Worsening of Kidney Function in Patients with Normal Baseline Kidney Function - (03/06/10)
     
  387. CROI: Chronic Renal Failure in HIV-Infected Patients: Incidence and Risk Factors (ANRS CO3 Aquitaine Cohort, France) - (03/06/10)
     
  388. CROI: Episodes of HIV Viremia and the Risk of Non-AIDS Events among Successfully Treated Patients (503) - (03/06/10)
     
  389. HbA1C Predicts Diabetes & CVD: Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic Adults - (03/05/10)
     
  390. CROI: DNA Damage and p16-mediated Growth Arrest in HIV-1-specific CD8+ T Cells - (03/05/10)
     
  391. CROI: Ritonavir and Lopinavir Boosted with Ritonavir Induce Endothelial dysfunction and Premature Senescence in Cultured Human Coronary Artery Endothelial Cells - (03/05/10)
     
  392. CROI: In vitro Effect of CCR5 Antagonists on Innate Immune System: Maraviroc Inhibits the Migration of Neutrophils, Macrophages and Dendritic Cells - (03/05/10)
     
  393. CROI: Vicriviroc Phase 3 at CROI 2010 - (03/05/10)
     
  394. CROI: Plasma Levels of Soluble CD14 (activation marker) Predict Mortality in HIV Infection - (03/05/10)
     
  395. CROI: Short-Term Raltegravir Monotherapy Does Not Predispose Patients to Develop RAL Resistance During Subsequent Combination Therapy: Analysis of Samples From Protocol 004 - (03/05/10)
     
  396. CROI:Pharmacokinetic (PK), Safety and Efficacy Data on Cohort IIA; youth aged 6-11 from IMPAACT P1066: A Phase I/II Study to Evaluate Raltegravir (RAL) in HIV-1 Infected Youth - (03/05/10)
     
  397. CROI:Maraviroc Fully Inhibits Dual-R5 Virus in Dual/Mixed HIV-1 Infected Patient - (03/04/10)
     
  398. CROI: Hepatic Safety & Efficacy of Raltegravir in Patients Co-infected with HIV and Hepatitis B (HBV) and/or C (HCV) Virus - (03/04/10)
     
  399. CROI: A Pharmacokinetic Comparison of Adult and Pediatric Formulations of Raltegravir (RAL) in Healthy Adults - (03/04/10)
     
  400. CROI: Screening for Hepatocellular Carcinoma (HCC) in HIV/HCV-Coinfected Patients: Impact on Staging, Therapy, and Survival - (03/04/10)
     
  401. CROI: Resistance Associated Mutations to Etravirine (TMC-125) in Antiretroviral Naïve Patients infected with non-B HIV-1 subtypes - (03/04/10)
     
  402. CROI: Determining HIV-1 Coreceptor Tropism Using PBMC Proviral DNA Derived from Aviremic Blood Samples, for Patients with Undetectable Viral Load - (03/04/10)
     
  403. CROI: The Prevalence of Darunavir Associated Mutations in PI-naive and PI-experienced HIV-1 Infected Children in the UK - (03/04/10)
     
  404. CROI: Maraviroc Fully Inhibits Dual-R5 Virus in Dual/Mixed HIV-1 Infected Patients - (03/04/10)
     
  405. CROI: Effect of the Intensification with a CCR5 Antagonist Maraviroc on the Decay of the HIV-1 Latent Reservoir and Residual Viremia - reduced activation - (03/04/10)
     
  406. CROI:Effect of CCL3L1 Copy Number Variation on CD4+ Cell Recovery in Treatment-Naïve Patients: 96-Week Results from the Maraviroc in Treatment-Naïve Patients (MERIT) Study - (03/04/10)
     
  407. CROI: Genotypic Analysis of the HIV-1 gp120 V3 Loop for Treatment-Experienced Patients Enrolled Into the MOTIVATE Studies and Who Received Maraviroc + Optimized Background Therapy - (03/03/10)
     
  408. CROI:Population-based Sequencing of the V3-loop is Comparable to the Enhanced Sensitivity Trofile Assay (ESTA) in Predicting Virologic Response to Maraviroc of Treatment-naïve Patients in the MERIT Trial - (03/03/10)
     
  409. CROI:Mechanisms of Virologic Failure With Maraviroc in Treatment-Naïve HIV-1-Infected Patients Through 96 Weeks - (03/03/10)
     
  410. CROI:Large-Scale Application of "Deep" Sequencing Using 454 Technology to HIV Tropism Screening - (03/03/10)
     
  411. CROI:HIV Did Not Worsen H1N1 Severity in Spanish Case-Control Study - written by Mark Mascolini - (03/03/10)
     
  412. CROI:Failure to Respond to HBV Vaccine Linked to Higher Cancer Risk With HIV - written by Mark Mascolini - (03/03/10)
     
  413. CROI:Prediction of X4-tropic Human Immunodeficiency Virus from Proviral Envelope Sequence in Patients with Suppressed Viral Load on Antiretroviral Therapy (ART). - (03/03/10)
     
  414. CROI: Four Non-AIDS Cancers on the Rise With HIV in Big North American Cohort - written by Mark Mascolini - (03/03/10)
     
  415. CROI:Correlation of Inflammatory Biomarkers with the Framingham Coronary Risk Score in Antiretroviral-naïve HIV-1 Infected Patients - (03/03/10)
     
  416. CROI:Trends in Cumulative Incidence of Cancer among HIV-infected Patients in North America: high cancer rates in HIV+ - (03/03/10)
     
  417. CROI: Prevalence (59%) and Correlates of Minor Neurocognitive Disorders in Asymptomatic HIV-infected Outpatients - (03/03/10)
     
  418. CROI: Summary from CROI for Hepatitis Coinfection - What are the challenges and how can we improve management of Hepatitis coinfection in HIV-Infected Patients? - written by Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/03/10)
     
  419. CROI: The Kidney at CROI - written by Christina M. Wyatt, MD Assistant Professor, Medicine/ Nephrology Mount Sinai School of Medicine New York, NY - (03/03/10)
     
  420. CROI: Chronic Inflammation in HIV: CROI 2010 - written by David H Shepp, MD Associate Professor of Medicine, Hofstra University School of Medicine Division of Infectious Diseases, North Shore University Hospital-Manhasset - (03/03/10)
     
  421. CROI: Modest Lipid and Body Fat Changes With Raltegravir vs Efavirenz in 96-Week Trial - written by Mark Mascolini - - (03/02/10)
     
  422. CROI: CDC Finds 1 in 6 Newly Diagnosed With HIV Had Resistant Virus in 2007 - written by Mark Mascolini - - (03/02/10)
     
  423. CROI: Chronic Kidney Disease and Exposure to ART in a Large Cohort with Long-term Follow-up: The EuroSIDA Study - abstract 107LB - (03/02/10)
     
  424. CROI: Higher Levels of Heart Cell Peptide Tied to Cardiovascular Disease in SMART Study Patients - written by Mark Mascolini - (03/01/10)
     
  425. CROI: D-Dimer But Not hsCRP Predicts Impending Cardiovascular Disease in Case-Control Study - written by Mark Mascolini - (03/01/10)
     
  426. CROI:Antiretrovirals for Prevention: Maraviroc Exposure in the Semen and Rectal Tissue of Healthy Male Volunteers after Single and Multiple Dosing - (03/01/10)
     
  427. CROI:Risk of Non-AIDS Death in HIV/HCV-Coinfected People in SMART - written by Mark Mascolini - (03/01/10)
     
  428. CROI: T cell Senescence and Proliferation Defects Persist in Treated HIV-infected Individuals Maintaining Viral Suppression and Are Associated with Poor CD4+ T Cell Recovery - (03/01/10)
     
  429. CROI: Impact of CD8+ T Cell Activation on CD4+ T Cell Recovery and Mortality in HIV-infected Ugandans Initiating Antiretroviral Therapy - (03/01/10)
     
  430. CROI: Valganciclovir Reduces CD8+ T Cell Activation among HIV-infected Patients with Suboptimal CD4+ T cell Recovery During Antiretroviral Therapy - (03/01/10)
     
  431. CROI:CD4 at HAART Initiation Predicts Long Term CD4 Responses and Mortality from AIDS and non-AIDS Causes in the HIV Outpatient Study (HOPS) - (03/01/10)
     
  432. CROI: Improved Genotypic Algorithm for Predicting Etravirine Susceptibility: Comprehensive List of Mutations Identified Through Correlation with Matched Phenotype - (03/01/10)
     
  433. CROI:Lack of Interaction between Etravirine and Raltegravir plus Darunavir/Ritonavir when Combined in Treatment Experienced Patients: a Substudy of the ANRS 139 TRIO Trial - (03/01/10)
     
  434. CROI: Antiretrovirals for Prevention: Maraviroc Exposure in the Semen and Rectal Tissue of Healthy Male Volunteers after Single and Multiple Dosing - (03/01/10)
     
  435. CROI: Antiretrovirals For Prevention: tenofovir, FTC, maraviroc; rectal, vaginal, semen. - (03/01/10)
     
  436. CROI:Maraviroc Fully Inhibits Dual-R5 Virus in Dual/Mixed HIV-1 Infected Patients - (03/01/10)
     
  437. CROI: Effect of Raltegravir-containing Intensification on HIV burden and T cell Activation in the Gut of HIV+ Adults on Suppressive Antiretroviral Therapy (ART) - reduced activation - (03/01/10)
     
  438. CROI:Nadir CD4 Count Under 350 Predicts Arterial Stiffness in Case-Control Study - written by Mark Mascolini - (02/28/10)
     
  439. CROI: Sociobehavioral Factors Affect Clinical Outcomes Apart From HIV Factors in Swiss Cohort - written by Mark Mascolini - (02/28/10)
     
  440. CROI:Darunavir Penetrates Semen Well With High Levels Through 24 Hours - written by Mark Mascolini - (02/28/10)
     
  441. CROI: Darunavir Concentrations in Seminal Plasma in patients receiving Darunavir/ritonavir(DRV/r) monotherapy: a MONOI-ANRS 136 substudy - (02/28/10)
     
  442. CROI: Darunavir Monotherapy Increased Limb Fat - Fat Tissue Distribution Changes in HIV-infected Patients with Viral Suppression Treated with Darunavir/ritonavir (DRV/r) monotherapy versus 2 NRTIs + DRV/r in the MONOI-ANRS 136 Randomized Trial : Results at 48 weeks - (02/28/10)
     
  443. CROI: Maraviroc Levels in Cerebrospinal Fluid (CSF) and Seminal Plasma from HIV-Infected Patients - (02/28/10)
     
  444. CROI: Correlates of Time-to-Loss-of-Viral-Response in CSF and Plasma in the CHARTER Cohort: CPE Score predicts CSF suppression (02/27/10)
     
  445. CROI: Neuropsychological Performance is Better in HIV-Infected Subjects Treated with Neuroactive HAART (02/27/10)
     
  446. CROI: Plasma HIV Load Strongest Predictor of CSF Load in CHARTER Cohort - written by Mark Mascolini - (02/26/10)
     
  447. CROI: Early Initiation of Antiretroviral Therapy in HIV-Infected Individuals Is Associated with Reduced Arterial Stiffness: a low nadir CD4+ T-cell counts are associated with arterial stiffness as assessed by Aix and PWV - (02/26/10)
     
  448. CROI:Inflammation Is Associated with Endothelial Dysfunction Among Individuals with Treated and Suppressed HIV Infection - (02/26/10)
     
  449. CROI:High Prevalence of Severe Vitamin D Deficiency in cART Naïve and Successfully Treated Swiss HIV Patients - (02/26/10)
     
  450. CROI: Vitamin D Deficiency and Bacterial Vaginosis among HIV-infected and -uninfected Women in the United States - (02/26/10)
     
  451. CROI:Assessment of Vitamin D Levels Among HIV-infected Persons in the Study To Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study) - (02/26/10)
     
  452. CROI: The Discovery of S/GSK1349572: A Once Daily Next Generation Integrase Inhibitor with a Superior Resistance Profile - (02/25/10)
     
  453. CROI: Positive HBV Vaccine Response Halves HIV Progression and Death Risk in US Military - written by Mark Mascolini - (02/25/10)
     
  454. CROI: Cell Studies Point to Antiinflammatory Activity of Maraviroc - written by Mark Mascolini - (02/25/10)
     
  455. CROI: Elvucitabine Versus 3TC in First-Line Regimens for 96 Weeks - see slides from poster below - written by Mark Mascolini - (02/25/10)
     
  456. CROI:Early Antiretrovirals in People Diagnosed With AIDS May Quell Inflammation Faster - written by Mark Mascolini - (02/25/10)
     
  457. CROI: The US Epidemic - Disparities in HIV Disease for African-Americans (02/25/10)
     
  458. CROI:Maraviroc (MVC) Intensification for Suboptimal CD4+ Response Despite Sustained Virologic Suppression: ACTG 5256 (02/25/10)
     
  459. CROI:CNS Toxicity of Antiretroviral Drugs (02/25/10)
     
  460. CROI:Inflammation and Mortality in HIV-infected Adults: Analysis of the FRAM Study Cohort (02/25/10)
     
  461. CROI:Effect of Atazanavir and Atazanavir/Ritonavir on the Pharmacokinetics of the Next Generation Integrase Inhibitor, S/GSK1349572 (02/25/10)
     
  462. CROI:S/GSK1349572 is a Potent Next Generation HIV Integrase Inhibitor and Demonstrates a Superior Resistance Profile Substantiated with 60 Integrase Mutant Molecular Clones (02/23/10)
     
  463. CROI:Worse Neuropsych Scores Tied to Viral Rebounds in CSF and Plasma; CPE Score Tied to CSF Rebound - written by Mark Mascolini - (02/23/10)
     
  464. CROI:Low CD4 Nadir Predicts Neurocognitive Problems Despite Good CD4 Gains - written by Mark Mascolini - (02/23/10)
     
  465. CROI: Metabolic complications of HIV infection at CROI 2010 (Feb 16-19) -Pablo Tebas, University of Pennsylvania. Philadelphia.- (02/23/10)
     
  466. CROI:Standard First Regimens Less Effective in US Blacks Than Others - written by Mark Mascolini - (02/23/10)
     
  467. Activation of CD8 T Cells Predicts Progression of HIV Infection in Women Coinfected with Hepatitis C Virus - (02/24/10)
     
  468. Can the further clinical development of bevirimat be justified? editorial - (02/24/10)
     
  469. CROI:ART Improves Cerebral Blood Flow--But Not to Levels in HIV-Negatives - written by Mark Mascolini - (02/23/10)
     
  470. CROI: Bone & Limb Fat Outcomes in ACTG5202- More Bone Loss With TDF/FTC Than ABC/3TC - written by Mark Mascolini - (02/23/10)
     
  471. CROI:Bone Fractures at CROI 2010 - see slides below - (02/23/10)
     
  472. CROI:Elevated Cancer Risks Remains in HAART Era: increasing mortality risk due to non-AIDS cancers- increased risk for these no-AIDS cancers - anal, liver, Hodgkin lymphoma, lung - (02/23/10)
     
  473. CROI:Recent CD4 Predicts Risk for Cancers; Increased Risk for Anal/liver/Hodgkin Lymphoma/oral cavity pharynx cancers in HIV+ - (02/23/10)
     
  474. CROI: Mixed Findings on Value of Brain-Penetrating Antiretroviral Scores - written by Mark Mascolini - (02/22/10)
     
  475. CROI: Bone Disease: Risk Factors - (02/22/10)
     
  476. CROI: Raltegravir Concentrations in the Cervicovaginal Compartment Exceed the Median Inhibitory Concentration in HIV-1-infected Women Treated with a Raltegravir-containing Regimen: DIVA 01 Study - (02/22/10)
     
  477. CROI: Sustained Antiretroviral Efficacy of Raltegravir after 192 Weeks of Combination ART in Treatment-Naive HIV-1 Infected Patients - (02/22/10)
     
  478. CROI: Rapid Progression of Atherosclerosis at the Carotid Bifurcation Is Linked to Inflammation in HIV-infected Patients - "These data strongly suggest that inflammation contributes to the higher risk of atherosclerosis noted in HIV-infected persons." - (02/22/10)
     
  479. CROI: CROI (2010 Feb 16-19) Selected Neurocognitive Abstracts - (02/22/10)
     
  480. CROI: Vitamin D Deficiency Prevalence and Associations - (02/22/10)
     
  481. CROI: A 48 week randomized study of uridine supplementation versus switch to tenofovir on limb fat, mitochondrial function, inflammation, and bone mineral density in HIV lipoatrophy - (02/22/10)
     
  482. CROI: Uridine supplementation in the management of HIV lipoatrophy: Results of ACTG 5229 - (02/22/10)
     
  483. CROI: Safety and Efficacy of TBR-652, a Chemokine Receptor 5 (CCR5) Antagonist, in HIV-1-Infected, Antiretroviral (ARV) Treatment-Experienced, CCR5 Antagonist-Naïve Patients - (02/22/10)
     
  484. CROI: Discovery of Potent HIV-1 Capsid Assembly Inhibitors - (02/22/10)
     
  485. CROI: T-cell Senescence and T-cell Activation Predict Carotid Atherosclerosis in HIV-infected Women - (02/22/10)
     
  486. CROI: T-Cell Activation and Senescence Linked to Carotid Lesions in HIV+ Women - written by Mark Mascolini - (02/21/10)
     
  487. CROI: Heart Risk Factors Tied to Neurocognitive Skills in SMART Substudy - written by Mark Mascolini - (02/21/10)
     
  488. CROI:Baseline Liver Disease is Independently Associated with Risk of Death among HIV/HCV co-infected Adults with Histologic Staging - (02/20/10)
     
  489. CROI:Interim Results from IMPAACT P1066: Raltegravir (RAL) Oral Chewable Tablet (OCT) Formulation in Children 6-11 Years - (02/20/10)
     
  490. CROI:High Triglycerides Independently Raise MI Risk in DAD Study - written by Mark Mascolini - (02/20/10)
     
  491. CROI: Three Years With More Than 500 CD4s Normalizes Mortality in HIV+ Men - written by Mark Mascolini - (02/20/10)
     
  492. CROI:Life Expectancy Approaches Normal in Dutch Without HIV Symptoms - written by Mark Mascolini - (02/20/10)
     
  493. CROI: Chronic HIV and HCV Swell Stroke Risk in Veterans Aging Cohort - written by Mark Mascolini - (02/20/10)
     
  494. CROI: Fast ART in Late Disease Means Slower Progression in Europe and Canada - written by Mark Mascolini - (02/20/10)
     
  495. CROI:Heart Risk Falls With Time Since Quitting Smoking in DAD - written by Mark Mascolini - (02/20/10)
     
  496. CROI: Metabolic Profiles and Body Composition Changes in Treatment-Naïve HIV-Infected Patients Treated with Raltegravir 400 mg bid-based vs. Efavirenz 600 mg qhs-based Combination Therapy: 96-Week Follow-Up - (02/20/10)
     
  497. CROI:Chronic kidney disease and exposure to ARTs in a large cohrt with long-term follow-up: EuroSida - (02/20/10)
     
  498. CROI: Bone & Limb Fat Outcomes in ACTG5202 Substudy: abacavir/3TC, tenofivir/FTC, efavirenz, atazanavir/r - (02/20/10)
     
  499. CROI: Inflammation and Fibrosis Markers Tied to AIDS or Death After Good Virologic Response - written by Mark Mascolini - (02/19/10)
     
  500. CROI:Inflammation Tied to Endothelial Dysfunction Despite Tight HIV Control - written by Mark Mascolini - (02/19/10)
     
  501. CROI:Antiretroviral Risk Factors for Kidney Disease in EuroSIDA: Tenofovir Is Not Alone - written by Mark Mascolini - (02/19/10)
     
  502. CROI:Most Non-AIDS Cancers Not Diagnosed at Earlier Age in People With AIDS - written by Mark Mascolini - (02/19/10)
     
  503. CROI:HIV Load Tied to Fibrosis Signal in Women Without Hepatitis or Alcohol Abuse - written by Mark Mascolini - (02/19/10)
     
  504. CROI: QUAD Four-in-One Pill as Strong as Atripla, But a Kidney Concern Arises - written by Mark Mascolini - (02/18/10)
     
  505. CROI: Maraviroc Does Not Boost Stalled CD4s in Virologically Suppressed People - written by Mark Mascolini - (02/18/10)
     
  506. CROI: Vicriviroc Does Not Outdo Placebo Regimen in Phase 3 Trials - written by Mark Mascolini - (02/18/10)
     
  507. CROI: Older Age, Lower CD4 Nadir, NNRTI Use Predict Slow CD4 Recovery in ATHENA - written by Mark Mascolini - (02/18/10)
     
  508. CROI: High Rate of Coronary Artery Problems in Young People Tied to TDF/FTC - written by Mark Mascolini - (02/18/10)
     
  509. CROI: Low-Level Viremia Quadruples Death Risk in Canadian Cohort Study - written by Mark Mascolini - (02/18/10)
     
  510. CROI: Side Effect and CD4 Differences in Four ACTG 5202 Arms at 96 Weeks - written by Mark Mascolini - (02/18/10)
     
  511. CROI: RNA Spikes Predict Heart Disease, CD4s Predict Liver and Kidney Disease - written by Mark Mascolini - (02/18/10)
     
  512. CROI: ODIN: efficacy and safety at 48 weeks of once-daily versus twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients with no darunavir resistance-associated mutations - (02/18/10)
     
  513. CROI: Bristol-Myers Squibb Media Statement on ACTG 5202 - (02/18/10)
     
  514. CROI: ACTG5202 - (02/11/10)
     
  515. CROI: New Data on ISENTRESS (raltegravir) Presented at the Conference on Retroviruses and Opportunistic Infections (CROI) - Merck announcement - (02/18/10)
     
  516. CROI: Bristol-Myers Squibb Media Statement on ACTG 5202 - (02/18/10)
     
  517. CROI: The Single-Tablet, Fixed-Dose Regimen of Elvitegravir/GS-9350/Emtricitabine/Tenofovir DF (Quad) Achieves a High Rate of Virologic Suppression and GS-9350 is an Effective Booster - (02/18/10)
     
  518. Aciclovir reduced risk of HIV-1 disease progression by 16% - (02/15/10)
     
  519. Treating HIV infection with drugs for HSV-2 infection? Commentary - (02/15/10)
     
  520. Early Immune Senescence in HIV Disease - (02/15/10)
     
  521. Barriers To Retention in Care in HIV and HCV - (02/10/10)
     
  522. FDA approves expanded rosuvastatin label, Includes CRP - (02/10/10)
     
  523. Neurologic Disease Despite Undetectable Viral Load & The Use of Drugs That Penetrate Well the CSF - pdf of full article attached - (02/08/10)
     
  524. Effects of Tesamorelin, a Growth Hormone-Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension - pdf attached - (02/08/10)
     
  525. HIV Brain Impairment - (02/08/10)
     
  526. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis - (02/08/10)
     
  527. C-reactive protein and cardiovascular risk: more fuel to the fire - Comment - (02/08/10)
     
  528. Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were HIV-infected in utero - (02/08/10)
     
  529. Immunosupportive therapies in aging - pdf attached - (02/05/10)
     
  530. The rate of mother-to-child HIV transmission among infants is 23 times higher for blacks than whites, the CDC reported. - (02/05/10)
     
  531. Bone Loss in HIV+ Premenopausal Women & Fracture Risk - (02/04/10)
     
  532. Protein in Urine Presages More Severe Problems - free full text link below - (02/04/10)
     
  533. Hepatitis C and the Risk of Kidney Disease and Mortality in Veterans With HIV: "veterans coinfected with HCV have significantly higher rates of CKD and mortality" - (02/04/10)
     
  534. Impairments in memory and hippocampal function in HIV-positive vs HIV-negative women (and men) - (01/29/10)
     
  535. NYS AIDS Institute guidelines on Acute HIV Seroconversion Updated Jan 2010 - (01/28/09)
     
  536. 11th Wrkshp Adverse Drug Reactions Co-morbidities: Key data from the 11th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV - Workshop report - (01/28/10)
     
  537. Life Expectancy & Comorbidities in HIV: - (01/27/09)
     
  538. Diagnosis and management of vitamin D deficiency - (01/27/09)
     
  539. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations:a nested case-control study - (01/27/09)
     
  540. Performance of anal cytology in a clinical setting when measured against histology and high-resolution anoscopy findings - (01/27/09)
     
  541. The anal Pap test as a screening tool- EDITORIAL - (01/27/09)
     
  542. Kidney function and the risk of cardiovascular events in HIV-1-infected patients - (01/27/09)
     
  543. High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor and HIV protease inhibitors - (01/27/09)
     
  544. Medication-assisted treatment and HIV/AIDS: aspects in treating HIV-infected drug users - (01/27/09)
     
  545. Incidence and Risk Factors for Chronic Elevation of Alanine Aminotransferase Levels in HIV-Infected Persons without Hepatitis B or C Virus Co-Infection - (01/27/09)
     
  546. Vicriviroc Effective in Treatment-Experienced Patients in Phase 2 Study VICTOR-E1 - (01/26/09)
     
  547. Proinflammatory IL-18 Increased in HIV+ Despite HAART - (01/26/09)
     
  548. Incidence and Risk Factors for Chronic Elevation of Alanine Aminotransferase Levels in HIV-Infected Persons without Hepatitis B or C Virus Co-Infection - (01/26/09)
     
  549. The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters in SMART - (01/25/09)
     
  550. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction - (01/25/09)
     
  551. HIV Infection and Aging Independently Affect Brain Function as Measured by Functional Magnetic Resonance Imaging - BRIEF REPORT - (01/25/09)
     
  552. Estimating the proportion of patients infected with HIV who will die of comorbid diseases - pdf attached - (01/20/09)
     
  553. Fish Oil Slows Telomere Aging - (01/20/09)
     
  554. Hormonal Contraception and Metabolic Outcomes in Women With or at Risk for HIV Infection - (01/19/09)
     
  555. HIV Life Expectancy Study Published - pdf attached - (01/19/09)
     
  556. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies - (01/19/09)
     
  557. Epidemiology of Hepatitis B Virus Infection in a US Cohort of HIV-Infected Individuals during the Past 20 Years - (01/17/09)
     
  558. Aerobic Exercise Improved Cognitive Function in Older Adults with Mild Cognitive Impairment - (01/17/09)
     
  559. Moderate Mid-Life Exercise Prevents Mild Cognitive Impairment - (01/17/09)
     
  560. Will HIV Drug Resistance Rates Increase? Improved Virological Outcomes in British Columbia Concomitant with Decreasing Incidence of HIV Type 1 Drug Resistance Detection - (01/17/09)
     
  561. Treatment of HIV-Related Inflammatory Cerebral Cryptococcoma with Adalimumab - brief report - (01/17/09)
     
  562. Quality-Of-Life Predicts Survival in HIV: HIV & aging - (01/17/09)
     
  563. The MONET trial: darunavir/ritonavir (monotherapy) with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml - (01/16/09)
     
  564. Visceral Fat Causes Inflammation and Cytokines Leading To Bone Loss - (01/16/09)
     
  565. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men - (01/15/09)
     
  566. Antihypertensive agents and prevention of dementia - Editorial - (01/14/09)
     
  567. Hypertension Medications Use To Prevent Dementia & Alzheimer's - (01/14/09)
     
  568. Study: Certain hypertension drugs may reduce Alzheimer's risk - (01/14/09)
     
  569. Raltegravir SWITCHMRK Study Published in The Lancet jan 13 2010 - publication pdf attached - (01/14/09)
     
  570. Association of C-Reactive Protein With Cognitive Impairment - (01/13/09)
     
  571. GS-9148 Nucleotide Active Against Resistance - (01/13/09)
     
  572. Chloroquine To Block Immune Activation - pdf attached - (01/13/09)
     
  573. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study - BMJ Jan 2010 - (01/12/09)
     
  574. Update on HIV Eradication.... Report from the 4th HIV Persistence Intl Wksp (Dec 8-11 2009, David Margolis, MD - written by David Margolis MD, University of North Carolina at Chapel Hill - (01/12/09)
     
  575. Investigational HIV agents for salvage - (01/11/09)
     
  576. HIV-Infected Postmenopausal Women at High Risk for Bone Fractures - pdf publication attached - (01/11/09)
     
  577. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa - (01/10/09)
     
  578. Cardiac Risk: Not So Simple - EDITORIAL COMMENTARY D.A.D Study - (01/10/09)
     
  579. Pioglitazone Compared with Metformin Increases Pericardial Fat Volume in Patients with Type 2 Diabetes Mellitus - (01/10/09)
     
  580. Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes - publication pdf attached - (01/10/09)
     
  581. Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients - (01/10/09)
     
  582. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa - (01/07/09)
     
  583. Low-Frequency K103N Strengthens the Impact of Transmitted Drug Resistance on Virologic Responses to First-Line Efavirenz or Nevirapine-Based Highly Active Antiretroviral Therapy - (01/07/09)
     
  584. hsCRP/inflammation & CVD in Patients with with low Framingham risk score & median CD4 of 500 & <50 HIV RNA - (01/07/09)
     
  585. (EPO) Erythropoiesis-Stimulating Agents - Time for a Reevaluation - (01/07/09)
     
  586. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa - (01/05/09)
     
  587. Many Americans Have Pre-Diabetes and Should Be Considered for Metformin Therapy - (01/05/09)
     
  588. Delay in Diagnosis of Diabetes Is Not the Patient's Fault - (01/05/09)
     
  589. Comparison of A1C and Fasting Glucose Criteria to Diagnose Diabetes Among U.S. Adults - (01/05/09)
     
  590. CD4 Recovery Severely Blunted After HAART Treatment Interruption - (01/05/09)
     
  591. CCR5 Deficiency Is a Risk Factor for Early Clinical Manifestations of West Nile Virus Infection but not for Viral Transmission - (12/29/09)
     
  592. Double-Edged Genetic Swords and Immunity: Lesson from CCR5 and Beyond EDITORIAL COMMENTARY - (12/29/09)
     
  593. Impact of Tenofovir on Renal Function in HIV-Infected, Antiretroviral-Naive Patients - (12/29/09)
     
  594. A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease - (12/29/09)
     
  595. Bypass Anemia Drugs in Chronic Kidney Disease, Expert Says - (12/29/09)
     
  596. Treatment of Anemia in Chronic Kidney Disease - Strategies Based on Evidence EDITORIAL - (12/29/09)
     
  597. Gender & Racial Differences in Discontinuation of HAART JAIDS Nov 2009 - (12/23/09)
     
  598. Factors Associated with HCV Transmission from Male to Female with No IDU History in WIHS - (12/23/09)
     
  599. Enhanced Reyataz & Efavirenz Co-Pay Benefit Program - (12/21/09)
     
  600. Testosterone: More Is Not Always Better - EDITORIAL - (12/21/09)
     
  601. Thyroid Function and Longevity: New Insights into an Old Dilemma - EDITORIAL - (12/21/09)
     
  602. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals - (12/17/09)
     
  603. White House Community Discussions in 14 Cities Videos - (12/17/09)
     
  604. EACS: Feedback Reports (clinical, translational) from the 11th International Workshop on Adverse Drug reactions and Co-morbidities in HIV reported at EACS 2009 Cologne (2) - (11/20/09)
     
  605. Paying the Price for Late Starts and Early Stops: Racial and Sex Disparities in HIV-Related Mortality - EDITORIAL COMMENTARY - (12/15/09)
     
  606. Racial and Sex Disparities in Life Expectancy Losses among HIV-Infected Persons in the United States: Impact of Risk Behavior, Late Initiation, and Early Discontinuation of Antiretroviral Therapy - (12/15/09)
     
  607. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men (AIDS Dec 7 2009)-- pdf full text attached for you to download - (12/14/09)
     
  608. EACS: The Impact of Maraviroc on Insulin Sensitivity, Lipids and Adipokines after 2 weeks in HIV Negative Male Volunteers - (12/10/09)
     
  609. EACS: Pros and Cons of Boosted PI Monotherapy - (12/10/09)
     
  610. Mediterranean Diet and Late-Life Cognitive Impairment -Editorial - (12/09/09)
     
  611. Physical Activity, Diet, and Risk of Alzheimer Disease: In this study, both higher Mediterranean-type diet adherence and higher physical activity were independently associated with reduced risk for AD. - (12/09/09)
     
  612. New Changes in DHHS Guidelines- HAART Recommended Earlier in HIV; new What To Start; DHHS Reasons for Changes - (12/04/09)
     
  613. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial - (12/04/09)
     
  614. Updated European (EACS) & USA Treatment Guidelines (DHHS) - (12/04/09)
     
  615. 11th Wrkshp Adverse Drug Reactions Co-morbidities: Framingham Risk and Lipoprotein Changes after 24 Weeks of Treatment with Abacavir/Lamivudine (ABC/3TC) and Raltegravir (RAL) in Antiretroviral-Naive HIV-1 Infected Subjects - (12/03/09)
     
  616. Physical Exercise Prevents Cellular Senescence in Circulating Leukocytes and in the Vessel Wall - (12/01/09)
     
  617. When and how to use maraviroc in HIV-infected patients - (12/01/09)
     
  618. New WHO HIV recommendations on HIV ART treatment, prevention & infant feeding to improve health, reduce infections and save lives - (12/01/09)
     
  619. Long-Term Evolution and Determinants of Renal Function in HIV-Infected Patients Who Began Receiving Combination Antiretroviral Therapy in 1997-1999, ANRS CO8 APROCO-COPILOTE - BRIEF REPORT - (11/30/09)
     
  620. Low Bone Mineral Density, Renal Dysfunction, and Fracture Risk in HIV Infection: A Cross-Sectional Study - (11/30/09)
     
  621. EACS: New EACS (European AIDS Clinical Society) HIV Guidelines: HIV treatment, comorbidities (prevention and management of metabolic diseases), management and treatment of chronic hepatitis B and C coinfection in HIV+
     
  622. IAS: HIV-1 INFECTION IN SUBJECTS OLDER THAN 70: A MULTICENTER CROSS-SECTIONAL ASSESSMENT IN CATALONIA, SPAIN - (11/29/09)
     
  623. EACS: The ARTEN study: 48 week efficacy data stratified by screening viral load and CD4+ cell count - (11/30/09)
     
  624. EACS: Pharmacokinetic interaction study between TMC278,an NNRTI, and the contraceptives norethindrone plus ethinylestradiol - (11/30/09)
     
  625. EACS: Absorption, metabolism and excretion of TMC278, an NNRTI, after a single oral dose of 150mg in healthy male volunteers - (11/30/09)
     
  626. EACS: Absence of a teratogenic potential from a novel next-generation NNRTI, TMC278 - (11/24/09)
     
  627. EACS: TMC278 25mg qd has no effect on corrected QT interval in a study in HIV-negative volunteers - (11/24/09)
     
  628. EACS: Framingham Risk and Lipoprotein Changes after 24 Weeks of Treatment with Abacavir/Lamivudine (ABC/3TC) and Raltegravir (RAL) in Antiretroviral-Naive HIV-1 Infected Subjects - (11/30/09)
     
  629. EACS: A Pilot Study of Abacavir/Lamivudine (ABC/3TC) and Raltegravir (RAL) in Antiretroviral Naive HIV-1 Infected Subjects - (11/30/09)
     
  630. EACS: Detrimental effect of current patient-reported drug holidays on long-term sub-optimal treatment out-come in advanced naive subjects initiating cART - (11/30/09)
     
  631. EACS: Association of effectiveness and adherence of antiretroviral treatment - (11/30/09)
     
  632. EACS: Impact of different types of adherence behaviours and of cART characteristics on plasma HIV-1 RNA detection under lower limit of quantification at real-time assay - (11/30/09)
     
  633. EACS: Moving from risk factor assessment to atherosclerosis imaging to select the most appropriate patient for primary prevention: CVD algorithms underestimate risk in HIV+ - (11/30/09)
     
  634. Oral Gonorrhea for Men & Women: pharynx a reservoir for gonorrhea - (11/24/09)
     
  635. Chlamydia trachomatis and Neisseria gonorrhoeae Transmission from the Oropharynx to the Urethra among Men Who Have Sex with Men - (11/24/09)
     
  636. FDA Approves Expanded Use of Selzentry for Appropriate Patients Starting HIV Antiretroviral Therapy for the First Time - (11/24/09)
     
  637. EACS: Adherence to and quality of life of a one-pill once-a-day HAART (Atripla). Results of the ADONE study - (11/24/09)
     
  638. EACS: The Effect of Antiretroviral Therapy Without CCR5-Antagonists on HIV-1 Tropism in the MOTIVATE Studies of Maraviroc in Treatment-Experienced Patients With R5 HIV-1 - (11/24/09)
     
  639. EACS: Safety Profile of HIV-1 Patients Co-Infected With Hepatitis B or C in the Maraviroc Expanded Access Program - (11/24/09)
     
  640. EACS: ASSESSMENT OF THE STEADY STATE PK PARAMETERS OF TWO EXTENDED RELEASE (XR) NEVIRAPINE (NVP) TABLETS 400 MG AND 300 MG QD COMPARED WITH IMMEDIATE RELEASE (IR) NVP TABLETS 200 MG BID IN HIV-1 INFECTED PATIENTS - THE ERVIR STUDY - (11/24/09)
     
  641. EACS: Gender-Based Differences in Antiretroviral-Naïve Patients Treated With Ritonavir-Boosted Protease Inhibitors: Results From the CASTLE Study Through 96 Weeks - (11/24/09)
     
  642. EACS: Feedback Reports (clinical, translational) from the 11th International Workshop on Adverse Drug reactions and Co-morbidities in HIV reported at EACS 2009 Cologne - (11/20/09)
     
  643. EACS: Viral Load Over 50 and Low CD4/CD8 Ratio Hoist MI Risk in French Cohort - Written Mark Mascolini - (11/20/09)
     
  644. EACS: Risk of Cardiovascular Disease in ART-Naive People Without Heart Symptoms, Carotid Artery Ultrasonography May Be Useful - Written Mark Mascolini - (11/20/09)
     
  645. EACS: Abdominal Adiposity Not Waning With Newer Antiretrovirals in France - Written Mark Mascolini - (11/20/09)
     
  646. EACS: Metabolic Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analogue, in HIV-infected Patients with Excess Abdominal Fat over a Period of 52 Weeks. A Pooled Analysis of 2 Multicenter, Double- blind, Placebo-controlled Phase 3 Trials with 816 Randomized Patients - (11/20/09)
     
  647. EACS: "Deep" Sequencing to Identify Treatment-Experienced Patients Who Respond to Maraviroc (MVC) - (11/20/09)
     
  648. EACS: Optimization of Clinically Relevant Cutpoints for the Determination of HIV Co-Receptor Usage to Predict Maraviroc Responses in Treatment Experienced (TE) Patients Using Population V3 Genotyping - (11/20/09)
     
  649. EACS: Improved Treatment Compliance with Once-Daily (QD) Compared to Twice-Daily (BID) Lopinavir/ritonavir (LPV/r) in HIV-1-Infected, Antiretroviral-Experienced Subjects - (11/20/09)
     
  650. EACS: Impact of Baseline Resistance on Virologic Outcome with Once-Daily (QD) or Twice-Daily (BID) Lopinavir/ritonavir (LPV/r) through 48 Weeks of Combination Antiretroviral Therapy in Treatment-Experienced, HIV-1-Infected Subjects - (11/20/09)
     
  651. EACS: Diagnosis and management of cognitive disorders during successful HIV treatment - (11/20/09)
     
  652. EACS: Simplified Antiretroviral Therapy in Special Populations: Clinical Outcomes at Week 48 of Lopinavir/ritonavir (LPV/r) Tablet Dosed Once Daily (QD) or Twice Daily (BID), Administered with ≥2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in Antiretroviral-experienced Subjects, Analyzed by Gender, Age, Race, Ethnicity, and Hepatitis Co-infection Status (Study M06-802) - (11/18/09)
     
  653. EACS: Etravirine demonstrates a favourable safety and tolerability profile versus placebo irrespective of hepatitis co-infection: Week 96 analysis from the DUET trials - (11/24/09)
     
  654. EACS: Kaletra QD Resistance Report: Lopinavir/ritonavir (LPV/r) with Tenofovir DF (TDF) and Emtricitabine (FTC) in Antiretroviral (ARV)-naïve Subjects - (11/18/09)
     
  655. EACS: Etravirine demonstrates a favourable safety and tolerability profile: pooled 96-week results from the Phase III DUET trials - (11/18/09)
     
  656. EACS: Safety and pharmacokinetics of etravirine in pregnant HIV-infected women - (11/18/09)
     
  657. EACS: Tesamorelin Health-Related Quality of Life in HIV+ regarding belly and weight image - (11/18/09)
     
  658. EACS: MIs, Cocaine/IVDUs French Database - (11/17/09)
     
  659. EACS: S/GSK1349572 Integrase Inhibitor Resistance Profile - (11/17/09)
     
  660. EACS: Potent Antiviral Activity of GSK Integrase S/GSK1349572 - (11/17/09)
     
  661. EACS: A Phase II, open-label trial in treatment-naive, HIV-1-infected patients who received DRV/r as induction monotherapy - (11/17/09)
     
  662. EACS: Twice Daily Darunavir to Replace Dual Boosted Protease Inhibitors in Virologically Suppressed Patients - (11/17/09)
     
  663. EACS: Simplification with fixed-dose tenofovir-emtricitabine or abacavir-lamivudine in adults with HIV infection: meta-analysis of two randomised, non-inferiority trials BICOMBO and STEAL - (11/17/09)
     
  664. EACS: Fatty Liver in HIV & HCV - (11/17/09)
     
  665. EACS: A Phase II, open-label trial in treatment-naïve, HIV-1-infected patients who received DRV/r as induction monotherapy - (11/15/09)
     
  666. EACS: Darunavir Maintenance Monotherapy - (11/15/09)
     
  667. EACS: Comparison of lipid profile with nevirapine versus atazanavir/ritonavir, both combined with tenofovir DF and emtricitabine (TDF/FTC), in treatment-naïve HIV-1 infected patients: ARTEN Study Week 48 results - (11/15/09)
     
  668. EACS: Body Composition Changes in Treatment-Naive Patients Treated with Boosted Protease Inhibitors Plus Tenofovir/Emtricitabine: Results From the CASTLE Study Through 96 Weeks - (11/15/09)
     
  669. EACS: Assessment of Safety and Efficacy of Abacavir/Lamivudine and Tenofovir/Emtricitabine in Treatment-Naïve HIV-1 Infected Subjects ASSERT: 48-Week Result - (11/15/09)
     
  670. EACS: Once-Daily Dosing Ups Risk of Stopping Antiretrovirals in Single-Clinic Study - written by Mark Mascolini - (11/15/09)
     
  671. EACS: Lower Intracellular Carbovir (Abacavir) Levels With Darunavir/Ritonavir - written by Mark Mascolini - (11/15/09)
     
  672. EACS: Darunavir Troughs Lower With Raltegravir in Cross-Sectional Study - written by Mark Mascolini - (11/15/09)
     
  673. EACS: More Evidence of Low Vitamin D in People Taking Antiretrovirals - written by Mark Mascolini - (11/15/09)
     
  674. EACS: Study of Once-Daily Boosted Darunavir Monotherapy as First-Line Therapy Had Difficulty - written by Mark Mascolini - (11/15/09)
     
  675. EACS: Multicohort Study Confirms Continuing Hodgkin Lymphoma Risk With HAART - written by Mark Mascolini - (11/15/09)
     
  676. EACS: Good 4-Year HIV Response in People Over 60, But High Cancer and Heart Disease Rates - written by Mark Mascolini - (11/15/09)
     
  677. EACS: Later Year and Age Over 50 Tied to Better Response After Triple-Class Failure - written by Mark Mascolini - (11/15/09)
     
  678. EACS: Hodgkin Lymphoma, Liver Cancer, Anal Cancer More Common With HIV - written by Mark Mascolini - (11/13/09)
     
  679. EACS: Mortality High With Non-AIDS Cancers in EuroSIDA Despite HAART - written by Mark Mascolini - (11/13/09)
     
  680. EACS: More Than Half in HIV Patient Series Carry High-Risk Human Papillomavirus - written by Mark Mascolini - (11/13/09)
     
  681. EACS: Rough Group Sex--Not Just Anal Sex--May Explain HCV Epidemic in HIV+ Gays - written by Mark Mascolini - (11/13/09)
     
  682. EACS: MONET Paints Noninferiority Picture With Darunavir/Ritonavir Monotherapy - written by Mark Mascolini - (11/13/09)
     
  683. EACS: Twice-Daily Darunavir/Ritonavir to Replace Double-Boosted PIs - written by Mark Mascolini - (11/13/09)
     
  684. Aging is a significant risk factor for cognitive impairment. As the HIV cohort ages, further investigation is needed into the effects of aging on HIV cognitive impairment. - (11/10/09)
     
  685. ViiV Healthcare Launches: GSK/Pfizer New HIV Company - (11/10/09)
     
  686. AASLD: HCV/MSM Sex Transmission in HIV+ in New York City - (11/05/09)
     
  687. IDSA: 144Week Efficacy & Safety of Raltegravir in TreatmentExperienced Patients, TripleClass Resistant - (11/01/09)
     
  688. IDSA: (IDSA) TMC278 25mg qd has no effect on corrected QT interval in HIV-negative volunteers - (11/01/09)
     
  689. IDSA: (IDSA) Predictors of Response in GRACE (Gender, Race And Clinical Experience) - (11/01/09)
     
  690. IDSA: (IDSA) Darunavir, Ritonavir, and Etravirine Steady-state Pharmacokinetics in the Cervicovaginal Fluid and Blood Plasma of HIV-infected Women Enrolled in the GRACE Study - (11/01/09)
     
  691. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study - (11/01/09)
     
  692. How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials - (11/01/09)
     
  693. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials - (11/01/09)
     
  694. Characteristics of non-Hodgkin lymphoma arising in HIV-infected patients with suppressed HIV replication - (11/01/09)
     
  695. Role of metabolic syndrome components in HIV-associated sensory neuropathy - (11/01/09)
     
  696. HIV infection and the risk of cancers with and without a known infectious cause - (11/01/09)
     
  697. 11th Wrkshp Adverse Drug Reactions Co-morbidities: Both once-daily saquinavir / ritonavir and atazanavir / ritonavir, when combined with tenofovir / emtricitabine conserve adipose tissue, only modestly affect lipids and exhibit similar mild reductions in glomerular filtration rate over 48 weeks: the BASIC trial - (10/28/09)
     
  698. 11th Wrkshp Adverse Drug Reactions Co-morbidities: Comparison of lipid profile with nevirapine versus atazanavir/ritonavir, both combined with tenofovir DF and emtricitabine (TDF/FTC), in treatment-naive HIV-1 infected patients: ARTEN Study Week 48 results - (10/28/09)
     
  699. 11th Wrkshp Adverse Drug Reactions Co-morbidities: Neuropsychiatric adverse events in the MONET trial: darunavir/ritonavir with and without nucleoside analogues for patients with HIV RNA <50 copies/mL at screening - (10/27/09)
     
  700. 11th Wrkshp Adverse Drug Reactions Co-morbidities: Correlation between laboratory parameters and use or discontinuation of nucleoside analogues in the MONET trial - (10/27/09)
     
  701. 11th Wrkshp Adverse Drug Reactions Co-morbidities: 48 week changes in Quality of Life and adherence in the MONET trial: darunavir/ritonavir with and without nucleoside analogues for patients with HIV RNA <50 at screening - (10/27/09)
     
  702. Cardiovascular Diseases and Risk of Hip Fracture - (10/27/09)
     
  703. ACG: ACE Inhibitor Use Linked to Liver Toxicity - (10/27/09)
     
  704. Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapy-Experienced Patients with HIV Infection in North America - (10/27/09)
     
  705. Transmission of Drug-Resistant HIV-1 Is Stabilizing in Europe - BRIEF REPORT - (10/27/09)
     
  706. HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy - (10/25/09)
     
  707. CDC Updated Oct 21 Interim Recommendations for H1N1 Influenza for HIV-Infected Adults and Adolescents - (10/25/09)
     
  708. Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection - (10/25/09)
     
  709. Raltegravir, Etravirine, and Ritonavir-Boosted Darunavir: A Safe and Successful Rescue Regimen for Multidrug-Resistant HIV-1 Infection - (10/25/09)
     
  710. Increased Peripheral Proinflammatory Cytokines in HIV-1-Infected Patients With Prolonged Viral Suppression Suffering From High Psychological Stress - (10/25/09)
     
  711. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand - (10/20/09)
     
  712. HIV Vaccine Trial Results - An Opening for Further Research EDITORIAL - (10/20/09)
     
  713. Adverse health effects of non-medical cannabis use - (10/17/09)
     
  714. High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment-Experienced Patients Infected with Multidrug-Resistant HIV: Results of the ANRS 139 TRIO Trial - (10/16/09)
     
  715. IL-2 in HIV: associated with vascular events, inflammation, and no clinical benefit despite CD4 increase - (10/16/09)
     
  716. New Approach To Targeting The Hidden Reservoir Of HIV: Siliciano Can Screen Compounds with new system - (10/16/09)
     
  717. Bone Loss in HCV/HIV Coinfection - (10/16/09)
     
  718. ICAAC:TBR-652, A CHEMOKINE RECEPTOR 5 (CCR5) ANTAGONIST, DEMONSTRATES GOOD ORAL BIOAVAILABILITY AND DESIRABLE PHARMACOKINETIC (PK) AND SAFETY PROFILES IN HEALTHY VOLUNTEERS - (10/13/09)
     
  719. ICAAC: IN VITRO ANTI-HIV EFFICACY OF THE CHEMOKINE RECEPTOR 5 (CCR5) ANTAGONIST TBR-652 IN COMBINATION WITH FOUR OTHER CLASSES OF ANTIRETROVIRAL AGENTS - (10/13/09)
     
  720. Target HbA1c levels still the subject of much debate, but tailored therapy should be the aim - (10/12/09)
     
  721. Clumsy FDA Antiviral Advisory Committee (Maraviroc hearing) for both HIV & HCV in the future - (10/12/09)
     
  722. Screening colonoscopy for the detection of neoplastic lesions in asymptomatic HIV-infected subjects: more colon lesions in HIV+ - (10/09/09)
     
  723. FDA Antivirals Advisory Panel Recommends Maraviroc for Naives Approval 10-4 - (10/09/09)
     
  724. "Current CD4 cell count was the most predictive risk factor for all malignancies apart from anal cancer" - - (10/09/09)
     
  725. Diabetes Can Impair Exercise Capacity: Abnormal oxygen uptake kinetic responses in women with type II diabetes mellitus - (10/07/09)
     
  726. Subcutaneous (lipoatrophy) Rather than Visceral Adipose Tissue Is Associated with Adiponectin Levels and Insulin Resistance in Young Men - (10/07/09)
     
  727. Sex Hormones and Frailty in Older Men: The Osteoporotic Fractures in Men (MrOS) Study - (10/07/09)
     
  728. Frontostriatal fiber bundle compromise in HIV infection without dementia - (10/06/09)
     
  729. Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels - (10/06/09)
     
  730. Persistent HIV RNA shedding in semen despite effective antiretroviral therapy - (10/06/09)
     
  731. New Approach To Targeting The Hidden Reservoir Of HIV - (10/05/09)
     
  732. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial - (10/04/09)
     
  733. Fall Prevention: how much vitamin D do you need? - (10/04/09)
     
  734. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial - (10/04/09)
     
  735. Doctors Prescribe Caution With Insulin's Cancer Ties - (10/04/09)
     
  736. ICAAC: HIV-Associated Neurocognitive Disorders in the Era of Potent Antiretroviral Therapy: risk factors/prevalence, CSF HIV-RNA, HCV, ART PK/penetration, assessment tools - (10/04/09)
     
  737. Lipoatrophy & Mortality, CVD - (09/30/09)
     
  738. A1C Underestimates Glycemia in HIV Infection - (09/30/09)
     
  739. Diabetes 2 Caused Brain Atrophy in Older Individuals - (09/30/09)
     
  740. Vitamin D Improves Muscle Function - (09/29/09)
     
  741. The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells (HIV eradication) - (09/29/09)
     
  742. Renal function with use of a tenofovir-containing initial antiretroviral regimen - (09/29/09)
     
  743. CCR5 antagonism in HIV infection: ways, effects, and side effects - (09/29/09)
     
  744. Evaluation of Adherence and Factors Affecting Adherence to Combination Antiretroviral Therapy Among White, Hispanic, and Black Men in the MACS Cohort - (09/29/09)
     
  745. Efavirenz Dose Reduction Is Safe in Patients With High Plasma Concentrations and May Prevent Efavirenz Discontinuations - (09/29/09)
     
  746. Pharmacokinetics and Safety of Etravirine Administered Once or Twice Daily After 2 Weeks Treatment With Efavirenz in Healthy Volunteers - (09/29/09)
     
  747. Incidence of Non-AIDS-Defining Malignancies Higher in HIV-Infected Versus Noninfected Patients in the HAART Era: Impact of Immunosuppression - (09/26/09)
     
  748. ICAAC: Acute HBV & HCV Infection Among MSM: CDC Data from Population-Based Surveillance, 2006-2008 - (09/25/09)
     
  749. Serum Immune Activation Markers Are Persistently Increased in Patients with HIV Infection after 6 Years of Antiretroviral Therapy despite Suppression of Viral Replication and Reconstitution of CD4+ T Cells - (09/25/09)
     
  750. ICAAC: Differential Effects of Maraviroc (MVC) and Efavirenz (EFV) on Markers of Immune Activation (IA) and Inflammation and Their Association with CD4 Cell Rises: A Sub-analysis of the MERIT (09/21/09)
     
  751. ICAAC: MERIT: Week 96 Virologic Response and Tropism at Virologic Failure by Baseline CD4+ Cell Count (09/21/09)
     
  752. ICAAC: Maraviroc (MVC) is Similar to Efavirenz (EFV) for Virologic Response (VR) Across Subgroups: MERIT 96-Week (09/21/09)
     
  753. Tenofovir Gel & Tablets PrEP Study: Clinical Trial of Antiretroviral-based HIV Prevention Strategies for Women Now Under Way (study in 5,000 women) - (09/21/09)
     
  754. ICAAC:Renal Disease in Diabetics with HIV: "higher rate of microalbuminuria than either HIV-positive patients without diabetes or diabetics without HIV infection" - (09/21/09)
     
  755. National HIV/AIDS and Aging Awareness Day (09/20/09)
     
  756. ICAAC: Safety and Effectiveness of Raltegravir-based HAART in HIV-Subjects after Solid Organ Transplantation (09/20/09)
     
  757. ICAAC: 24 Week Safety and Efficacy from IMPAACT P1066: A Phase I/II, Multicenter, Open-Label, Noncomparative Study to Evaluate Raltegravir (RAL) in HIV-1 Infected Youth (09/20/09)
     
  758. National HIV/AIDS and Aging Awareness Day (09/20/09)
     
  759. ICAAC: Phenotypic Screening for HIV Tropism versus both Population-based and "Deep" Sequencing (09/20/09)
     
  760. ICAAC: Direct comparison with 454 pyrosequencing validates V3-loop based genotyping in patients eligible for Maraviroc initiation (09/20/09)
     
  761. ICAAC: Prediction of HIV Disease Progression Using a Modification of the Enhanced Sensitivity (ES) Trofile Assay (09/20/09)
     
  762. ICAAC:Prevalence of HIV-1 CCR5 Co-Receptor Tropism Differs by Env (gp41) Subtype in a Large Commercial Dataset (09/20/09)
     
  763. ICAAC: The composition of dual-mixed HIV-1 populations can be discerned from the level of CXCR4-mediated infectivity (09/20/09)
     
  764. ICAAC: Incorporation of Optimized Primers into the Trofile Assay Substantially Improves Determination of Viral Tropism in Genetically Diverse HIV Subtypes (09/20/09)
     
  765. ICAAC: "Deep" Sequencing to Quantify in vivo Viral Fitness after Transmission of Resistant HIV (09/20/09)
     
  766. ICAAC:Raltegravir in CSF: "Raltegravir Concentrations in CSF Exceed The Median Inhibitory Concentration" (09/20/09)
     
  767. ICAAC: Darunavir in the CSF: "Darunavir Concentrations in CSF Exceed The Median Inhibitory Concentration" (09/20/09)
     
  768. ICAAC: ART Helps Bring Lungs Up to Par in Nonsmokers, But Not Smokers - written by Mark Mascolini - (09/19/09)
     
  769. ICAAC: Pharmacokinetics and Safety of a Novel 100 mg Tablet Formulation of MPC-4326 in Subjects with HIV-1 Infection (09/19/09)
     
  770. ICAAC: The Effect of Ritonavir-Boosted Protease Inhibitors on the HIV Integrase Inhibitor, S/GSK1349572, in Healthy Subjects (09/19/09)
     
  771. ICAAC: Lack of Interaction between the HIV Integrase Inhibitor, S/GSK1349572, and Tenofovir Disoproxil Fumarate (TDF) in Healthy Subjects (09/19/09)
     
  772. ICAAC: Meta-Analysis of Safety for Short-term Dosing of an HIV Integrase Inhibitor, S/GSK1349572, from Seven Clinical Studies (09/19/09)
     
  773. ICAAC: In Vitro Passage of Drug Resistant HIV-1 against a Next Generation Integrase Inhibitor (INI), S/GSK1349572 (09/19/09)
     
  774. ICAAC: Evaluation of Antacid and Multivitamin (MVI) Effects on S/GSK1349572 Pharmacokinetics (PK) in Healthy Subjects (09/19/09)
     
  775. ICAAC: Endothelial Function Drops in First Month of Antiretroviral Therapy - written by Mark Mascolini - (09/18/09)
     
  776. ICAAC: Peripheral Endothelial Function is Reduced after Initiation of Antiretroviral Therapy in Treatment Naïve HIV Patients: A Prospective Longitudinal Study (09/18/09)
     
  777. ICAAC: Steady State Evaluation of Two Extended Release (XR) Nevirapine (NVP) Tablets 400 mg QD Compared with Immediate Release (IR) NVP Tablets 200 mg BID in HIV-1 Infected Patients (09/18/09)
     
  778. ICAAC: Pharmacokinetic interaction between etravirine and lopinavir/ritonavir (09/18/09)
     
  779. ICAAC: Bevirimat Antiviral Activity & Safety, 14-Day Monotherapy Study (09/18/09)
     
  780. ICAAC: GRACE (Gender, Race And Clinical Experience): Outcomes by Race at Week 48 (09/17/09)
     
  781. Eradication Drug Research: Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors - (09/17/09)
     
  782. ICAAC: Sharp Drop in ICU Mortality After Introduction of HAART in Netherlands - written by Mark Mascolini - (09/17/09)
     
  783. ICAAC: Vicriviroc Long-term Safety and Efficacy: 96-Week Results from the Extension of VICTOR-E1 Stud - (09/17/09)
     
  784. ICAAC: INSPIRE Study: Effects of r-hIL-7 on T Cell Recovery and Thymic Output in HIV-infected Patients Receiving c-ART - Interim Analysis of a Phase I/IIa Multicenter Study - (09/17/09)
     
  785. ICAAC: Pharmacokinetic Boosting of Atazanavir with the Pharmacoenhancer GS-9350 versus Ritonavir - (09/17/09)
     
  786. ICAAC: Effect of Food on Pharmacokinetics of Elvitegravir, Emtricitabine, Tenofovir DF and the Pharmacoenhancer GS-9350 as a Fixed- Dose Combination Tablet - (09/17/09)
     
  787. ICAAC: Fasted Lipid Changes after Administration of Maraviroc or Efavirenz, both with Zidovudine and Lamivudine, to Treatment-Naive HIV-Infected Patients: 96-Week Results from MERIT - (09/17/09)
     
  788. ICAAC: Antiviral Activity of S/GSK1265744, a Once-Daily, Unboosted Integrase Inhibitor in Clinical Development, Evaluated in Phase 1-2a Study in Healthy and HIV-Infected Subjects GSK press release - (09/17/09)
     
  789. ICAAC: Improvement in Fasting Lipids but Minimal Recovery of Limb Fat Were Seen 96 Weeks After Switching from Lamivudine/Zidovudine Plus Efavirenz to Fixed-Dose Efavirenz/Emtricitabine/Tenofovir DF in HIV-Infected Patients - (09/17/09)
     
  790. ICAAC: Phase 2a Study of PRO 140 in HIV-Infected Adults - (09/17/09)
     
  791. ICAAC: Can IL-7 Succeed Where IL-2 Failed in People With HIV? - written by Mark Mascolini - (09/17/09)
     
  792. ICAAC: Once-Daily Replacement Raltegravir as Good as Twice-Daily in Pilot Trial - written by Mark Mascolini - (09/17/09)
     
  793. ICAAC: Another Small Study Suggests Viability of Unboosted Atazanavir/Raltegravir Maintenance - written by Mark Mascolini - (09/17/09)
     
  794. ICAAC: Faster Viral Decay With Nevirapine Than Atazanavir/Ritonavir in ARTEN Trial - written by Mark Mascolini - (09/17/09)
     
  795. ICAAC: Gut-Shielding Mix Slows CD4 Drop in People Not Taking Antiretrovirals - written by Mark Mascolini - (09/17/09)
     
  796. ICAAC: Gilead GS-9350 Protease Inhibitor Booster - written by Mark Mascolini - (09/17/09)
     
  797. ICAAC: Raltegravir Reaches Good Nervous System Levels 4.3 Fold x EC50 - written by Mark Mascolini - (09/17/09)
     
  798. ICAAC: GSK "Backup" Integrase Inhibitor Looks Strong in People With HIV: 10-day monotherapy study - written by Mark Mascolini - (09/17/09)
     
  799. ICAAC: Early Virological and Immunological Response is Comparable between Nevirapine and RTV-boosted Atazanavir: An ARTEN Sub-analysis - (09/17/09)
     
  800. ICAAC: A Pilot Study assessing Raltegravir QD versus BID in HIV patients included in a Simplification Trial - (09/17/09)
     
  801. ICAAC: Dual Maintenance Therapy with Raltegravir 400 mg BID with Atazanavir 400 mg qD in Patients with no Prior PI Resistance and Intolerance to Other ARV Regimens: Preliminary Report - (09/17/09)
     
  802. ICAAC: SCHERING-PLOUGH REPORTS LONG-TERM VICRIVIROC DATA FROM PHASE II OPEN-LABEL EXTENSION STUDY IN TREATMENT-EXPERIENCED HIV-INFECTED PATIENTS - Schering-Plough press releaser - (09/17/09)
     
  803. ICAAC: Discovery of GS-9350: A Novel Pharmacoenhancer without Anti-HIV Activity - (09/17/09)
     
  804. ICAAC: Pharmacokinetics (PK) and Safety in Healthy and HIV-Infected Subjects and Short-Term Antiviral Efficacy of S/GSK1265744, a Next Generation Once Daily HIV Integrase Inhibitor - (09/17/09)
     
  805. ICAAC: Metabolic Profiles and Body Composition Changes in Treatment-Naïve HIV-Infected Patients Treated with Raltegravir 400 mg bid-based vs. Efavirenz 600 mg qhs-based Combination Therapy: 48-Week Data - (09/17/09)
     
  806. ICAAC: Antiviral Activity of S/GSK1265744, a Once-Daily, Unboosted Integrase Inhibitor in Clinical Development, Evaluated in Phase 1-2a Study in Healthy and HIV-Infected Subjects - (09/14/09)
     
  807. Gardasil HPV vaccine for boys - FDA Hearing Oct 21 - (09/11/09)
     
  808. ICAAC: Weighted Antiretroviral Sensitivity Score May Be Better Predictor of Short-Term Response - written by Mark Mascolini - (09/14/09)
     
  809. ICAAC: Seven Short Studies Suggest Good Safety Profile of New Integrase Inhibitor - written by Mark Mascolini - (09/14/09)
     
  810. ICAAC: Merck's ISENTRESS (raltegravir) Tablets Studied in Comparison to Efavirenz in Combination Therapy Through 96 Weeks in HIV-1 Treatment-Naïve Patients - Merck press release - (09/14/09)
     
  811. ICAAC: Raltegravir Demonstrates Durable Efficacy Through 96 Weeks: Results from STARTMRK, A Phase III Study of Raltegravir-based vs. Efavirenz-based Therapy in Treatment-Naïve HIV+ Patients - (09/14/09)
     
  812. ICAAC: Effects of CYP2B6 Single Nucleotide Polymorphisms (SNPs) and Substance Abuse on Efavirenz (EFV) Pharmacokinetics - (09/14/09)
     
  813. ICAAC: Tobacco and Marijuana Uses Significantly Decrease Atazanavir (ATV) Trough Concentrations in HIV Infected Individuals - (09/14/09)
     
  814. ICAAC: Pharmacokinetic interaction between darunavir in combination with low-dose ritonavir and buprenorphine/naloxone - (09/14/09)
     
  815. ICAAC: Early Changes in HCV Viral Load During the First 24 Hours of Treatment Exhibit a Very High Negative Predictive Value of Sustained Virological Response in HCV/HIV Coinfected Patients - (09/14/09)
     
  816. ICAAC:Role for Short-Term Enfuvirtide to Boost CD4s After Late Diagnosis? - written by Mark Mascolini - (09/14/09)
     
  817. ICAAC: Lab Study Suggests High Barrier to Resistance With New Integrase Inhibitor - written by Mark Mascolini - (09/14/09)
     
  818. ICAAC: Smoking and Drinking Alcohol Linked to Lower Efavirenz Levels - written by Mark Mascolini - (09/14/09)
     
  819. ICAAC: Tobacco and Marijuana Tied to Lower Atazanavir Concentrations - written by Mark Mascolini - (09/14/09)
     
  820. ICAAC: DC Emergency Patients Who Decline HIV Test Have Twice Higher HIV Rate - written by Mark Mascolini - (09/14/09)
     
  821. ICAAC: Impact of One-Time or Annual HIV Screening on Life Expectancy in France - written by Mark Mascolini - (09/14/09)
     
  822. ICAAC: HCV Load Decay in First Day of PegIFN Treatment Predicts Long-Term Failure - written by Mark Mascolini - (09/14/09)
     
  823. HIV and Aging: The Long-term Consequences of Successful Antiretroviral Therapy - (09/11/09)
     
  824. HIV, HAART & Brain Damage & Repair - (09/11/09)
     
  825. Effect of HAART on Risk of Sexual Transmission of HIV & Superinfection - CDC Report - (09/11/09)
     
  826. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients - (09/11/09)
     
  827. Sex Steroids & Fracture Risk in Men - (09/06/09)
     
  828. Lipodystrophy & Bone Loss - (09/06/09)
     
  829. Vitamin D, Diabetes & Bone in African-Americans - (09/06/09)
     
  830. Inflammation & Diabetes, Interventions - (09/06/09)
     
  831. The model for end-stage liver disease score (MELD) is the best prognostic factor in HIV 1-infected patients with end-stage liver disease: A prospective cohort study - (09/03/09)
     
  832. Viable strategies to facilitate liver transplantation for HIV/HCV coinfection - Editorial - (09/03/09)
     
  833. A Potential Role for Vitamin D on HIV Infection? - (09/03/09)
     
  834. Vitamin D Immunomodulator EDITORIAL - (09/03/09)
     
  835. Low Vitamin D Levels Increased Risk for HIV MTCT: Perinatal Outcomes, Including Mother-to-Child Transmission of HIV, and Child Mortality and Their Association with Maternal Vitamin D Status in Tanzania - (09/03/09)
     
  836. Resting cerebral blood flow A potential biomarker of the effects of HIV in the brain - (09/03/09)
     
  837. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients in TITAN - (09/03/09)
     
  838. HIV-1 RNA concentration and cognitive performance in a cohort of HIV-positive people - (08/29/09)
     
  839. Neurological Impairment Persists Despite HAART: "adjunctive therapies needed" - (08/29/09)
     
  840. Insulin Resistance Is Associated With Cognition Among HIV-1-Infected Patients: The Hawaii Aging With HIV Cohort - (08/29/09)
     
  841. HCV Coinfection & Neurologic Impairment - (08/29/09)
     
  842. 5th IAS: Association between activation of inflammatory and coagulation pathways and mortality during long-term follow up in SMART - (08/29/09)
     
  843. 5th IAS: HAART Interruption Increased Inflammation - IMPACT OF HAART INTERRUPTION ON PLASMA INFLAMMATORY MARKERS ASSOCIATED WITH CARDIOVASCULAR DISEASE FINAL 36-MONTH RESULTS FROM A RANDOMIZED STUDY - (08/29/09)
     
  844. 5th IAS: HAART Did Not Control Immune Activation - (08/29/09)
     
  845. 5th IAS: HAART Interruption Increases Immune Activation - (08/29/09)
     
  846. 5th IAS: Kaletra Protects Mitochondria - (08/29/09)
     
  847. Untreated HIV Infection and Large and Small Artery Elasticity - "Untreated HIV infection is associated with impaired arterial elasticity" - (08/28/09)
     
  848. Higher CPE Score Improved Cognition, Changes in Cognition During Antiretroviral Therapy: Comparison of 2 Different Ranking Systems to Measure Antiretroviral Drug Efficacy on HIV-Associated Neurocognitive Disorders - (08/28/09)
     
  849. 5th IAS: Prevalence of HIV-1-Associated Neurocognitive Disorders in Argentina - (08/28/09)
     
  850. Oxidized lipids enhance RANKL production by T lymphocytes: Implications for lipid-induced bone loss - pdf attached - (08/27/09)
     
  851. Mild Glucose Intolerance In Pregnancy May Be Associated With Cardiovascular Risk - (08/26/09)
     
  852. The clot thickens-oxidized lipids and thrombosis - (08/26/09)
     
  853. Oxidized lipids: a key to heart disease? - (08/26/09)
     
  854. Aging/HIV Clinical Care & Research - New IDSA Guidelines - (08/26/09)
     
  855. Thyroid Dysfunction, Hypogonadism, Testosterone, Bone, Prostate Cancer, HIV & HAART - (08/26/09)
     
  856. Aging & HIV Recognized as a Serious Concern But No Real Discussion, Still Ignored. 2007 NIH Workshop recommendations - (08/26/09)
     
  857. Improvement of Mitochondrial Toxicity in Patients Receiving a Nucleoside Reverse-Transcriptase Inhibitor-Sparing Strategy: Results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA) - (08/21/09)
     
  858. Vitamin D Deficiency/Muscle Function/Frailty - (08/21/09)
     
  859. GSK says latest Avandia findings are flawed: new pio vs rosiglitazone study - (08/20/09)
     
  860. Diagnosis and management of neuropathic pain - Clinical Review - (08/20/09)
     
  861. NIH Workshop on HIV in Older Adults Oct 20 2007 - (08/18/09)
     
  862. A serum 25-hydroxyvitamin D level below 50 nmol/l has been associated with increased body sway and a level below 30 nmol/l with decreased muscle strength. - (08/18/09)
     
  863. Vitamin D deficiency, muscle function, and falls in elderly people1,2 Review Article - (08/18/09)
     
  864. 5th IAS: IAS: darunavir & etravirine studies - (08/16/09)
     
  865. New IDSA HIV Guidelines Push 'Adherence to Care' - (08/17/09)
     
  866. FDA Approves Generic Fixed Dose Efavirenz/FTC/Tenofovir - (08/14/09)
     
  867. 5th IAS: Kaletra Once-Daily Dosing, IAS Summary - (08/14/09)
     
  868. 5th IAS: Reyataz Studies at IAS - (08/14/09)
     
  869. 5th IAS: Maraviroc IAS Reports: MERIT (naives), Genotype vs Tropism (MOTIVATE), Malignancies Report (MOTIVATE) - (08/14/09)
     
  870. Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a - (08/14/09)
     
  871. Coinfection with Hepatitis C Virus and HIV: More than Double Trouble - EDITORIAL COMMENTARY - (08/14/09)
     
  872. 5th IAS: Abacavir & MIs - IAS Summary - (08/12/09)
     
  873. 5th IAS: Cancers & HIV at IAS Summary Report - (08/12/09)
     
  874. Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy (HCV, IVDU) - (08/12/09)
     
  875. New Expanded Access Rules to Investigational Drugs for Treatment Use and Charging for Investigational Drugs - (08/12/09)
     
  876. FDA Expands Access to Investigational Drugs - (08/12/09)
     
  877. Lipoatrophy and lipohypertrophy are independently associated with hypertension - (08/12/09)
     
  878. Physical Activity, Diet, and Risk of Alzheimer Disease (65% reduction in risk) - (08/12/09)
     
  879. Mediterranean Diet and Late-Life Cognitive Impairment EDITORIAL - (08/12/09)
     
  880. tenofovir & abacavir - Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients  - (08/12/09)
     
  881. Study Suggests Immune Systems of Untreated HIV-Infected Individuals May Deteriorate Faster than Previously Thought - NIH BULLETIN - (08/12/09)
     
  882. Midlife Serum Cholesterol and Increased Risk of Alzheimer's and Vascular Dementia Three Decades Later- pdf attached - (08/12/09)
     
  883. Structural biology: Aerial view of the HIV genome - (08/12/09)
     
  884. Oral Cancer In Men Associated With HPV - (08/12/09)
     
  885. Virological Response to Initial Antiretroviral Regimens Containing Abacavir or Tenofovir - New UK CHIC Study BRIEF REPORT - (08/12/09)
     
  886. Thiazolidinediones and Fractures in Men and Women - (08/12/09)
     
  887. Bone Guidelines Excerpted From New IDSA Guidelines- pdf of full paper attached  - (08/12/09)
     
  888. Prevalence and Associations of 25-Hydroxyvitamin D Deficiency in US Children: NHANES 2001-2004 - pdf of published report attached - (08/12/09)
     
  889. 5th IAS: New Drugs, New strategies - written by Joe Eron MD - (08/12/09)
     
  890. WHO May Recommend HAART for PMTCT: IAS - (08/07/09)
     
  891. Lower Risk of Resistance After Short-Course HAART Compared With Zidovudine/Single-Dose Nevirapine Used for Prevention of HIV-1 Mother-to-Child Transmission - (08/07/09)
     
  892. WHO may change ARV guidelines for pregnant mothers: HAART reduces HIV transmission while breastfeeding - (08/07/09)
     
  893. New review endorses CV benefits of fish oil - (08/06/09)
     
  894. Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Diseases - (08/06/09)
     
  895. HIV-associated brain dysfunction in the era of HAART - Editorials, Reasons for hope, but continued concern - (08/06/09)
     
  896. The Pathogenetic Role of Cortisol in the Metabolic Syndrome (and lipodystrophy): A Hypothesis - (08/06/09)
     
  897. Continuous antiretroviral therapy decreases bone mineral density in SMART - (08/06/09)
     
  898. 5th IAS: Similar Declines in HIV-1 RNA (Viral load, VL) from Baseline (BL) to 96 Weeks Observed in Subjects Randomized to ABC/3TC or TDF/FTC each with Lopinavir/Ritonavir (LPV/r) in the HEAT Trial (EPZ104057) - (08/04/09)
     
  899. 5th IAS: Efficacy, safety and tolerability of dual therapy with raltegravir 400mg bid and atazanavir 200mg bid in antiretroviral experienced patients. - (08/04/09)
     
  900. 5th IAS: 91% Have Low Vitamin D Levels in UK Cohort, 34% Severely Deficient; Efavirenz use is associated with severe Vitamin D deficiency in a large, ethnically diverse, urban UK HIV cohort - (08/04/09)
     
  901. Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative Women - it accumulated at high levels quickly in CVF & vaginal tissue - (08/04/09)
     
  902. Bone mineral density and disorders of mineral metabolism in chronic liver disease: Cirrhotics Have Low Bone Density & Low Vitamin D Levels - (08/04/09)
     
  903. -2.5% Bone Loss Over 96 Weeks on PI or NNRTI in study reported - (08/04/09)
     
  904. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial -- attached is pdf and appendix with adverse events - (08/04/09)
     
  905. Scientists learn why even treated genital herpes sores boost the risk of HIV infection - (08/04/09)
     
  906. 5th IAS: Earlier HAART at 350 CD4 Instead of Current 200 in Developing World Recommended - (08/01/09)
     
  907. 5th IAS: Preliminary analyses suggest a higher rate of HIV seroconversion among men who were HPV positive at baseline - (08/01/09)
     
  908. 5th IAS: Virologic Suppression on Maraviroc in Treatment-Naive Patients With R5 HIV-1 is Similar to Efavirenz at High Baseline Viral Load, and Maraviroc Discontinuations for Adverse Events are Less Likely to Show Drug Resistance: 48-Week Results From the MERIT Study - (08/01/09)
     
  909. 5th IAS: Duration of Viral Suppression Strongly Modifies the Adherence-Viral Rebound Relationship - (08/01/09)
     
  910. Initiation of HAART at Higher CD4 Cell Counts Is Associated With a Lower Frequency of Antiretroviral Drug Resistance Mutations at Virologic Failure - (07/31/09)
     
  911. 5th IAS: Neurocognitive Disorders Despite Undetectable HIV RNA - (07/31/09)
     
  912. 5th IAS: Management of Treatment-Experienced Patients - written by Rafael E. Campo, MD Professor of Clinical Medicine Division of Infectious Diseases University of Miami Leonard M. Miller School of Medicine Miami, Florida (07/31/09)
     
  913. 5th IAS: 48 week lipid- and glucose-related safety profile of darunavir/ritonavir in treatment-experienced, paediatric patients in DELPHI - (07/31/09)
     
  914. 5th IAS: HIV Infection Modulates Cellular Proteins Associated With Cardiovascular Disorders - (07/31/09)
     
  915. 5th IAS: Switch from Enfuvirtide to Raltegravir in Virologically Suppressed Multidrug-Resistant HIV-1 Infected Patients: Final Results of the Randomized ANRS 138 Trial (EASIER). - (07/31/09)
     
  916. CROI: Unexpectedly high failure rate in LPV/r monotherapy arm, involving CNS, and association with low nadir CD4 count in the MOST study - (06/02/09)
     
  917. 5th IAS: HIV Prevention at IAS 2009 - written by Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (07/30/09)
     
  918. 5th IAS: Genital HIV-1 RNA Concentrations and Heterosexual HIV-1 Transmission Risk: 'higher genital HIV levels increase HIV sex transmission risk' - (07/30/09)
     
  919. 5th IAS: MIs & ARTs: Nested Control Study in Quebec Cohort - (07/30/09)
     
  920. 5th IAS: Predictive factors of serious vascular events in HIV patients in LATINA (LATInamerican Network on AIDS) - (07/30/09)
     
  921. 5th IAS: Influence of patient baseline clinical and demographic characteristics on choice of initial antiretroviral therapy regimen: evidence of channeling bias in HIV clinical care - (07/30/09)
     
  922. 5th IAS: Metabolic Complications of HIV infection Update form the 5th IAS Conference in Cape Town - Pablo Tebas MD, University of Pennsylvania - (07/30/09)
     
  923. 5th IAS: Persistence and Progression of HIV-associated Neurocognitive Impairment (NCI) in the Era of Combination Antiretroviral Therapy (CART) and the Role of Comorbidities: The CHARTER Study - (07/30/09)
     
  924. Bioavailability of Efavirenz Capsule Contents (Sprinkles) Mixed with a Small Amount of Food Compared with Intact Capsules in Healthy Adults - (07/29/09)
     
  925. 5th IAS: The Safety, Efficacy, and Steady State Pharmacokinetics of Atazanavir/Ritonavir (ATV/r) Once Daily During Pregnancy: Results of Study AI424182 - (07/30/09)
     
  926. 5th IAS: Glomerular dysfunction and associated risk factors through four years following initiation of ART in adults with HIV Infection in Africa in the DART trial - (07/30/09)
     
  927. 5th IAS: Landmark Five-Year African Study Indicates That HIV Therapy May Be Given Safely in Resource-Limited Settings Without Routine Laboratory Monitoring - press release - (07/30/09)
     
  928. 5th IAS: DART Study Slide Presentation at IAS - (07/30/09)
     
  929. 5th IAS: Omega-3 polyunsaturated fatty acids inhibit the release of matrix metalloproteinases: therapeutic implications for HIV-associated immune activation - (07/30/09)
     
  930. CHMP Recommends Expanded Use of ISENTRESS® (raltegravir), from MSD, in Treatment-Naïve Adult Patients with HIV-1 Infection - (07/29/09)
     
  931. 5th IAS: Efavirenz Linked to Severe Vitamin D Deficit in Diverse London Clinic - written by Mark Mascolini - (07/29/09)
     
  932. Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz - (07/29/09)
     
  933. HIV Can Kill Chimps; Infectious diseases: An ill wind for wild chimps? - (07/29/09)
     
  934. 5th IAS: What CD4 Cell Count Levels are Associated With a Reduced Risk of Cancer? 'When To Begin HAART' - (07/29/09)
     
  935. 5th IAS: HIV Regimens Lacking Nucleosides Tied to Higher SVR Rate With HCV Therapy - written by Mark Mascolini - (07/29/09)
     
  936. 5th IAS: Varying Risk of AIDS and Non-AIDS Cancers in Diverse CD4 Brackets - written by Mark Mascolini - (07/29/09)
     
  937. 5th IAS: Half in US HIV Group Have Neurocognitive Impairment, Which Improves With NNRTIs - written by Mark Mascolini - (07/29/09)
     
  938. 5th IAS: Two Triple PEP Regimens With Truvada Look Safer Than Older PEPs - written by Mark Mascolini - (07/29/09)
     
  939. 5th IAS: TB Rate in South African Township Plummets After Antiretrovirals Arrive - written by Mark Mascolini - (07/29/09)
     
  940. 5th IAS: Anal Cancer Rates Keep Climbing in US HIV Group Despite HAART - written by Mark Mascolini - (07/29/09)
     
  941. 5th IAS: Triple Antiretrovirals Cut Breastfeeding HIV Transmission Rate Below 1% - written by Mark Mascolini - (07/29/09)
     
  942. 5th IAS: Adding Raltegravir to Suppressive Regimen Does Not Cut Low-Level Viremia - written by Mark Mascolini - (07/29/09)
     
  943. 5th IAS: More Time With Low CD4 Count Boosts Non-AIDS Cancer Risk - written by Mark Mascolini - (07/29/09)
     
  944. 5th IAS: THE FOTOSTUDY 48 week Results to assess durability of the strategy of taking Efavirenz, Tenofovir and Emtricitabine Five-days-On, Two-days-Off each week in virologically suppressed patients - (07/29/09)
     
  945. 5th IAS: ARTEMIS: Week 96 safety and efficacy of darunavir/r by gender, age and race - (07/29/09)
     
  946. 5th IAS: Efficacy and Safety of Atazanavir/RTV vs. Lopinavir/RTV in Treatment-Naïve Patients with Advanced Disease: CASTLE Study 96-Week Results - (07/29/09)
     
  947. 5th IAS: Clinical endpoints reduced through etravirine use in treatment-experienced, HIV-1-infected patients: pooled 96-week results from the Phase III DUET trials - (07/29/09)
     
  948. 5th IAS: Etravirine demonstrates durable efficacy in treatment-experienced patients in the DUET trials: pooled 96-week results - (07/29/09)
     
  949. 5th IAS: Long-term safety profile of etravirine in treatment-experienced, HIV-1-infected patients: pooled 96-week results from the Phase III DUET trials - (07/29/09)
     
  950. 5th IAS: Efficacy and Safety of raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: 48-week results from the ANRS 139 TRIO trial - (07/29/09)
     
  951. 5th IAS: Comparable Safety and Efficacy With Once-daily (QD) Versus Twice-daily (BID) Dosing of Lopinavir/ritonavir (LPV/r) Tablets With Emtricitabine (FTC) + Tenofovir DF (TDF) in Antiretroviral (ARV)-naïve, HIV-1-infected Subjects: 96-Week Results of the Randomized Trial M05-730 - (07/28/09)
     
  952. 5th IAS: Highly prevalent vitamin D deficiency and insufficiency among an urban cohort of human immunodeficiency virus (HIV)-infected men under care - (07/28/09)
     
  953. 5th IAS: ARTs Cause Bone Loss - (07/28/09)
     
  954. 5th IAS: Bone mineral density (BMD) in a population of healthy HIV-negative young African adults enrolling in a pre-exposure prophylaxis (PrEP) trial in Botswana - (07/28/09)
     
  955. 5th IAS: Cumulative & Current Viral Replication & Low CD4 Increases NHL Risk: Immune deficiency, uncontrolled HIV replication and non-Hodgkin's lymphoma, ANRS CO3 Aquitaine Cohort, 1998-2006. - (07/28/09)
     
  956. 5th IAS: ISENTRESS (raltegravir), from Merck, was as Effective as Efavirenz at Suppressing HIV Viral Load and Increasing CD4 Cell Counts in Treatment-Naïve Patients up to 144 Weeks When Used in Combination Therapy - (07/23/09)
     
  957. Tight Glucose Control Raises Mortality Risk in Heart Failure in a New Study - (07/23/09)
     
  958. HIV & Kidney Disease: African-Americans with HIV are more susceptible to type of kidney disease known as HIVAN - (07/23/09)
     
  959. 5th IAS: Screening for HIV Tropism using Population-based V3 Genotypic Analysis: a Retrospective Virologic Outcome Analysis Using Stored Plasma Screening Samples from the MOTIVATE Studies of Maraviroc in Treatment Experienced Patients - (07/23/09)
     
  960. 5th IAS: Abacavir Not Associated with MIs, 2 Studies Report at IAS - (07/23/09)
     
  961. 5th IAS: Swiss Suicide Risk Still High With HIV, But HAART Made a Difference - written by Mark Mascolini - (07/22/09)
     
  962. 5th IAS: Atazanavir Effective After Atazanavir/Ritonavir Induction in Naive Patients - written by Mark Mascolini - (07/22/09)
     
  963. 5th IAS: Kaletra Once vs Twice Daily - (07/22/09)
     
  964. 5th IAS: Once- and Twice-Daily Lopinavir/Ritonavir Equivalent in Antiretroviral Experienced - written by Mark Mascolini - (07/22/09)
     
  965. 5th IAS: Lower Glucose and HIV Load Linked to Fibrosis Regression in 5-Year Study - written by Mark Mascolini - (07/22/09)
     
  966. 5th IAS: Lower Glucose and HIV Load Linked to Fibrosis Regression in 5-Year Study; HCV Therapy Quadrupled Chance For Fibrosis Regression - written by Mark Mascolini - (07/22/09)
     
  967. 5th IAS: Second Trial of Darunavir Monotherapy Seems Less Convincing - written by Mark Mascolini - (07/22/09)
     
  968. 5th IAS: Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on lipid parameters and anthropometrics in treatment-naive, HIV-1-infected ARTEMIS patients at Week 96 - (07/22/09)
     
  969. 5th IAS: Antiviral Activity of S/GSK1349572, the Only Once-Daily, Unboosted Integrase Inhibitor In Clinical Development, Evaluated In Phase 2 Study - GSK press release - (07/22/09)
     
  970. 5th IAS: Reyataz Induction/Maintenance From Boosted to Unboosted: Similar Efficacy and Tolerability of Atazanavir (ATV) Compared to Atazanavir/Ritonavir (ATV/r), each with Abacavir/Lamivudine (ABC/3TC) after Initial Suppression with ABC/3TC + ATV/r: 84 Week Results of the ARIES Trial - (07/22/09)
     
  971. 5th IAS: Genetic Test Predicts Response to Maraviroc in Treatment-Experienced HIV Patients - press release - (07/22/09)
     
  972. 5th IAS: EPZICOM + atazanavir regimen provided comparable efficacy to EPZICOM + atazanavir/ritonavir regimen in treatment-naive HIV-infected patients - press release - (07/22/09)
     
  973. 5th IAS:Incidence and Risk Factors for Malignancies in Treatment-experienced (TE) Patients in the MOTIVATE Studies of Maraviroc (MVC) + Optimized Background Therapy (OBT): 96-Week Follow-up - (07/22/09)
     
  974. 5th IAS: A randomized multicenter study to compare the efficacy of a monotherapy of darunavir to a triple therapy with 2 nucleosides analogues combined to darunavir/r in HIV infected patients with full viral suppression: MONOI ANRS 136 - (07/22/09)
     
  975. 5th IAS: Long-Term Bone Loss Similar With PI- and NRTI-Sparing Regimens - written by Mark Mascolini - (07/21/09)
     
  976. 5th IAS: Blacks and Women Have Worse Virologic Response in Trial of ABC/3TC vs TDF/FTC - written by Mark Mascolini - (07/21/09)
     
  977. 5th IAS: Raltegravir Rescue Regimens Do Well With or Without a PI - written by Mark Mascolini - (07/21/09)
     
  978. 5th IAS: Nevirapine Combo May Work for Some Kids Exposed to Single-Dose Nevirapine - written by Mark Mascolini - (07/21/09)
     
  979. 5th IAS: Adding More NRTIs to Salvage May Lower Chance of Response - written by Mark Mascolini - (07/21/09)
     
  980. 5th IAS: Once-Daily Darunavir Monotherapy Effective for 48 Weeks After Viral Control - written by Mark Mascolini - (07/21/09)
     
  981. 5th IAS: New Once-Daily Integrase Inhibitor Looks Strong in Early Trial - written by Mark Mascolini - (07/21/09)
     
  982. 5th IAS: Attacking LDL Cholesterol in People on ARVs Has Mixed Results - written by Mark Mascolini - (07/21/09)
     
  983. 5th IAS: Recovery of Functional Immunity over 48 Weeks with Darunavir-based Therapy in the GRACE Immunology Substudy - (07/21/09)
     
  984. 5th IAS: The MONET trial: darunavir/ritonavir monotherapy shows non-inferior efficacy to standard HAART, for patients with HIV RNA <50 copies/mL at baseline - (07/21/09)
     
  985. 5th IAS: Antiviral Activity of S/GSK1349572, the Only Once-Daily, Unboosted Integrase Inhibitor In Clinical Development, Evaluated In Phase 2 Study - GSK press release - (07/21/09)
     
  986. 5th IAS: The MERIT Study of Maraviroc in Antiretroviral-Naive Patients With R5 HIV-1: 96-Week Results - (07/21/09)
     
  987. 5th IAS: 96-Week Merit Es Analysis Shows Efficacy Of Pfizer's HIV/AIDS Treatment Celsentri/Selzentry (Maraviroc) In Treatment-Naive HIV Patients; Results Consistent With 48-Week Analysis - Pfizer press release - (07/21/09)
     
  988. 5th IAS: Potent Antiviral Activity of S/GSK1349572, A Next Generation Integrase Inhibitor (INI), in INI-Naïve HIV-1-Infected Patients: ING111521 Protocol - (07/21/09)
     
  989. 5th IAS: Sustained Antiretroviral Efficacy of Raltegravir as part of Combination ART in Treatment-Naive HIV-1 infected patients: 144-week data - (07/21/09)
     
  990. 5th IAS: Pharmacokinetic (PK) and Pharmacodynamic (PD) Relationship of S/GSK1349572, a Next Generation Integrase Inhibitor (INI), in HIV-1 Infected Patients - (07/21/09)
     
  991. 5th IAS: Pharmacokinetics (PK) and Safety in Healthy Subjects of S/GSK1349572, a Next Generation, Once-Daily HIV Integrase Inhibitor (INI) - (07/21/09)
     
  992. 5th IAS: GRACE: New HIV Study Shows that Large Numbers of Women and People of Color can be Successfully Enrolled in U.S. HIV Clinical Studies - (07/21/09)
     
  993. 5th IAS: African-American Women Need Services is Highlighted in: GRACE (Gender, Race And Clinical Experience): 48-Week Results of Darunavir/r-based Therapy in the Largest Trial in North America to Focus on Treatment-experienced Women - (07/21/09)
     
  994. 5th IAS: Differences in Virologic Response Among African Americans and Females Regardless of Therapy in the HEAT Study: African-Americans Have Lower Viral Response Rates - (07/21/09)
     
  995. Darunavir Concentrations in Cerebrospinal Fluid and Blood in HIV-1-Infected Individuals - (07/20/09)
     
  996. 5th IAS: One Third With Undetectable HIV RNA Have Asymptomatic Neurocognitive Impairment - written by Mark Mascolini - (07/20/09)
     
  997. 5th IAS: Raltegravir and Unboosted Atazanavir as Simple Maintenance Regimen - written by Mark Mascolini - (07/20/09)
     
  998. 5th IAS: Abacavir Heart Attack Controversy: Kidney Disease Appears to Matter - written by Mark Mascolini - (07/20/09)
     
  999. 5th IAS: New results from ARTEN study of nevirapine plus tenofovir and emtricitabine (TDF/FTC) versus boosted protease inhibitor regimen of atazanavir/ritonavir plus TDF/FTC revealed - BI Press Release For U.S. Media Only - (07/20/09)
     
  1000. 5th IAS: S/GSK1349572: A Next Generation Integrase Inhibitor with Activity Against Integrase Inhibitor-Resistant Clinical Isolates from Patients Experiencing Virologic Failure while on Raltegravir Therapy - (07/20/09)
     
  1001. 5th IAS: 96-WEEK SAFETY AND EFFICACY FINDINGS PRESENTED FOR INTELENCETM (ETRAVIRINE) AS PART OF HIV COMBINATION THERAPY - Tibotec press release - (07/20/09)
     
  1002. 5th IAS: S/GSK1349572 is a Potent Next Generation HIV Integrase Inhibitor - (07/20/09)
     
  1003. 5th IAS: Prospective randomised comparison of Nevirapine and Atazanavir/ritonavir both combined with Tenofovir DF/Emtricitabine in treatment-naive HIV-1 infected patients: ARTEN Study week 48 results - (07/20/09)
     
  1004. 5th IAS: NEW HIV STUDY SHOWS THAT LARGE NUMBERS OF WOMEN AND PEOPLE OF COLOR CAN BE SUCCESSFULLY ENROLLED IN U.S. HIV CLINICAL STUDIES - Tibtec press release - (07/20/09)
     
  1005. 5th IAS: IAS Opening Session - Recession Impact - (07/20/09)
     
  1006. 5th IAS: Thinking Through the CNS: The Importance of Considering the Blood-Brain Barrier. Slide talk by Scott Letende, GSK satellite meeting at IAS 2009 - (07/19/09)
     
  1007. 5th IAS: European Researchers Issuing Guidelines on Bone Disease - (07/19/09)
     
  1008. HIV-1 Infection Is Associated With an Earlier Occurrence of Frailty....in MACS - (07/18/09)
     
  1009. Male Circumcision Didn't Reduce HIV Transmission To Women in African Study - (07/18/09)
     
  1010. Male circumcision and HIV risks and benefits for women - EDITORIAL - (07/18/09)
     
  1011. Mortality in WIHS, Women of Color: non-AIDS Events, Viral Replication & low CD4, Depression, Violence, HCV/HBV, Drug Use: Federal AIDS funding neglects inner-city women of color - (07/17/09)
     
  1012. HIV Viral Replication Causes Non-AIDS Events - (07/17/09)
     
  1013. TMC278+Truvada Coformulation Announced by Gilead & Tibotec - (07/17/09)
     
  1014. Lopinavir/Ritonavir in Pregnancy - (07/16/09)
     
  1015. Vicriviroc/Reyataz Nuke-Sparing HAART: Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV - (07/16/09)
     
  1016. Virologic Outcomes of Changing Enfuvirtide to Raltegravir in HIV-1 Patients Well Controlled on an Enfuvirtide Based Regimen: 24-Week Results of the CHEER Study - (07/16/09)
     
  1017. Growth Hormone and Sex Steroid Effects on Serum Glucose, Insulin, and Lipid Concentrations in Healthy Older Women and Men - (07/16/09)
     
  1018. MRI Findings May Track Risk of Cognitive Impairment in Healthy Seniors - (07/16/09)
     
  1019. Lower Testosterone Levels Predict Incident Stroke and Transient Ischemic Attack in Older Men - (07/16/09)
     
  1020. Low Serum Testosterone and Estradiol Predict Mortality in Elderly Men - (07/16/09)
     
  1021. Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the united states population - (07/15/09)
     
  1022. DDI Associated with NonCirrhotic Portal Hypertension - (07/14/09)
     
  1023. Grinding to a Halt: The Effects of the Increasing Regulatory Burden on Research and Quality Improvement Efforts - IDSA POLICY PRINCIPLES - (07/10/09)
     
  1024. FDA: Isentress (raltegravir) indication extended for the treatment of HIV-1 infection in treatment-naïve patients - (07/10/09)
     
  1025. Glutamic Acid (Vegetables) May Lower Blood Pressure - (07/10/09)
     
  1026. Impairments in memory and hippocampal function in HIV-positive vs HIV-negative women - A preliminary study - (07/10/09)
     
  1027. New HIV Research Finds Early Disabled Immune Response - (07/09/09)
     
  1028. Independent effects of physical activity in patients with nonalcoholic fatty liver disease: exercise improves fatty liver & metabolics - (07/08/09)
     
  1029. Nitrates May Be Environmental Trigger For Alzheimer's, Diabetes And Parkinson's Disease - (07/08/09)
     
  1030. Global Consequences of the Future of Aging with HIV - (07/08/09)
     
  1031. Stepped-Dose vs. Full-Dose Efavirenz for HIV Infection and Neuropsychiatric Adverse Events A Randomized Trial - (07/08/09)
     
  1032. Study finds no increased progression of retinopathy with sanofi-aventis' Lantus - (07/08/09)
     
  1033. Epidemilogical Trends Strongly Suggest Exposures as Etiologic Agents in the Pathogenesis of Sporadic Alzheimer's Disease, Diabetes Mellitus, and Non-Alcoholic Steatohepatitis - (07/08/09)
     
  1034. A Vital Role for Interleukin-21 in the Control of a Chronic Viral Infection - full text pdf attached - (07/07/09)
     
  1035. IL-21R on T Cells Is Critical for Sustained Functionality and Control of Chronic Viral Infection - pdf full text attached - (07/07/09)
     
  1036. IL-21 Is Required to Control Chronic Viral Infection - pdf full text attached - (07/07/09)
     
  1037. Immunology Controlling Chronic Viral Infections, EDITORS' CHOICE - (07/07/09)
     
  1038. A Chronic Need for IL-21 EDITORIAL - (07/07/09)
     
  1039. Proton-Pump Inhibitor Therapy Induces Acid-Related Symptoms in Healthy Volunteers After Withdrawal of Therapy - (07/04/09)
     
  1040. Evidence That Proton-Pump Inhibitor Therapy Induces the Symptoms it Is Used to Treat EDITORIAL - (07/04/09)
     
  1041. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy - (07/04/09)
     
  1042. Are Markers of Inflammation More Strongly Associated with Risk for Fatal Than for Nonfatal Vascular Events? - (07/03/09)
     
  1043. IL-7 Increased T-Cells CD4/CD8/Naive/Memory: In HIV, Cytokine Boosts Immune System  - (07/03/09)
     
  1044. Association of Serum C-Reactive Protein Level with Sex-Specific Type 2 Diabetes Risk: A Prospective Finnish Study - (07/03/09)
     
  1045. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance - (07/03/09)
     
  1046. Data are lacking for quantifying HIV transmission risk in the presence of effective antiretroviral therapy EDITORIAL - (07/03/09)
     
  1047. Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients - (07/03/09)
     
  1048. Metabolic bone disease in HIV infection: HIV, ART Implicated EDITORIAL - (07/02/09)
     
  1049. First line AZT/3TC/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir - (07/02/09)
     
  1050. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials - (07/02/09)
     
  1051. Inflammation Marker hsCRP & CVD- Cause or Effect: Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease - (07/02/09)
     
  1052. Novel and Conventional Biomarkers for Prediction of Incident Cardiovascular Events in the Community: "Minimal Benefit In Predicting CVD Compared To Traditional Risk Factors" - (07/02/09)
     
  1053. Biomarkers and Cardiovascular Disease: Determining Causality and Quantifying Contribution to Risk Assessment - Editorial - (07/02/09)
     
  1054. CRP, other biomarkers, not clinically useful to predict CVD risk - (07/02/09)
     
  1055. New meta-analysis: Statins of benefit in primary prevention: improved survival & CVD risk in patients with only risk factors - (07/02/09)
     
  1056. HIV Resistance Wksp: Bulk sequence-detectable resistance mutations in peripheral RNA following single-dose nevirapine are associated with poorer treatment responses but do not adequately explain treatment failure (06/26/09)
     
  1057. HIV Resistance Wksp: Addition of extended zidovudine to extended nevirapine prophylaxis reduces resistance in infants who were HIV-infected in utero: the PEPI- Malawi Study - (06/28/09)
     
  1058. HIV Resistance Wksp: Resistance mutations detected by OLA of HIV-1 DNA at the initiation of nevirapine containing ART are associated with virologic failure - (06/28/09)
     
  1059. HIV Resistance Wksp: Pre-Existing Low-Levels of the K103N HIV-1 RT Mutation Above a Threshold is Associated with Virological Failure in Treatment-Naïve Patients Undergoing EFV-Containing Antiretroviral Treatment (06/16/09)
     
  1060. Raltegravir With Unboosted Atazanavir 300 mg Twice Daily in Antiretroviral Treatment-Experienced Participants - (06/27/09)
     
  1061. Monitoring bone mineral density during antiresorptive treatment for osteoporosis - Editorial - (06/27/09)
     
  1062. Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data - (06/27/09)
     
  1063. The Value of Bone Density Testing - (06/27/09)
     
  1064. Anatomy of health effects of Mediterranean diet: Greek EPIC prospective cohort study - (06/27/09)
     
  1065. Head-to-head 96-week study shows EPZICOM® was comparable to Truvada® -- in efficacy and safety measures -- for HIV treatment-naïve patients - (06/27/09)
     
  1066. HIV Resistance Wksp: Raltegravir With Unboosted Atazanavir 300 mg Twice Daily in Antiretroviral Treatment-Experienced Participants - (06/27/09)
     
  1067. HIV Resistance Wksp: CCR5 Tropism Genotype vs Trofile - (06/27/09)
     
  1068. HIV Resistance Wksp: Virco: Population and clonal tropism phenotyping of clinical isolates and comparison with next generation sequencing and prediction tools - (06/27/09)
     
  1069. HIV Resistance Wksp:Quest Tropism Assay: Performance of an HIV-1 Co-receptor Tropism Assay Utilizing Replicate V3 Loop Sequencing and Heteroduplex Analysis with Capillary Electrophoresis - (06/27/09)
     
  1070. HIV Resistance Wksp: Virco: Detection limit of X4 minority virus in abundant R5-tropic virus populations in standard genotypic and phenotypic assays - (06/27/09)
     
  1071. HIV infection and the risk of diabetes mellitus in Vets - (06/26/09)
     
  1072. Association of C-Reactive Protein and HIV Infection With Acute Myocardial Infarction - (06/26/09)
     
  1073. Analysis of HIV-1 Viremia and Provirus in Resting CD4+ T Cells Reveals a Novel Source of Residual Viremia in Patients on Antiretroviral Therapy - (06/26/09)
     
  1074. New HIV Eradication Theory: 2nd reservoir identified, HAART + IL-7 Inhibition - (06/26/09)
     
  1075. HIV Resistance Wksp: HIV Reservoirs and Potential Eradication - Written by Mark A. Wainberg, Ph.D. Professor and Director, McGill University AIDS Centre - (06/26/09)
     
  1076. HIV Resistance Wksp: PERSISTENCE, RESERVOIRS AND ELIMINATION STRATEGIES - Reported by David Margolis, University of North Carolina (06/26/09)
     
  1077. New Anti-Inflammation Modulator Improves Kidney/Diabetes Functions; for CNS disease too - (06/21/09)
     
  1078. Early antiretroviral treatment prevents the development of central nervous system abnormalities in simian immunodeficiency virus-infected rhesus monkeys - (06/19/09)
     
  1079. HIV Resistance Wksp: Phenotypic Resistance and Response to Tipranavir, evidence for Hypersusceptibility (06/19/09)
     
  1080. HIV Resistance Wksp: Emergence of mutations and phenotypic resistance with tipranavir treatment in protease inhibitor experienced patients (06/19/09)
     
  1081. HIV Resistance Wksp: Tipranavir & Darunavir, Prevalences of mutations in patients with discordant phenotypic resistance from Monogram Biosciences database of routine clinical samples from 2006 - 2008 (06/19/09)
     
  1082. HIV Resistance Wksp: Tipranavir - Phenotypic protease inhibitor resistance in the clinic from 2006 to 2008: available treatment options (06/19/09)
     
  1083. Interleukin-2: Trials and Tribulations; IL-2 Fails Again, EDITORIAL COMMENTARY - (06/17/09)
     
  1084. HIV Resistance Wksp: Genotypic, Phenotypic and Virtual Phenotypic Resistance Patterns for Darunavir and Tipranavir: An Independent Analysis of a Quebec HIV-1 Cohort Highly Resistant to all Other Protease Inhibitors (06/17/09)
     
  1085. HIV Resistance Wksp: Amino Acid Changes in gp41 of HIV-1 Associated with Coreceptor Tropism (06/17/09)
     
  1086. HIV Resistance Wksp: Transitions from CCR5 to CXCR4 use in the absence of antiretroviral drug pressure proceed incrementally and may occur through a multitude of genetic pathways: Monogram Report, Vs loop changes vary (06/17/09)
     
  1087. HIV Resistance Wksp: PI-Resistant Virus Seems More Prone to Emergence of Bevirimat Mutations - written by Mark Mascolini (06/16/09)
     
  1088. HIV Resistance Wksp: Genotypic and Phenotypic Weighted Optimized Background Therapy Susceptibility Scores Are Similarly Strong Predictors of Virologic Response <50 Copies/mL at Week 48 in MOTIVATE 1 and 2 (06/16/09)
     
  1089. HIV Resistance Wksp: 48-Week Results From the Phase 3 Study A4001026 (MERIT) -"Time to Loss of Virologic Response" Virology Analysis of Failures in the Enhanced Trofile®-Censored Subpopulation (06/16/09)
     
  1090. 7th Euro HIV Drug Resis Wrkshp: Ultradeep pyrosequencing and phenotypic analysis to characterize the V3 genetic diversity among HIV-1 primary isolates and their responses to maraviroc - (06/16/09)
     
  1091. HIV Resistance Wksp: High -Prevalence of bevirimat resistance mutations in non-B subtypes and in PI resistant HIV isolates (06/16/09)
     
  1092. HIV Resistance Wksp: Resistance Mutations in the Viral Protease Alter Bevirimat Resistance Patterns in vitro (06/16/09)
     
  1093. HIV Resistance Wksp: Prevalence and Clinical Significance of Transmitted Drug Resistant HIV Mutations by Ultra-Deep Sequencing in HIV-Infected ARV-Naïve Subjects in the CASTLE Study (06/16/09)
     
  1094. HIV Resistance Wksp: Confirmation of the negative impact of protease mutations I47V, I54M, T74P and I84V and the positive impact of protease mutation V82A on virological response to darunavir/ritonavir (06/16/09)
     
  1095. HIV Resistance Wksp: Swiss Cohort Analysis Reveals Clusters of Transmitted Resistant HIV: "make sure patient names remain unlinked to transmission analyses" - written by Mark Mascolini - (06/16/09)
     
  1096. HIV Resistance Wksp: Low-Level K103N in Primary Infection Can Reappear After Suppressive Therapy - written by Mark Mascolini - (06/16/09)
     
  1097. HIV Resistance Wksp: CCR5 and CCR5 Screening Assays Comparisons: genotype, 454 Ultra-Deep Sequencing and Trofile (06/15/09)
     
  1098. HIV Resistance Wksp: Screening for HIV Tropism Using Population-Based V3 Genotypic Analysis: A Retrospective Virological Outcome Analysis Using Stored Plasma Screening Samples From MOTIVATE 1 (06/15/09)
     
  1099. HIV Resistance Wksp: In-vitro resistance profile of TMC278, a next-generation NNRTI: evidence of a higher genetic barrier and a more robust resistance profile than first-generation NNRTIs (06/15/09)
     
  1100. HIV Resistance Wksp: Weighted Genotype and Phenotypic Scores Predict Response to Maraviroc - written by Mark Mascolini - (06/15/09)
     
  1101. HIV Resistance Wksp: Key Etravirine Mutations Also Render HIV Resistant to Rilpivirine - written by Mark Mascolini - (06/15/09)
     
  1102. HIV Resistance Wksp: STD History Tied to Infection With Resistant HIV in San Francisco - written by Mark Mascolini - (06/15/09)
     
  1103. HIV Resistance Wksp: Low-Level Etravirine Mutations With K103N After NNRTI Failure - written by Mark Mascolini - (06/15/09)
     
  1104. HIV Resistance Wksp: Low-Level Q148R in People Without Integrase Inhibitor Experience - written by Mark Mascolini - (06/15/09)
     
  1105. HIV Resistance Wksp: Evolving Mutation Patterns Traced During Elvitegravir Failure - written by Mark Mascolini - (06/15/09)
     
  1106. HIV Resistance Wksp: Rising Rates of 3-Class Exposure But Falling Failure Rate in US Cities - written by Mark Mascolini - (06/15/09)
     
  1107. HIV Resistance Wksp: Transmitted Multidrug-Resistant HIV Persists in PBMC DNA for Years - written by Mark Mascolini - (06/15/09)
     
  1108. HIV Resistance Wksp: The HIV-1 RT Mutant Q151L Shows Decreased Replication Capacity, Selective High-Level Resistance to GS-9148 and Hypersusceptibility to Tenofovir and Zidovudine - (06/15/09)
     
  1109. HIV Resistance Wksp: HBV Resistance to Lamivudine at Undetectable and Low Levels of Viremia - written by Mark Mascolini - (06/15/09)
     
  1110. HIV Resistance Wksp: Early Response to Maraviroc Equivalent With Coreceptor Genotyping and Trofile Phenotyping - written by Mark Mascolini - (06/15/09)
     
  1111. HIV Resistance Wksp: Most Low-Level Pretreatment Mutations Did Not Affect Outcome in PI Trial - written by Mark Mascolini - (06/15/09)
     
  1112. HIV Resistance Wksp: Cutoffs Suggested for Predicting Efavirenz Failure With Low-Level K103N - written by Mark Mascolini - (06/15/09)
     
  1113. HIV Resistance Wksp: Regimens Lacking CCR5 Antagonists Have Minimal Impact on Coreceptor Use - written by Mark Mascolini - (06/12/09)
     
  1114. HIV Resistance Wksp: Lower M184V Rates With FTC/TDF Than With 3TC/TDF - written by Mark Mascolini - (06/12/09)
     
  1115. HIV Resistance Wksp: Raltegravir Did Not Lower HIV DNA Levels in Cell Reservoirs in Salvage Patients in 24 Weeks - written by Mark Mascolini - (06/12/09)
     
  1116. HIV Resistance Wksp: Intensification of Already Suppressive Therapy with Raltegravir Had No Impact on Low-Level (sub-50-copy) Viremia - written by Mark Mascolini - (06/12/09)
     
  1117. HIV Resistance Wksp: HIV Genetic Diversity Does Not Change Much After Complete Viral Control - written by Mark Mascolini - (06/12/09)
     
  1118. HIV Resistance Wksp: NNRTI/PI Regimen More Prone to Resistance Than Standard Triple Combos - written by Mark Mascolini - (06/12/09)
     
  1119. HIV Resistance Wksp: Success Rate With Genotype-Guided First Regimen Near 90% in California - written by Mark Mascolini - (06/12/09)
     
  1120. Thiazolidinediones and clinical outcomes in type 2 diabetes Comment - (06/09/09)
     
  1121. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial - (06/09/09)
     
  1122. PPI Use & Risk For Hip Fracture (Tagamet & Zantac to) - (06/09/09)
     
  1123. Drug Interactions with New and Investigational Antiretrovirals: darunavir, etravirine, rilpivirine (TMC278), maraviroc, vicriviroc, raltegravir, elvitegravir, INCB 9471 (CCR5), bevirimat [Review Articles] - (06/09/09)
     
  1124. Can HIV Be Eradicated? - (06/08/09)
     
  1125. Study in Neurology journal (Aug 2008) Reports Alzheimers Appears to Precede Frailty and Study in Jnl of Geronotology (2007) in the MACS Cohort Reports Risk of Frailty Higher in HIV+ vs HIV-; is early onset of Alzheimers or some other brain or cognitive dysfunction related to early onset and higher rates of frailty among HIV+? - (06/08/09)
     
  1126. DATA ON INVESTIGATIONAL DRUG TMC207 FOR TREATMENT OF MDR-TUBERCULOSIS, PUBLISHED IN NEW ENGLAND JOURNAL OF MEDICINE - Tibotec announcement - (06/05/09)
     
  1127. TMC207, New Drug for TB MultiDrug Resistant (MDR) & XDR (extensively drug resistant) - (06/05/09)
     
  1128. Aspirin in CVD primary prevention: sex and baseline risk matter - (06/04/09)
     
  1129. Gardasil in Older Women Aged 24-45 Years - (06/04/09)
     
  1130. FDA Approves Zoledronic Acid - Reclast(R) - to Prevent Osteoporosis in Postmenopausal Women With Convenient Less Frequent Dosing, Once Every 2 Years - (06/03/09)
     
  1131. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy - (06/03/09)
     
  1132. Maraviroc Safety/CD4 - A Double-Blind, Placebo-Controlled Trial of Maraviroc in Treatment-Experienced Patients Infected with Non-R5 HIV-1 - (06/03/09)
     
  1133. HIV Viremia and the Development of AIDS-Related Lymphoma in Patients Treated with Highly Active Antiretroviral Therapy - EDITORIAL COMMENTARY - (06/03/09)
     
  1134. Cumulative HIV Viremia during Highly Active Antiretroviral Therapy Is a Strong Predictor of AIDS-Related Lymphoma - (06/03/09)
     
  1135. CROI: Quantification of HIV Tropism by "Deep" Sequencing Shows a Broad Distribution of Prevalence of X4 Variants in Clinical Samples that Is Associated with Virological Outcome - (06/02/09)
     
  1136. Antiaging Therapy with TAT2: Telomerase-Based Pharmacologic Enhancement of Antiviral Function of Human CD8+ T Lymphocytes - (06/02/09)
     
  1137. Modulation of T Lymphocyte Replicative Senescence via TNF-{alpha} Inhibition: Role of Caspase-31 - (06/01/09)
     
  1138. Duration of antihypertensive drug use and risk of dementia: "Antihypertensive drug use was associated with 8% risk reduction of dementia per year of use for persons <75 years." - (05/29/09)
     
  1139. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons - (05/29/09)
     
  1140. Hypertension and late-life dementia - Editorial - (05/29/09)
     
  1141. Routine Use of Antihypertensive Medications Recommended For All Older People Even Those Who Do Not Have High Blood Pressure - (05/29/09)
     
  1142. Give blood pressure drugs to all - Criticism/Commentary - (05/29/09)
     
  1143. Editorials Management of blood pressure in primary care - (05/29/09)
     
  1144. In NFL, Higher Rates of Hypertension/Prehypertension & BMI (large size) Associated with Increased Cardiovascular Risk - (05/28/09)
     
  1145. Review of Prostate Cancer Treatment A 64-Year-Old Man With Low-Risk Prostate Cancer - (05/28/09)
     
  1146. Simplification of Antiretroviral Therapy to a Single-Tablet Regimen Consisting of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate Versus Unmodified Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients - (05/28/09)
     
  1147. Improvement in Lipid Profiles in Antiretroviral-Experienced HIV-Positive Patients With Hyperlipidemia After a Switch to Unboosted Atazanavir - (05/28/09)
     
  1148. Lopinavir-Ritonavir Monotherapy Versus Lopinavir-Ritonavir and 2 Nucleosides for Maintenance Therapy of HIV: 96-Week Analysis - (05/28/09)
     
  1149. Lipoatrophy Influenced by Genetics - (05/28/09)
     
  1150. Lipoatrophy and lipohypertrophy (belly fat not associated after BMI factored in) are independently associated with hypertension - (05/27/09)
     
  1151. Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? - (05/27/09)
     
  1152. Hyperglycaemia and coronary heart disease: the meta picture - EDITORIAL - (05/27/09)
     
  1153. It is "premature to conclude that glucose control has no part to play." - (05/27/09)
     
  1154. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials - (05/27/09)
     
  1155. The Nucleoside Backbone Affects Durability of Efavirenz- or Nevirapine-Based Highly Active Antiretroviral Therapy in Antiretroviral-Naive Individuals - (05/27/09)
     
  1156. Sustained release of microbicides by newly engineered vaginal rings - TMC120/tenofovir/AZT - (05/26/09)
     
  1157. Interaction of Ginkgo biloba with efavirenz - (05/26/09)
     
  1158. Efavirenz and bone health - (05/22/09)
     
  1159. Maturation Inhibitor Bevirimat, now called MPC-4326, Starting Phase 2b in 2nd Half 2009 - (05/22/09)
     
  1160. Efavirenz and bone health - (05/22/09)
     
  1161. Maturation Inhibitor Bevirimat, now called MPC-4326, Starting Phase 2b in 2nd Half 2009 - (05/22/09)
     
  1162. Does HIV Increase Prostate Cancer Risk? - (05/21/09)
     
  1163. Effects of Oxidation and Inflammation, Cancer, Prostate Cancer - (05/21/09)
     
  1164. ACTG 5142 Published: Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment - (05/21/09)
     
  1165. HIV viremia and changes in kidney function - (05/21/09)
     
  1166. ACTG 5164 Published: Early HAART Reduces AIDS/Death in Individuals with Acute OIs - (05/21/09)
     
  1167. Anal human papillomavirus infection is associated with HIV acquisition in men who have sex with men - (05/21/09)
     
  1168. Immune Exhaustion in Aging and AIDS: Parallel Mechanisms and Possible Solutions - (05/21/09)
     
  1169. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis - (05/20/09)
     
  1170. Evidence of a Large, International Network of HCV Transmission in HIV-Positive Men Who Have Sex With Men - (05/18/09)
     
  1171. Kidney Damage in Metabolic Syndrome: Nip It in the Bud - EDITORIAL - (05/18/09)
     
  1172. Kidney Pathological Changes in Metabolic Syndrome: A Cross-sectional Study - (05/18/09)
     
  1173. C-Reactive Protein, Statins, and Cardiovascular Risk: What Can JUPITER Teach Us? - (05/18/09)
     
  1174. 10th Int PK Wrkshp: 10th International Workshop on Clinical Pharmacology of HIV Therapy Written by Courtney V. Fletcher, Pharm.D. - (05/18/09)
     
  1175. Predicting risk of dementia in older adults. The late-life dementia risk index - Aging !!!! - (05/15/09)
     
  1176. Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence - REVIEW ARTICLE - (05/15/09)
     
  1177. Ejaculation Frequency and Subsequent Risk of Prostate Cancer - "high ejaculation frequency was related to decreased risk of total prostate cancer." - (05/15/09)
     
  1178. Data on the Use of GARDASIL in Men Presented at the 25th Annual International Papillomavirus Conference - (05/15/09)
     
  1179. THE EFFFICACY OF QUADRIVALENT HPV (TYPES 6/11/16/18) VACCINE AGAINST HPV-RELATED GENITAL DISEASE AND INFECTION IN YOUNG MEN - (05/15/09)
     
  1180. Risk of Myocardial Infarction and Abacavir Therapy: No Increased Risk Across 52 GlaxoSmithKline-Sponsored Clinical Trials in Adult Subjects - (05/14/09)
     
  1181. Association between hypothyroidism and hepatocellular carcinoma: A case-control study in the United States; Increased Hypothyroidism Reported un HIV+ - (05/14/09)
     
  1182. Elevated A1C in Adults Without a History of Diabetes in the U.S. - (05/14/09)
     
  1183. Tenative approval of lamivudine/zidovudine fixed dose combination tablets plus nevirapine tablets - (05/14/09)
     
  1184. Raltegravir+Etravirine - Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort - (05/14/09)
     
  1185. Increased Reporting of Detectable Plasma HIV-1 RNA Levels at the Critical Threshold of 50 Copies per Milliliter With the Taqman Assay in Comparison to the Amplicor Assay - (05/14/09)
     
  1186. Implementation of HIV Testing at 2 New York City Bathhouses: From Pilot to Clinical Service (4% HIV+) - (05/14/09)
     
  1187. Availability of HIV Postexposure Prophylaxis Services in Los Angeles County - (05/14/09)
     
  1188. RNA Testing for HIV Instead of Antibody Testing Could Detect Early Stage of HIV Infection And Would Likely Improve Prevention AND Allow for Early HAART' Could it Prevent Accelerated Aging? - (05/13/09)
     
  1189. Dementia with features of Alzheimer's disease and HIV-associated dementia in an elderly man with AIDS (case study) - (05/13/09)
     
  1190. Cancers in HIV Review in AIDS May 15 2009 - (05/13/09)
     
  1191. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial - (05/13/09)
     
  1192. Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival (NA-ACCORD): deferring HAART til <500 CD4s increased risk of death 94% - (05/11/09)
     
  1193. WHO Guidance for HIV Patient Care & Swine Flu - (05/11/09)
     
  1194. HIV/AIDS Research Network Recommends Use of Abbott RealTime Viral Load Test for NIH-Sponsored Clinical Trials - (05/11/09)
     
  1195. Hypoglycemia Increased Risk for Death in Diabetics with Chronic Kidney Disease: - (05/11/09)
     
  1196. 10th Int PK Wrkshp: First-Dose and Steady-State Pharmacokinetics of Raltegravir in the Genital Tract of HIV Negative Women - (04/30/09)
     
  1197. Interim Results of Abbott's PROGRESS Study Show Rapid Viral Decline in Dual-Therapy Regimen of Kaletra® (lopinavir/ritonavir) and Raltegravir - Abbott press release - (04/30/09)
     
  1198. Sunlight and Vitamin D Both Good for Cardiovascular Health - (04/22/09)
     
  1199. Tight Glycemic Control NOT Recommended for Diabetics in Annals Review - (04/22/09)
     
  1200. A Systematic Review of the Evidence Supporting a Causal Link Between Dietary Factors and Coronary Heart Disease - (04/22/09)
     
  1201. 10th Int PK Wrkshp: Raltegravir Levels in Cervicovaginal Fluid May Prompt PEP and PrEP Studies - written by Mark Mascolini - (04/21/09)
     
  1202. 10th Int PK Wrkshp: Merck Offers Unique Perspective on Second-Generation Integrase Inhibitor - written by Mark Mascolini - (04/20/09)
     
  1203. 10th Int PK Wrkshp: Differing Darunavir Troughs With Once- and Twice-Daily Dosing in Practice - written by Mark Mascolini - (04/20/09)
     
  1204. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial - (04/20/09)
     
  1205. Glucocorticoid-induced osteoporosis: hope on the HORIZON-COMMENT once yearly infusion therapy better than once weekly - (04/20/09)
     
  1206. Reversing HIV T-Cell Aging - (04/20/09)
     
  1207. HIV-1 Infection Is Associated With an Earlier Occurrence of a Phenotype Related to Frailty: HIV+ men in MACS 10-Times More Likely to Exhibit Frailty than HIV-negative Men. - (04/20/09)
     
  1208. MACS Frailty/HIV/CD4 Study Misses The Point - (04/20/09)
     
  1209. Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance - (04/20/09)
     
  1210. PrEP, Microbicides and IL-2 - (04/20/09)
     
  1211. 15th Annual British HIV Conference April 1-3 2009 Abstracts/Presentations - (04/20/09)
     
  1212. Poly-l-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up - (04/20/09)
     
  1213. Lopinavir/Ritonavir (LPV/r) Combined With Raltegravir (RAL) Provides More Rapid Viral Decline Than LPV/r Combined With Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in Treatment-naïve HIV-1 Infected Subjects - (04/20/09)
     
  1214. Ignoring Addiction in Prison/Jails Increases HIV & HCV Infections - (04/20/09)
     
  1215. Hypoglycemic Episodes and Risk of Dementia in Older Patients With Type 2 Diabetes Mellitus - (04/20/09)
     
  1216. the REYATAZ and SUSTIVA Co-pay Benefit Program - (04/20/09)
     
  1217. Treatment Interruption Revisited with LOTTI Study: authors reported interruptions were not inferior to continuous HAART in this study - (04/20/09)
     
  1218. Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases - (04/20/09)
     
  1219. 10th Int PK Wrkshp: Unboosted Atazanavir Plus Raltegravir Analyzed as Two-Drug Replacement Regimen - written by Mark Mascolini - (04/20/09)
     
  1220. 10th Int PK Wrkshp: Etravirine Levels Higher When Added After Darunavir vs With Darunavir - written by Mark Mascolini - (04/20/09)
     
  1221. 10th Int PK Wrkshp: Enfuvirtide-to-Raltegravir Switch Lowers Levels of Darunavir and Tipranavir - written by Mark Mascolini - (04/20/09)
     
  1222. CROI: Prevention of Rectal Simian HIV Transmission in Macaques by Intermittent Pre-exposure Prophylaxis with Oral Truvada - (04/17/09)
     
  1223. 10th Int PK Wrkshp: Efavirenz Lowers Levels of Darunavir Given as 900/100 mg Once Daily With Ritonavir - (04/16/09)
     
  1224. 10th Int PK Wrkshp: Early Look at Once-Daily Darunavir/Ritonavir for Treatment-Experienced Patients - written by Mark Mascolini - (04/16/09)
     
  1225. 10th Int PK Wrkshp: How Much (or How Little) Ritonavir Do You Need to Boost Another PI? - written by Mark Mascolini - (04/16/09)
     
  1226. 10th Int PK Wrkshp: Lopinavir/Ritonavir Monotherapy as an Antiretroviral Stopping Strategy - written by Mark Mascolini - (04/16/09)
     
  1227. 10th Int PK Wrkshp: Genetic Markers Tied to Early Discontinuation of Three Antiretrovirals - (04/16/09)
     
  1228. IDUs Risky Behavior: < 32% share syringes/63% have unprotected vaginal sex, CDC Study - (04/10/09)
     
  1229. Screening for Albuminuria Identifies Individuals at Increased Renal Risk - (04/10/09)
     
  1230. Should the CD4 threshold for starting ART be raised? Commentary - (04/10/09)
     
  1231. Phase III Study of Gilead's Darusentan for Resistant Hypertension Meets Primary Endpoints - (04/10/09)
     
  1232. Vitamin D Deficiency in Older Men - (04/09/09)
     
  1233. Relationships of Serum 25-Hydroxyvitamin D to Bone Mineral Density and Serum Parathyroid Hormone and Markers of Bone Turnover in Older Persons - (04/09/09)
     
  1234. The Relationship Between Prolonged Antiretroviral Therapy and Cryptogenic Liver Disease - (04/09/09)
     
  1235. Whither Recombinant Human Leptin Treatment for HIV-Associated Lipoatrophy and the Metabolic Syndrome? EDITORIAL - (04/09/09)
     
  1236. Leptin Improved Belly Fat/Dyslipidemia - The Effects of Recombinant Human Leptin on Visceral Fat, Dyslipidemia, and Insulin Resistance in Patients with Human Immunodeficiency Virus-Associated Lipoatrophy and Hypoleptinemia - Pilot Study - (04/09/09)
     
  1237. Belly Fat & Women. Adipokines, Inflammation, and Visceral Adiposity across the Menopausal Transition: A Prospective Study - (04/09/09)
     
  1238. Broccoli sprouts appear to reduce risk for stomach cancer, reduced inflammation in stomach. - (04/08/09)
     
  1239. End-Stage Liver Disease in HIV+ in France A Leading Cause of Death - (04/03/09)
     
  1240. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalite 2005 study - (04/03/09)
     
  1241. 'When to Start HAART' Experts Disagree-NEJM Study - (04/03/09)
     
  1242. Does Inflammation Fuel the Fire in CKD? - (04/03/09)
     
  1243. HPV Test vs Cytologic Testing or Visual Inspection: HPV Screening for Cervical Cancer in Rural India - (04/03/09)
     
  1244. When to Start Antiretroviral Therapy - Ready When You Are? EDITORIAL (NA-ACCORD) - (04/03/09)
     
  1245. Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes - (04/02/09)
     
  1246. Aspirin, salicylates, and cancer - (03/31/09)
     
  1247. JUPITER Study Reports Reducing hsCRP & LDL to Low Levels with Statin rosuvastatin Further Reduced Cardiovascular Risk - (03/31/09)
     
  1248. JUPITER: Rosuvastatin reduces risk of VTE in healthy subjects - (03/31/09)
     
  1249. EHDRW: Comparison of two etravirine weighted genotypic scores with phenotypic susceptibility and virological response data (03/31/09)
     
  1250. EHDRW: No Darunavir & Kaletra Major PI Mutations in ARTEMIS 96 Weeks (03/31/09)
     
  1251. EHDRW: Low-Level Transmitted K103N Mutation Predicts Virologic Failure - Written by Mark Mascolini (03/31/09)
     
  1252. EHDRW: No Resistance to Darunavir or Lopinavir After 96 Weeks in ARTEMIS - Written by Mark Mascolini (03/31/09)
     
  1253. EHDRW: Weighted Genotyping Scores Work Equally Well in Predicting Response to Etravirine - Written by Mark Mascolini (03/31/09)
     
  1254. EHDRW: Weighted Genotypic Score Predicts Response to Maraviroc in MOTIVATE Trials - Written by Mark Mascolini (03/30/09)
     
  1255. ART Interruption in Pregnancy Increases MTCT - (03/30/09)
     
  1256. Tight glucose control may increase mortality in critically ill patients - (03/30/09)
     
  1257. Intensive versus Conventional Glucose Control in Critically Ill Patients The NICE-SUGAR Study Investigators - (03/30/09)
     
  1258. Glucose Control in the ICU - How Tight Is Too Tight? EDITORIAL - (03/30/09)
     
  1259. Transfer of HIV between T Cells Captured on Video - (03/30/09)
     
  1260. Application of Lower Sodium Intake Recommendations to Adults --- United States, 1999--2006 - (03/30/09)
     
  1261. Tea drinking habits and oesophageal cancer in a high risk area in northern Iran: population based case-control study - (03/30/09)
     
  1262. Prevalence and Pathogenesis of Diabetes Mellitus in HIV-1 Infection Treated With Combined Antiretroviral Therapy - (03/30/09)
     
  1263. EHDRW: Genotyping for Coreceptor Use Concordant With Trofile in PBMCs and Plasma: from Jules- genotyping this falls short - Written by Mark Mascolini - (03/27/09)
     
  1264. EHDRW: HIV-Induced CD4 Declines Affect Immune Response to HBV in Untreated People - Written by Mark Mascolini - (03/27/09)
     
  1265. Prevention of Viral Sexually Transmitted Infections - Foreskin at the Forefront (male circumcision) EDITORIAL - (03/27/09)
     
  1266. Midlife Patients With HIV or AIDS Require Care for Chronic Conditions: "HIV simulates aging" - (03/27/09)
     
  1267. Prevalence, Clearance, and Incidence of Anal Human Papillomavirus Infection in HIV-Infected Men: The HIPVIRG Cohort Study - (03/27/09)
     
  1268. Avexa Reaches First Critical Evaluation Point for new NRTI ATC's Phase III Trial - (03/27/09)
     
  1269. Tight glucose control may increase mortality in critically ill patients - (03/27/09)
     
  1270. Male Circumcision for the Prevention of HSV-2 and HPV Infections and Syphilis: circumcision prevents HSV-2 and HPV - (03/27/09)
     
  1271. EHDRW: Viral Loads--But Not Transmission of Resistant Virus--Falling in Italian Cohort - Written by Mark Mascolini - (03/27/09)
     
  1272. EHDRW: Resistance Testing Is Not Standard-of-Care After Antiretroviral Failure in Europe - Written by Mark Mascolini - (03/27/09)
     
  1273. EHDRW: Cumulative Resistance Score Gives Broader View of Potential Antiretroviral Activity - Written by Mark Mascolini - (03/27/09)
     
  1274. CROI: Non-HIV Markers Add to HIV Signals in Predicting VA Cohort Deaths - written by Mark Mascolini - (03/25/09)
     
  1275. CROI: US and Canadian Studies Trace Impact of Resistance Results on Mortality - written by Mark Mascolini - (03/25/09)
     
  1276. CROI: Higher Rate of Non-AIDS Infection-Related Cancers With HIV May Be Waning in HAART Era - written by Mark Mascolini - (03/25/09)
     
  1277. ISHLVD: Use of Tenofovir Disoproxil Fumarate (TDF) in Pregnancy: Findings from the Antiretroviral Pregnancy Registry (APR) - (03/25/09)
     
  1278. ISHLVD: Developing HBV/HCV Associated Liver Cancer At A Young Age < 40 Yrs Old - (03/25/09)
     
  1279. ISHLVD: Estimated Prevalence of Chronic Hepatitis B (CHB) in Foreign-Born (FB) Persons Living in the United States (U.S.) by Country/Region of Origin - (03/23/09)
     
  1280. ISHLVD: Federal Government's Response to Viral Hepatitis - (03/23/09)
     
  1281. ISHLVD: Key Health Care Provisions in Stimulus Legislation - (03/23/09)
     
  1282. ISHLVD: HCV Burden of Disease and Associated Costs: An Overview - (03/23/09)
     
  1283. ISHLVD: Barriers to HCV Care - (03/23/09)
     
  1284. Plasma Levels of Bacterial DNA Correlate with Immune Activation and the Magnitude of Immune Restoration in Persons with Antiretroviral-Treated HIV Infection - (03/24/09)
     
  1285. Is HIV Eradication Feasible? - (03/20/09)
     
  1286. CROI: Neurologic Complications of HIV Disease and Their Treatment - written by Scott L. Letendre, M.D. et al - (03/19/09)
     
  1287. HIV-Specific IgG in Cervicovaginal Secretions of Exposed HIV-Uninfected Female Sexual Partners of HIV-Infected Men - (03/19/09)
     
  1288. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants: ART before age 3 months dramatically reduces AIDS/death - (03/19/09)
     
  1289. Etravirine, a Next-Generation Nonnucleoside Reverse-Transcriptase Inhbitor - (03/19/09)
     
  1290. Vicriviroc Does Not Increase Epstein-Barr Virus Replication: CCR5 and lymphoma - (03/19/09)
     
  1291. Changes in Cancer Mortality among HIV-infected Patients: The Mortalite 2005 Survey - (03/19/09)
     
  1292. Malignancy-Related Deaths among HIV-Infected Patients: increasing problems with cancers & non-AIDS events - EDITORIAL COMMENTARY - (03/19/09)
     
  1293. New Apricitabine 96 Week Data, Phase 3 Data Expected - (03/19/09)
     
  1294. Depletion of CD4+ T Cells in Semen During HIV Infection and Their Restoration Following Antiretroviral Therapy - (03/19/09)
     
  1295. Relationship Between HIV Coreceptor Tropism and Disease Progression in Persons With Untreated Chronic HIV Infection: naives with D/m progress more quickly, early ART? - (03/19/09)
     
  1296. CROI: Mitochondrial DNA Levels in Pregnancy Are Not Decreased in ARV-treated Women Compared to HIV- Controls - (03/18/09)
     
  1297. CROI: Raltegravir In Children and Adolescents: The French Expanded Access Program - (03/18/09)
     
  1298. CROI: Prognosis of Non-Hodgkin's Lymphoma in HIV-infected Patients - (03/18/09)
     
  1299. CROI: Influence of ART on Incidence and Prognosis of HIV-1-associated Non-Hodgkin's Lymphoma: European Multi-Cohort Study, CD4 Predicts Non-Hodgkin's Lymphoma - (03/18/09)
     
  1300. CROI: Effect of HIV Co-infection on the Outcome of Viral Cirrhosis Liver Transplant Candidates on the Waiting List at a Reference Center from 2001 to 2008 - (03/17/09)
     
  1301. CROI: Liver Transplantation in 88 HIV-infected Patients - (03/17/09)
     
  1302. CROI: HCV Causes Neurcognitive Impairment in HIV+ - (03/17/09)
     
  1303. CROI: HCV Inflames the Brain in HIV Coinfected in Acute HCV - (03/17/09)
     
  1304. CROI: Review of HIV+ Patient's Immunological Response Rate to High-dose HBV Re-vaccination Series: Cd4 & viral load predict response - (03/17/09)
     
  1305. CROI: 5-Year Survival of HCV/HIV-co-infected Liver Transplant Recipients in Spain: A Case/Control Study - (03/17/09)
     
  1306. CROI: Predictors of Chronic HBV Infection in HIV-infected Individuals: HAART Can Prevent Chronic HBV - (03/17/09)
     
  1307. CROI: Interruption of ART and Changes in Hyaluronic Acid as Marker of Liver Fibrosis Progression in Strategies for Management of ART Viral Hepatitis-co-infected Participants and Matched Controls - (03/17/09)
     
  1308. CROI: Hyaluronic Acid as a Prognostic Marker of Hepatic Coma and Liver-related Death in HIV/Viral Hepatitis Co-infected Patients - (03/17/09)
     
  1309. CROI: The Long-term Use of Tenofovir in HIV/HBV Co-infection Induces a Marked Decrease in Liver Fibrosis - (03/17/09)
     
  1310. CROI: ART Reinitiation and HBV Rebound among HIV/HBV-co-infected Patients following ART Interruption in the Strategies for the Management of ART Study - (03/17/09)
     
  1311. CROI: Association of Non-cirrhotic Portal Hypertension in HIV-infected Persons and ART with Didanosine - (03/17/09)
     
  1312. CROI: Prolonged ART and Risk for Chronic Elevation of Alanine Aminotransferase in HIV-infected Persons without HBV or HCV Co-infections - (03/17/09)
     
  1313. CROI: Incidence and Predictors of Acute Renal Failure in an Urban Cohort of Patients with HIV and Hepatitis C Co-infection - (03/17/09)
     
  1314. CROI: High Prevalence of Hepatic Fibrosis and Steatosis in HIV/AIDS Patients without Chronic Viral Hepatitis but with Chronically Elevated Transaminases on ART - (03/17/09)
     
  1315. CROI: Progression of Liver Fibrosis in a Large Cohort of HIV Patients Over 4 Years: Emerging Contribution of Antiretrovirals and Metabolic Abnormalities - (03/17/09)
     
  1316. Human Immunodeficiency Virus in Semen and Plasma: Investigation of Sexual Transmission Risk Behavioral Correlates - (03/16/09)
     
  1317. CROI: Rosiglitazone Improves Lipoatrophy in Patients Receiving Thymidine-sparing Regimens - (03/16/09)
     
  1318. CROI: Platelet Hyper-Reactivity in HIV-1-infected Patients on Abacavir-containing ART - (03/16/09)
     
  1319. CROI: Association of Abacavir and HIV Disease Factors with Endothelial Function in Patients on Long-Term Suppressive Antiretroviral Therapy - (03/16/09)
     
  1320. CROI: HIV in Semen Despite Undetectable in Blood: "residual risk of transmission is still possible during unprotected intercourse" - (03/16/09)
     
  1321. HIV-1 Can Persist in Aged Memory CD4+ T Lymphocytes With Minimal Signs of Evolution After 8.3 Years of Effective Highly Active Antiretroviral Therapy - (03/12/09)
     
  1322. Gemini: A Noninferiority Study of Saquinavir/Ritonavir Versus Lopinavir/Ritonavir as Initial HIV-1 Therapy in Adults - (03/12/09)
     
  1323. CROI: Inflammatory Markers among Abacavir and non-Abacavir Recipients in the Womens' Interagency HIV Study and the Multicenter AIDS Cohort Study - (03/13/09)
     
  1324. CROI: High-density Lipoprotein Particles but Not Low-density Lipoprotein Particles Predict Cardiovascular Disease Events in HIV Patients: Strategies for Management of ART Study - (03/13/09)
     
  1325. How Inflammatory Disease Causes Fatigue: chronic inflammation infiltrates the brain but can be blocked - (03/10/09)
     
  1326. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction - (03/10/09)
     
  1327. New Microbcide Discovery in Monkeys from Ashley Haase - (03/10/09)
     
  1328. CROI: Microbicide gel PRO 2000 may help against HIV -Commentary - (03/10/09)
     
  1329. Response (safety, efficacy) to Newly Prescribed Lipid-Lowering Therapy in Patients With and Without HIV Infection - (03/10/09)
     
  1330. National Women and Girls HIV/AIDS Awareness Day March 10, 2009 - - (03/10/09)
     
  1331. Use of Cognitive Enhancement Drugs - (03/10/09)
     
  1332. CROI: Antiretroviral agents that inhibit CCR5-utilizing HIV-1 - written by Eric S. Daar, M.D. (03/10/09)
     
  1333. CROI: Quantification of HIV Tropism by "Deep" Sequencing Shows a Broad Distribution of Prevalence of X4 Variants in Clinical Samples that Is Associated with Virological Outcome - (03/10/09)
     
  1334. CROI: Association between Modifiable and Non-modifiable Risk Factors and Specific Causes of Death in the HAART Era: The Data Collection on Adverse Events of Anti-HIV Drugs Study -DAD Study - (03/09/09)
     
  1335. CROI: Activation (Inflammation) and Coagulation Biomarkers are Independent Predictors for the Development of Opportunistic Disease in Patients with HIV Infection - (03/09/09)
     
  1336. CROI: Biological Determinants of Immune Reconstitution following Long-term HAART: host factors & persistent gut microbial translocation drive chronic immune activation - (03/09/09)
     
  1337. The Challenge of Finding a Cure for HIV Infection - (03/09/09)
     
  1338. CROI: HIV+ Die More Quickly in FRAM & Low CD4 Predicts Death - (03/09/09)
     
  1339. CROI: Inflammation, Cancers and Other Life Threats for People Living with HIV - written by David Alain Wohl, MD - (03/06/09)
     
  1340. WHO | The unexplored story of HIV and ageing - (03/05/09)
     
  1341. CROI: Osteopenia and Osteoporosis in HIV-infected Patients Are Associated with Reduced Frequency of Central Memory CD8+CD127+ T Cells: T-cell activation/senescence associated with bone loss - (03/05/09)
     
  1342. CROI: Evidence of persistent low-level viremia in long-term HAART-suppressed individuals - (03/05/09)
     
  1343. CROI: Brain Damage, Comorbidities and Early Death Threaten HIV+ - (03/05/09)
     
  1344. CROI: Tenofovir and PI Use Are Associated with an Increased Prevalence of Proximal Renal Tubular Dysfunction in the Swiss HIV Cohort Study: boosted PI+TDF associated with renal function - (03/05/09)
     
  1345. CROI: Viral Hepatitis is Associated with Reduced Bone Mineral Density in HIV-Infected Women but Not Men - (03/04/09)
     
  1346. CROI: First Report of Dose/Response Data of HIV-infected Men Treated with Vitamin D3 Supplements - (03/04/09)
     
  1347. CROI: Effects of Aging on HIV-1 Pathogenesis: HIV causes inflammation & T-cell activation, reported here to be more in postmenopausal women - (03/04/09)
     
  1348. CROI: Raltegravir Intensification, Viral Replication, HIV Reservoirs & HAART - (03/04/09)
     
  1349. CROI: Bone/Osteoporosis CROI 2009 Update - written by Todd Brown, MD, PhD (03/04/09)
     
  1350. CROI: Persisting High Prevalence of HIV Distal Sensory Peripheral Neuropathy in the Era of Combination ART: Correlates in the CHARTER Study - (03/04/09)
     
  1351. CROI: Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome and Mortality during a Randomized Trial of Early versus Deferred ART in the Setting of Acute Opportunistic Infections (ACTG A5164) - (03/04/09)
     
  1352. CROI: The Long Term Use of Tenofovir Disoproxil in HIV-HBV Co-Infection Induces a Marked Decrease in Liver Fibrosis - (03/04/09)
     
  1353. CROI: Viro-Immunologic Abnormalities in Gut Associated Lymphoid Tissue Caused by Acute HIV Infection are not Reverted by Early Initiation of HAART - (03/04/09)
     
  1354. CROI: Ongoing Viral Replication in the Gut Despite HAART Suppressive Viral Control: Lack of Compartmentalization of HIV HIV-1 Quasispecies and Circulation of CXCR4 using HIV-1 between Gut Associated Lymphoid Tissue (GALT) and the Peripheral Blood (PB) - (03/04/09)
     
  1355. CROI: HIV-1 Induces Apoptosis in primary Osteoblasts: an Alternative Mechanism in the Osteopenia/Osteoporosis Development - (03/04/09)
     
  1356. CROI: GENDER AND GONADAL FUNCTION DIFFERENCES IN THE PREVALENCE OF BONE MASS REDUCTION: higher rates of osteopenia and osteoporosis for men vs women and at early ages, in their 40s. - (03/04/09)
     
  1357. CROI: Immune Senescence, Activation and Abnormal T cell Homeostasis Despite Effective HAART, A Hallmark of Early Aging in HIV Disease - (03/03/09)
     
  1358. CROI: Changes in Bone Turnover, OPG/RANKL, and Inflammation with ART Initiation: A Comparison of Tenofovir- and Non-Tenofovir-Containing Regimens - (03/03/09)
     
  1359. CROI: Evaluation of peripheral DEXA Bone Densitometry to identify low bone mineral density in HIV- infected men in UK: 60% osteopenia, 13% osteoporosis- median age 41 yrs; t-score/dexa predicts fracture in HIV - (03/03/09)
     
  1360. CROI: Clinical Determinants of Bone Mineral Density (BMD) in Perinatally HIV-Infected Children - (03/03/09)
     
  1361. CROI: HIV Drug Pipeline at CROI - (03/03/09)
     
  1362. CROI: Bone Mineral Density in HIV+ Women: Relationship to Body Composition - (03/03/09)
     
  1363. CROI: Preferential Bone Demineralization at the Hip in Treated HIV+ Males: Another Example of Premature Aging? - (03/03/09)
     
  1364. CROI: Determinants (HIV, Cytokines) of Low Bone Density in Postmenopausal HIV+ Women - (03/03/09)
     
  1365. CROI: Short term bone loss in HIV infected premenopausal women - (03/03/09)
     
  1366. CROI: Back to Basics: the science at CROI focuses the tough questions that remain in HIV pathogenesis, Part 2 (focal points for new therapies.) - written by David Margolis MD, University of North Carolina - (03/03/09)
     
  1367. CROI: Back to Basics: the science at CROI focuses on the tough questions that remain in HIV pathogenesis - written by David Margolis, MD, University of North Carolina - (02/24/09)
     
  1368. CROI: HIV-Associated Peripheral Neuropathy in the HAART Era: Results from AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) Protocol A5001 - (03/02/09)
     
  1369. Kaletra + Raltegravir PROGRESS Study - (03/02/09)
     
  1370. Kidney Disease in Patients with HIV Infection and AIDS - (03/02/09)
     
  1371. CROI: Metabolic Syndrome, Diabetes, and Cognitive Impairment in the Era of Combination Antiretroviral Therapy - (03/02/09)
     
  1372. CROI: HIGH FREQUENCY (50%) OF NEUROCOGNITIVE DISORDERS IN OLDER (>60 yrs) HIV-INFECTED PATIENTS DESPITE A SUSTAINED VIROLOGICAL AND IMMUNOLOGICAL RESPONSE ON CART: THE SIGMA STUDY - (03/02/09)
     
  1373. CROI: Microbicide PRO 2000/0.5% Gel Shows Promise - (03/02/09)
     
  1374. CROI: Summary of Antiretroviral Treatment Naïve Studies from CROI: Still Looking for a Consensus on When to Start - written by Susan J. Little, M.D. Associate Professor of Medicine University of California San Diego, USA - (02/27/09)
     
    -
  1375. Dairy Food, Calcium, and Risk of Cancer in the NIH-AARP Diet and Health Study - (02/27/09)
     
  1376. Telbivudine has activity against HIV-1 - (02/27/09)
     
  1377. HAART Does Not Reverse Premature T-Cell Aging Caused by HIV - (02/27/09)
     
  1378. Incomplete Peripheral CD4+ Cell Count Restoration in HIV-Infected Patients Receiving Long-Term Antiretroviral Treatment - (02/27/09)
     
  1379. EDITORIAL COMMENTARY The Paradox of Incomplete CD4+ Cell Count Restoration Despite Successful Antiretroviral Treatment and the Need to Start Highly Active Antiretroviral Therapy Early - (02/27/09)
     
  1380. CROI: HBV Blippers and Rebounders under Treatment with Tenofovir in HIV/HBV Co-infection - (02/27/09)
     
  1381. CROI: Aging with HIV - Lessons from CROI 2009 - Victor Valcour MD - (02/27/09)
     
  1382. CROI: Cognitive Impairment & Neuropathy Persist Despite HAART and Are Associated With Metabolic Syndrome - (02/27/09)
     
  1383. CROI: Phase 1, Single Ascending Oral Dose Study of the Safety, Tolerability, and Pharmacokinetics of MPC-9055 a Novel HIV-1 Maturation Inhibitor in HIV Negative Healthy Subjects - (02/27/09)
     
  1384. CROI: Anti-viral Characterization in vitro of a Novel Maturation Inhibitor, MPC-9055 - (02/27/09)
     
  1385. CROI: RDEA427 and RDEA640 are Novel NNRTIs with Potent Anti-HIV Activity Against NNRTI-Resistant Viruses - (02/27/09)
     
  1386. CROI: In Vitro Resistance Selection Study and Favorable Human Pharmacokinetic Properties of RDEA427, a New HIV NNRTI - (02/27/09)
     
  1387. CROI: Clinical Pharmacology at CROI 2009: Pharmacoenhancement, Pharmacogenetics, Drug Interactions and the Pharmacotherapy of HIV Infection - written by Courtney V. Fletcher, Pharm.D. - (02/26/09)
     
  1388. CROI: Pharmacology at the 2009 Conference on Retroviruses and Opportunistic Infections - written by Stephen Becker MD - (02/26/09)
     
  1389. CROI: Cervicovaginal Shedding of HIV-1 Is Related to Genital Tract Inflammation Independent of Changes in Vaginal Microbiota - (02/26/09)
     
  1390. CROI: Forty-Fold Elevated Risk for Lymphoepithelial Carcinoma of Salivary Gland Among People with AIDS in the United States written by Kishor Bhatia, F Shebl, and E Engels NCI, NIH, Bethesda, MD, - (02/26/09)
     
  1391. CROI: Update on Kidney Disease in HIV Infection: CROI 2009 - written by Christina M. Wyatt and Paul E. Klotman, Mt Sinai Hospital, New York City - (02/26/09)
     
  1392. CROI: Impairment in Kidney Tubular Function in Patients Receiving Tenofovir Is Associated with Higher Plasma Tenofovir Levels - (02/26/09)
     
  1393. CROI: HIV & HAART Interruption Increase Inflammation and Disease - (02/26/09)
     
  1394. CROI: Weekly and Biweekly Subcutaneous PRO 140 Demonstrates Potent, Sustained Antiviral Activity: 2-week study - (02/26/09)
     
  1395. CROI: Lopinavir/ritonavir+Tenofovir/Emtricitabine Is Superior to Nevirapine+Tenofovir/Emtricitabine for Women with prior Exposure to Single-dose Nevirapine: A5208 ("OCTANE") - (02/25/09)
     
  1396. CROI: No Association of Abacavir (ABC) Use with Risk of Myocardial Infarction (MI) or Severe Cardiovascular Disease Events (SCVD): Results from ACTG A5001/ALLRT - (02/25/09)
     
  1397. CROI: Progression of High-grade Anal Intraepithelial Neoplasia to Invasive Anal Cancer among HIV+ Men Who Have Sex with Men - (02/25/09)
     
  1398. CROI: Prevalence of Cervical Cancer Screening Among HIV-Infected Women in the United States: 23% Did Not Receive Pap tests within last year - (02/25/09)
     
  1399. CROI: Serious Fatal and Non-fatal Non-AIDS-defining Illnesses in Europe: most common no-AIDS events malignancies/CVD/liver in EuroSida - (02/25/09)
     
  1400. CROI: Causes of Death in Patients Treated with ART (IDUs vs non-IDUs), 1996 to 2006: Collaborative Analysis of 13 Cohort Studies - (02/25/09)
     
  1401. CROI: Relationship between Current Level of Immunodeficiency and Non-AIDS-defining Malignancies, EuroSida: "Immunosuppression ...current CD4 count....was associated with an excess risk of NADM" - (02/25/09)
     
  1402. CROI: Infection-related Non-AIDS-defining Cancer Risk in HIV-infected and -uninfected Persons: Increased Rates in HIV+ vs HIV-negatives in Kaiser - (02/25/09)
     
  1403. CROI: New HIV Agents - written by Joe Eron, MD, University of North Carolina - (02/25/09)
     
  1404. CROI: Resistance Report - written by Mark A. Wainberg McGill University AIDS Centre, Montreal - (02/25/09)
     
  1405. CROI: New HIV Drug Candidates in Pre-Clinical Development - (02/24/09)
     
  1406. CROI: A Single-dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OBP-601, a Novel NRTI, in Healthy Subjects - (02/24/09)
     
  1407. CROI: CMX157 Conjugate of tenofovir, prodrug: Hexadecyloxypropyl Tenofovir Associates Directly with HIV and Subsequently Inhibits Viral Replication in Untreated Cells - (02/24/09)
     
  1408. CROI: Inhibitors of the RNase H Activity of Reverse Transcriptase as an Approach to New HIV-1 Antiretroviral Agents: Merck program - (02/24/09)
     
  1409. CROI: Summary from CROI for Hepatitis Coinfection - What are the challenges and how can we improve outcome of Hepatitis coinfection in HIV-Infected Patients? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (02/24/09)
     
  1410. CROI: High HCV Viral Load Is Associated with an Increased Risk for Mortality in HIV/HCV-co-infected Individuals - (02/24/09)
     
  1411. CROI: A Pilot Study to Determine the Effect on Dyslipidemia of the Addition of Tenofovir to Stable ART in HIV-infected Subjects: Results from A5206 Study Team v - (02/24/09)
     
  1412. CROI: Single Dose Tenofovir Disoproxil Fumarate (TDF) with and without Emtricitabine (FTC) in HIV-1 Infected Pregnant Women and Their Infants: Pharmacokinetics (PK) and Safety - - (02/24/09)
     
  1413. CROI: Cardiovascular complications 16th CROI - written by Pablo Tebas, MD University of Pennsylvania - (02/24/09)
     
  1414. CROI: Back to Basics: the science at CROI focuses on the tough questions that remain in HIV pathogenesis - written by David Margolis, MD, University of North Carolina - (02/24/09)
     
  1415. CROI: HIV Infection May Make the Brain 15 to 20 Years Older: HIV slows cerebral blood flow and stimulus response in MRI study - written by Mark Mascolini - (02/23/09)
     
  1416. CROI: Framingham Risk Score Linked to Other Heart Risk Factors in HIV Cohort - written by Mark Mascolini - (02/23/09)
     
  1417. CROI: No Residual Raltegravir Activity After Resistance Emerges - written by Mark Mascolini - (02/23/09)
     
  1418. CROI: Effects of Aging on HIV Pathogenesis: aging is associated with higher t-cell activation in women than men, effects of menopause on inflammation and immune activation...." (02/23/09)
     
  1419. CROI: Bone Loss at Baseline and Week 144 in Study 903 TDF vs d4T + EFV (02/23/09)
     
  1420. CROI: Safety and Efficacy of Raltegravir (RAL) in Pediatric HIV Infection. Preliminary Analysis From IMPAACT P1066 (02/23/09)
     
  1421. CROI: Telbivudine Has Activity against HIV (02/23/09)
     
  1422. CROI: Abacavir Use is Not Associated with Lack of Virologic Response in ARV-treated HIV/HCV-Coinfected Patients Receiving PEG-IFN and Ribavirin (02/23/09)
     
  1423. CROI: Telbivudine Has No In Vitro Activity Against Laboratory and Clinical HIV-1, Including 5 Clades and Drug Resistant Clinical Isolates (02/23/09)
     
  1424. CROI: Heart Disease Marker Rises in Women During 96 Weeks of Suppressive Efavirenz - written by Mark Mascolini - (02/20/09)
     
  1425. CROI: Liver Fibrosis Marker Rises in SMART Interrupters and Predicts Non-AIDS Deaths - written by Mark Mascolini - (02/20/09)
     
  1426. CROI: Diverse Disease Markers Up in SMART Patients Regardless of Antiretroviral Therapy: inflammation markers linked to death, ART interruption, HIV, aging, & ART - written by Mark Mascolini - (02/20/09)
     
  1427. CROI: Immune Activators Stay High Despite Long-Term HIV Suppression With Antiretrovirals: affects CD4 recovery - written by Mark Mascolini - (02/20/09)
     
  1428. CROI: Pharmacokinetics and Safety of Twice Daily Atazanavir 300 mg and Raltegravir 400 mg in Healthy Subjects - (02/20/09)
     
  1429. CROI: Epidemic of Acute HCV Among MSM in Europe and New York City - (02/20/09)
     
  1430. CROI: Neurocognitive Disorders Threaten HIV+ - (02/20/09)
     
  1431. CROI: Immune Senescence, Activation, and Abnormal T Cell Homeostasis despite Effective HAART, a Hallmark of Early Aging in HIV Disease: "HIV-infected subjects (median 56 years) with good immune reconstitution and viral suppression had immune changes comparable to older (median 88 years) HIV-negative subjects" - (02/20/09)
     
  1432. CROI: High Prevalence of Hepatic Fibrosis and Steatosis in HIV/AIDS Patients without Chronic Viral Hepatitis but with Chronically Elevated Transaminases on ART: 35% without HCV or HBV had significant liver disease - (02/20/09)
     
  1433. CROI: CCR5-tropic Resistance to Maraviroc is Uncommon Even Among Patients on Functional MVC Monotherapy or with Ongoing Low-level Replication - (02/20/09)
     
  1434. CROI: Management of Treatment-Experienced Patients - written by Rafael E. Campo, MD University of Miami, Jackson Memorial Hospital (02/20/09)
     
  1435. CROI: HIV Prevention at CROI 2009 - written by Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington (02/20/09)
     
  1436. CROI: New HIV Drugs: NNRTI, PRO140, Maturation (02/19/09)
     
  1437. CROI: Markers of Inflammation, Coagulation and Renal Function in HIV-infected Adults in SMART and in two Large Population-Based Studies, CARDIA and MESA: HIV+ have higher levels of inflammatory markers on and off HAART, "markers appear to predict mortality & disease progression in HIV" (02/19/09)
     
  1438. CROI: No Association of Abacavir Use with Risk of Myocardial Infarction or Severe Cardiovascular Disease Events: Results from ACTG A5001 (02/19/09)
     
  1439. CROI: Subgroup Analyses from STARTMRK, a Phase III Study of Raltegravir (RAL)-Based vs Efavirenz (EFV)-Based Combination Therapy in Treatment-Naive HIV-Infected Patients (02/19/09)
     
  1440. CROI: Factors affecting virologic response to darunavir/ritonavir and lopinavir/ritonavir in treatment-naive HIV-1-infected patients in ARTEMIS at 96 weeks (02/19/09)
     
  1441. CROI: Characterization of virologic failures in the randomized, controlled, Phase III ARTEMIS trial in treatment-naive patients (Week 96 analysis) (02/19/09)
     
  1442. CROI: Emerging Patterns of Resistance to Integrase Inhibitors (02/19/09)
     
  1443. CROI: Assessment of Renal Findings of Abacavir/Lamivudine (ABC/3TC) Compared to Tenofovir/Emtricitabine (TDF/FTC) in Combination with QD Lopinavir/Ritonavir (LPV/r) Over 96 Weeks in the HEAT Study (02/19/09)
     
  1444. CROI: Similar Reductions in Markers of Inflammation and Endothelial Activation after Initiation of Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC) in the HEAT Study (02/19/09)
     
  1445. CROI: Efficacy and Safety of Abacavir/Lamivudine Compared to Tenofovir/Emtricitabine in Combination with Once-Daily Lopinavir/Ritonavir through 48 Weeks in the HEAT Study (02/19/09)
     
  1446. CROI: HIV-1 INFECTION IS ASSOCIATED WITH ACCELERATED VASCULAR AGING (02/18/09)
     
  1447. CROI: SIMPLIFICATION WITH FIXED-DOSE TENOFOVIR-EMTRICITABINE OR ABACAVIRLAMIVUDINE IN ADULTS WITH SUPPRESSED HIV REPLICATION (THE STEAL STUDY): A RANDOMIZED, OPEN-LABEL, 96-WEEK, NON-INFERIORITY TRIAL (02/18/09)
     
  1448. CROI: Neurocognitive (and neuropathy) Impairment Rate Remains High in Diverse US Cohort - written by Mark Mascolini - (02/18/09)
     
  1449. CROI: Antiretrovirals Have Not Banished Brain Injury in 7-Center US Imaging Study: brain damage persists despite HAART- inflammation and neuronal damage - written by Mark Mascolini - (02/18/09)
     
  1450. CROI: HCV Independently Adds to Hospital, Emergency Room, and Disability Days With HIV: days in hospital doubled - written by Mark Mascolini - (02/18/09)
     
  1451. CROI: Suspending Antiretrovirals Has Fast Negative Impact on HDL Particle Concentrations: interruptions reduce HDL and this predicts risk for cardiovascular disease in SMART - written by Mark Mascolini - (02/18/09)
     
  1452. CROI: First Double-Blind HIV+ Trial of Ezetimibe Plus Statin Finds Falling LDL Cholesterol - written by Mark Mascolini - (02/18/09)
     
  1453. CROI: Endothelial Function, Inflammatory Markers Do Not Change 24 Weeks After Switch to Atazanavir - written by Mark Mascolini - (02/18/09)
     
  1454. CROI: Two Inflammation Markers (hsCRP & IL-6) Predict Higher Risk of Opportunistic Disease in SMART - written by Mark Mascolini - (02/18/09)
     
  1455. CROI: Platelet Function & Heart Attacks in HIV+ & ART (02/17/09)
     
  1456. CROI: Pharmacokinetics and dose selection of etravirine in HIV-infected children between 6 and 17 years, inclusive (02/17/09)
     
  1457. CROI: HIV Progression Not Affected by Hormonal Contraception in Africa Study (02/17/09)
     
  1458. CROI: The Safety and Efficacy of Tenofovir DF (TDF) in Combination with Lamivudine (3TC) and Efavirenz (EFV) in Antiretroviral-naive Patients Through Seven Years (02/17/09)
     
  1459. CROI: HIV, Cancer and Immunity (02/17/09)
     
  1460. CROI: HIV Sometimes Detectable in Semen When Undetectable in Blood - written by Mark Mascolini - (02/13/09)
     
  1461. CROI: Low-Level HIV in CSF When HIV-RNA is < 50 Tied to Type of ART and Worse Cognitive Function - written by Mark Mascolini - (02/13/09)
     
  1462. CROI: Multicohort D:A:D Study Pinpoints Non-HIV Death Risk Factors People Can Change - written by Mark Mascolini - (02/13/09)
     
  1463. CROI: Helping HIV Patients Stop Smoking--Worthy Goal But Tough Work - written by Mark Mascolini - (02/13/09)
     
  1464. CROI: HIV Has as Much Impact on Heart Health as Traditional Risk Factors - written by Mark Mascolini - (02/13/09)
     
  1465. CROI: K103N and Efavirenz vs Nevirapine Tied to Better Response to Etravirine - written by Mark Mascolini - (02/13/09)
     
  1466. CROI: Preclinical and Early Clinical Evaluation of SPI-452, a New Pharmacokinetic Enhancer (PKE) - (02/12/09)
     
  1467. CROI: Review of Cancer Incidence in Raltegravir (RAL) Clinical Trials - (02/12/09)
     
  1468. CROI: 96-Week Results from BENCHMRK 1&2, Phase III Studies of Raltegravir (RAL) in Patients (pts) Failing Antiretroviral Therapy (ART) with Triple-Class Resistant HIV - (02/12/09)
     
  1469. CROI: Abacavir - (02/12/09)
     
  1470. CROI: 3 Studies on Abacavir & MI Risk: French Cohort, D.A.D. (slides), ALLRT with 2 Different Results - (02/12/09)
     
  1471. CROI: Switch to Raltegravir From Lopinavir in Highly Treatment-Experienced Patient Group: SWITCHMRK 1 & 2 Studies - written by Mark Mascolini - (02/12/09)
     
  1472. CROI: Replacing Enfuvirtide With Raltegravir in France - written by Mark Mascolini - (02/12/09)
     
  1473. CROI: Lower CD4 Count Linked to Non-AIDS Cancers in EuroSIDA Study - written by Mark Mascolini - (02/12/09)
     
  1474. CROI: Risk of non-Hodgkin Lymphoma Death Still Higher With HIV Infection - written by Mark Mascolini - (02/12/09)
     
  1475. CROI: Extra CD4s With IL-2 Confer No Clinical Benefit in Two Randomized Trials - written by Mark Mascolini - (02/12/09)
     
  1476. CROI: High HCV Load Doubles the Death Risk in People Coinfected With HIV - written by Mark Mascolini - (02/12/09)
     
  1477. CROI: Peginterferon (Pegasys) and Weight-Based Ribavirin for 72 Weeks in HIV+ Early Responders - written by Mark Mascolini - (02/12/09)
     
  1478. CROI: MI Rates Converge in California Health System Groups With and Without HIV: trend down in HIV+ - written by Mark Mascolini - (02/12/09)
     
  1479. CROI: Non-AIDS Illness More Common Than AIDS--and More Deadly--in EuroSIDA - written by Mark Mascolini - (02/12/09)
     
  1480. CROI: French Hospital Study and Further D:A:D Analyses Suggest MI Risk With Abacavir - written by Mark Mascolini - (02/12/09)
     
  1481. BMS Co-Payment Assistance Program - (02/11/09)
     
  1482. CROI: GS-9350: A Pharmacoenhancer Without anti-HIV Activity - (02/11/09)
     
  1483. CROI: Gilead Announces Data Demonstrating Pharmacokinetic Boosting Activity of GS 9350 - (02/11/09)
     
  1484. CROI: Complete Protection against Repeated Vaginal Simian HIV Exposures in Macaques by a Topical Gel Containing Tenofovir Alone or with Emtricitabine - (02/11/09)
     
  1485. CROI: Switching from Stable Lopinavir/Ritonavir (LPV/r)-Based to Raltegravir (RAL)-Based Combination Antiretroviral Therapy (ART) Resulted In a Superior Lipid Profile at Week 12 but Did Not Demonstrate Non-Inferior Virologic Efficacy at Week 24 (SWITCHMRK) - (02/11/09)
     
  1486. CROI: Smoking Emerges as Top Death Risk Factor in FRAM Participants With HIV - written by Mark Mascolini - (02/11/09)
     
  1487. CROI: HIV and Diabetes/Hyperlipidemia Cause Kidney Decline - written by Mark Mascolini - (02/11/09)
     
  1488. Causes of Accelerated Aging in HIV: HIV Induces Aging of T-Cells - (02/10/09)
     
  1489. CROI: World Health Organization CD4 Criteria Fall Far Short in Predicting Antiretroviral Failure written by Mark Mascolini - (02/10/09)
     
  1490. Does Early Antiretroviral Treatment Prevent Liver Fibrosis in HIV/HCV-Coinfected Patients? [Letters to the Editor] - (02/07/09)
     
  1491. Vitamin D's Expanding Role EDITORIAL - (02/07/09)
     
  1492. Vitamin D Status and Muscle Function in Post-Menarchal Adolescent Girls - (02/07/09)
     
  1493. GSK Acquires New HIV NNRTI IDX899 From Idenix - (02/07/09)
     
  1494. Is Dual Therapy With Raltegravir and Protease Inhibitors a Feasible Option in Rescue Strategy in HIV-1 Infection? [Letters to the Editor] - (02/07/09)
     
  1495. Use of Saliva as a Lubricant in Anal Sexual Practices Among Homosexual Men - (02/07/09)
     
  1496. FDA grants traditional approval of Isentress (raltegravir) - (02/06/09)
     
  1497. Patient Information Page from The Hormone Foundation: Vitamin D, Calcium, and Bone Health - (02/06/09)
     
  1498. Tibotec Submits Application to U.S. Food and Drug Administration Seeking Traditional Approval for INTELENCE(TM) (etravirine) - (02/06/09)
     
  1499. Once-Daily Prezista® (darunavir) for Treatment-Naive Adults with HIV-1 Receives Approval in the European Union as Part of Combination Therapy - (02/06/09)
     
  1500. Mortality Risk Associated With Low-Trauma Osteoporotic Fracture and Subsequent Fracture in Men and Women - (02/05/09)
     
  1501. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients - (02/05/09)
     
  1502. Oral HIV-exposure elicits mucosal HIV-neutralizing antibodies in uninfected men who have sex with men - (02/05/09)
     
  1503. Oral Cancer In Men Associated With HPV - (02/05/09)
     
  1504. Glomerular filtration rates in HIV-infected patients treated with and without tenofovir: a prospective, observational study - (02/05/09)
     
  1505. New Gene Therapy Disrupts CCR5/HIV Entry: Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases - (02/04/09)
     
  1506. Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS - (02/04/09)
     
  1507. High Frequency of Vitamin D Deficiency in Ambulatory HIV-Positive Patients - (02/03/09)
     
  1508. Vitamin D Deficiency in Older Men - (01/30/09)
     
  1509. New Norvir Tablet Application Submitted to FDA by Abbott - (01/29/09)
     
  1510. Ultrasensitive Assessment of Residual HIV Viraemia in HAART-Treated Patients With Persistently Undetectable Plasma HIV-RNA: A Cross-Sectional Evaluation - (01/29/09)
     
  1511. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity: review by Steve Deeks and Andrew Phillips - (01/28/09)
     
  1512. Aerobic + Strength Exercise is Optimal for Insulin Resistance and Improved Health & Frailty in Study of Obese and Older, Average Age 67 Yrs - (01/28/09)
     
  1513. Methicillin-Resistant Staphylococcus aureus (MRSA) Strain ST398 Is Present in Midwestern U.S. Swine and Swine Workers - (01/28/09)
     
  1514. Heart Association Recommends Daily Intake of Omega-6 Fatty Acids - (01/28/09)
     
  1515. TNX-355 survives Tanox: new Phase 2 Dose-Finding StudyStudy - (01/28/09)
     
  1516. VRX496 Update, Novel HIV Gene Therapy - (01/27/09)
     
  1517. FRONTLINE: the age of aids: interviews: martin delaney | PBS - (01/27/09)
     
  1518. Fauci Statement - Martin Delaney - (01/27/09)
     
  1519. Martin Delaney, HIV treatment activist, dies at 63 - (01/27/09)
     
  1520. AIDS Activist Martin Delaney Honoured By NIAID - (01/27/09)
     
  1521. AGING AND INFECTIOUS DISEASES: effects of aging; Immunosenescence and Vaccination in Nursing Home Residents - (01/22/09)
     
  1522. Once-Daily HAART Modestly Beats Twice-Daily on Adherence & Viral Suppression: meta-analysis - (01/22/09)
     
  1523. Reduced susceptibility to lamivudine and emtricitabine associated with the novel K66N mutation in HIV-1 reverse transcriptase - (01/22/09)
     
  1524. HIV Prematurely Accelerates Aging - (01/22/09)
     
  1525. HIV Super-Infection Not Found Among MSM Couples: Immunity to HIV-1 Is Influenced by Continued Natural Exposure to Exogenous Virus - (01/21/09)
     
  1526. Effects of Omeprazole on Plasma Levels of Raltegravir - (01/21/09)
     
  1527. New Article Criticizes Term "on the Down low": Moving beyond "the Down Low": A critical analysis of terminology guiding HIV prevention efforts for African American men who have secretive sex with men - (01/21/09)
     
  1528. Persistent Minority K103N Mutations among Women Exposed to Single-dose Nevirapine and Virologic Response to Nonnucleoside reverse-Transcriptase Inhibitor-Based Therapy - (01/21/09)
     
  1529. Single-Dose Nevirapine to Prevent Mother-to-Child Transmission of HIV Type 1: Balancing the Benefits and Risks EDITORIAL COMMENTARY - (01/21/09)
     
  1530. YouTube - Anthony Fauci Tribute to Martin Delaney - (01/20/09)
     
  1531. NIAID Honors AIDS Activist Martin Delaney - (01/20/09)
     
  1532. CDC Updates New HIV Cases Surveillance Estimates: "the disease continues to affect the MSM population more than any other in the United States" - (01/14/09)
     
  1533. Risk Factors for Early and Late Transmission of HIV via breast-feeding among Infants Born to HIV-Infected Women in a Randomized Clinical Trial in Botswana - (01/17/09)
     
  1534. ICAAC: The New Antitubercular Drugs SQ109 and TMC207 Act Synergistically In Vitro to Kill M. tuberculosis - (01/17/09)
     
  1535. ICAAC: Interim analysis of a double- blind, placebo-controlled study with TMC207 in patients with Multi-Drug Resistant (MDR) Tuberculosis: effective and safe - (01/17/09)
     
  1536. CDC Updates New HIV Cases Surveillance Estimates: "the disease continues to affect the MSM population more than any other in the United States" - (01/14/09)
     
  1537. C-Reactive Protein and Reclassification of Cardiovascular Risk in the Framingham Heart Study - (01/14/09)
     
  1538. Researchers Identify IL-7 New Regulatory Circuit Controlling Immune Cell Production in Mice - (01/13/09)
     
  1539. Prolonged Nevirapine Use In Breast-Fed Babies Prevents HIV, Increased Resistance Risk - (01/13/09)
     
  1540. Factors Associated with Acquisition and Clearance of Human Papillomavirus Infection in a Cohort of US Men: A Prospective Study - (01/13/09)
     
  1541. Our results suggest that HIV-1 infection induces an accelerated aging of T lymphocytes, which is associated with the clinical progression to AIDS and death - (01/13/09)
     
  1542. Insulin Resistance (25%) Is Associated With Advanced Liver Fibrosis and High Body Mass Index in HIV/HCV-Coinfected Patients [Letters to the Editor] - (01/12/09)
     
  1543. Cardiovascular Complications in HIV Management: Past, Present, and Future [Critical Review: Clinical Science] - (01/12/09)
     
  1544. Predictive Factors for Long-Term Non-Progressors - (01/12/09)
     
  1545. Racial Disparities in HIV Virologic Failure: Do Missed Visits Matter? - (01/12/09)
     
  1546. The Absence of CD4+ T Cell Count Recovery Despite Receipt of Virologically Suppressive Highly Active Antiretroviral Therapy: Clinical Risk, Immunological Gaps, and Therapeutic Options - (01/12/09)
     
  1547. Incomplete Reconstitution of T Cell Subsets on Combination Antiretroviral Therapy in the AIDS Clinical Trials Group Protocol 384 - (01/12/09)
     
  1548. CD4+ T Cell Recovery with Antiretroviral Therapy: More Than the Sum of the Parts, EDITORIAL COMMENTARY - (01/12/09)
     
  1549. Increased Melanoma Rates in USA Are Real and Aging/HIV - (01/09/09)
     
  1550. Public Citizen issues list of 56 drugs to be avoided with Erectyle Dysfunction therapies - (01/07/09)
     
  1551. Prospective study of physical fitness, adiposity, and inflammatory markers in healthy middle-aged men and women - (01/07/09)
     
  1552. ICAAC: New CCR5 Drug PRO 140 Reduced Viral Load by 2 Logs With Single 10 mg Intravenous Dose; 5/5 patients with single 10 mg dose had >2 log reduction in viral load - (01/06/09)
     
  1553. Osteonecrosis of the Jaw & Bisphohosphonates for Osteoporosis Treatment - (01/06/09)
     
  1554. Giant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy - (01/06/09)
     
  1555. Childhood Trauma and Neurological Development and Stress, and Chronic Fatigue Syndrome - (01/06/09)
     
  1556. AIDS Denialism by South African Govt Leader Pres Mbeki Loses 330,000 Lives & 35,000 HIV+ Babies Born - (01/05/09)
     
  1557. The incidence of and risk factors for MRSA bacteraemia in an HIV-infected cohort in the HAART era - (01/05/09)
     
  1558. Long-term consequences of the delay between virologic failure of HAART and regimen modification - (01/05/09)
     
  1559. Minority Quasispecies of Drug-Resistant HIV-1 That Lead to Early Therapy Failure in Treatment-Naive and -Adherent Patients - (01/05/09)
     
  1560. The Management of Treatment-Experienced HIV-Infected Patients: New Drugs and Drug Combinations - (01/05/09)
     
  1561. Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens: a meta-analysis of randomized controlled trials - (01/02/09)
     
  1562. Lipoatrophy among HIV-infected patients is associated with higher levels of depression than lipohypertrophy - (01/02/09)
     
  1563. Keeping Blood Sugar Low May Help Stem Geriatric Memory Loss - (01/02/09)
     
  1564. History and Death of AIDS Denialist Christine Maggiore and Her Dead Daughter - (12/31/08)
     
  1565. Annual Zoledronate Increases Bone Density in Highly Active Antiretroviral Therapy-Treated Human Immunodeficiency Virus-Infected Men: A Randomized Controlled Trial - (12/30/08)
     
  1566. Once A Year Zoledronate Bone Therapy Increased Bone Density & T-Scores - (12/30/08)
     
  1567. Thyroid Dysfunction & Bone Disease in HIV & HCV; Thyroid Testing Recommended by UK Group - (12/30/08)
     
  1568. Predictors of severe hepatic steatosis using abdominal ultrasound in HIV-infected patients - (12/30/08)
     
  1569. Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study - (12/30/08)
     
  1570. Generic FTC 200 mg Caps Approved - (12/30/08)
     
  1571. Report on the 10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV - written by Jacqueline Capeau MD - (12/23/08)
     
  1572. Central obesity and increased risk of dementia more than three decades later - (12/22/08)
     
  1573. Visceral Fat & Neurotoins, Insulin Resistance & Alzheimer Disease/Dementia EDITORIAL - (12/22/08)
     
  1574. Impaired insulin secretion increases the risk of Alzheimer disease - (12/22/08)
     
  1575. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes - (12/22/08)
     
  1576. Associations between Male Anogenital Human Papillomavirus Infection and Circumcision by Anatomic Site Sampled and Lifetime Number of Female Sex Partners - (12/22/08)
     
  1577. Effect of a Low-Glycemic Index or a High-Cereal Fiber Diet on Type 2 Diabetes: "6-month treatment with a low-glycemic index diet resulted in moderately lower HbA1c levels compared with a high-cereal fiber diet." - (12/19/08)
     
  1578. The START Study Controversy: conducting a "When To Begin Study" - (12/19/08)
     
  1579. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV - (12/19/08)
     
  1580. Low atazanavir concentrations in cerebrospinal fluid - (12/18/08)
     
  1581. Male Circumcision and [reduced] Risk of HIV Infection among Heterosexual African American Men Attending Baltimore Sexually Transmitted Disease Clinics - (12/18/08)
     
  1582. Associations between Male Anogenital Human Papillomavirus Infection and Circumcision by Anatomic Site Sampled and Lifetime Number of Female Sex Partners - (12/22/08)
     
  1583. The Role of Male Circumcision in the Prevention of Human Papillomavirus and HIV Infection - EDITORIAL COMMENTARY - (12/18/08)
     
  1584. Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin - (12/18/08)
     
  1585. Federal Government NIAID Aging Funding Opportunities - (12/16/08)
     
  1586. HIV & Kidney Disease: ART Interruption In SMART - (12/16/08)
     
  1587. 10th Intl Workshp Adverse Drug Reactions & Lipo: Report from the 10th Intl Workshop on Adverse Drug Reactions and Lipodystrophy in HIV - written by Michael Dube, MD - (12/13/08)
     
  1588. ICAAC: Perceptions of Care by HIV-Infected Women of Color in the United States - (12/15/08)
     
  1589. ICAAC: Roles of Race, Drug Use & Health Insurance in Use of HAART Among HIV-Positive Women: 2002-2005 - (12/15/08)
     
  1590. Anal intraepithelial neoplasia in a multisite study of HIV-infected and high-risk HIV-uninfected women: "Our findings show that the prevalence of AIN among HIV-infected women is high and significantly increased above a comparison group of HIV-uninfected women." - (12/15/08)
     
  1591. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study - (12/15/08)
     
  1592. DART: Hydroxyurea+ddI Returns, Franco Lori Presents: A "Virostatic" Approach to Antiretroviral Therapy: Beyond ddI/Hydroxyurea? - Written for NATAP by Mark Mascolini - (12/15/08)
     
  1593. DART: This is Your Brain Off Drugs: Neurocognitive Function before and after Antiretroviral Treatment Discontinuation in Patients with High CD4 Nadir (ACTG A5170). - (12/15/08)
     
  1594. DART: Women's HIV Care and Treatment Access for African-Americans and the GRACE Study - (12/15/08)
     
  1595. Merck Announces FDA Acceptance of Supplemental New Drug Application for ISENTRESS (raltegravir) in Adult Patients Previously Untreated for HIV-1 - (12/12/08)
     
  1596. DART: Raltegravir Efficacy and Safety After 96 Weeks of Phase 2 Trial - Written for NATAP by Mark Mascolini - (12/12/08)
     
  1597. DART: Darunavir vs Lopinavir at 96 Weeks in People With Naïve Advanced HIV - ARTEMIS Study - Written for NATAP by Mark Mascolini - (12/12/08)
     
  1598. DART: Dropout Rate in Study of US Minority Women Near 25% at 24 Weeks Written for NATAP by Mark Mascolini - (12/11/08)
     
  1599. DART: Siliciano Proposes Novel Gauge of Antiretroviral Activity Written for NATAP by Mark Mascolini - (12/11/08)
     
  1600. DART: Foot-Fractures in HIV+ Men Written for NATAP by Mark Mascolini - (12/11/08)
     
  1601. DART: Early Results With Antiretrovirals Plus Immunotoxins That Target Viral Reservoirs Written for NATAP by Mark Mascolini - (12/11/08)
     
  1602. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection - (12/11/08)
     
  1603. Enhancing SIV-specific immunity in vivo by PD-1 blockade - (12/11/08)
     
  1604. Antibody fights AIDS-like disease in monkeys - (12/11/08)
     
  1605. ICAAC: DELPHI: Safety, tolerability and efficacy of darunavir/ritonavir over 48 weeks in ARV treatment-experienced children and adolescents Final analysis (12/11/08)
     
  1606. Targeting HIV Entry: 4th Interntnl Wrkshp: Enfuvirtide-Plus-Raltegravir Salvage Trial Cuts Off Recruitment Early - Written by Mark Mascolini - (12/10/08)
     
  1607. Targeting HIV Entry: 4th Interntnl Wrkshp: HIV Becomes More Flexible in CCR5 and CXCR4 Use as Infection Progresses - Written by Mark Mascolini - (12/10/08)
     
  1608. Targeting HIV Entry: 4th Interntnl Wrkshp: Low Enfuvirtide and Maraviroc Penetration of CSF--and CSF Resistance to Enfuvirtide - written by Mark Mascolini - (12/10/08)
     
  1609. Targeting HIV Entry: 4th Interntnl Wrkshp: Vicriviroc Phase 3 Trial and Naive Study May Afford New Angle on Role of CCR5 Blockers - written by Mark Mascolini - (12/10/08)
     
  1610. Targeting HIV Entry: 4th Interntnl Wrkshp: Almost 40% of Viruses in Treatment-Experienced German Group Use CXCR4 - written by Mark Mascolini - (12/10/08)
     
  1611. Neurological/Cognitive Impairment on HAART: 50% on HAART have cognitive impairment - (12/10/08)
     
  1612. ICAAC: AIDS-Defining Conditions (ADCs) in the BENCHMRK -1 and -2 Trials: 48 Week Analysis (12/10/08)
     
  1613. ICAAC: Analysis of Resistance to the HIV-1 Integrase Inhibitor Raltegravir: Results from BENCHMRK-1 and -2 (12/10/08)
     
  1614. ICAAC: Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Raltegravir (RAL) in Phase III Studies in Treatment Experienced HIV- Infected Patients Following 48 Weeks of Treatment (12/10/08)
     
  1615. 10th Intl Workshp Adverse Drug Reactions & Lipo: A Comparison of Cardiac Function Between HIV-Infected and HIV-Seronegative People With and Without the Metabolic Syndrome. - (12/10/08)
     
  1616. 10th Intl Workshp Adverse Drug Reactions & Lipo: COMPARISON OF THE EFFECTS OF NEVIRAPINE RESPECT TO EFAVIRENZ ON DIFFERENTIATING AND MATURE HUMAN ADIPOCYTES IN CULTURE - (12/10/08)
     
  1617. 9th Interntl Drug Thrpy HIV: The Effect of Food on Ritonavir Bioavailability Following Administration of Ritonavir 100 mg Film-Coated Tablet in Healthy Adult Subjects - (12/09/08)
     
  1618. 9th Interntl Drug Thrpy HIV: Population Pharmacokinetic/Pharmacodynamic Analyses of Lopinavir and Ritonavir in Subjects Receiving the Tablet Formulation - (12/09/08)
     
  1619. 9th Interntl Drug Thrpy HIV: Pharmacokinetics of Once-Daily Etravirine (ETR) Without and With Once-Daily Darunavir/ Ritonavir (DRV/r) in Antiretroviral-Naï ve HIV-1 Infected Adults - (12/09/08)
     
  1620. The cell biology of bone metabolism - (12/09/08)
     
  1621. Poor Glycemic Control in Diabetes and the Risk of Incident Chronic Kidney Disease Even in the Absence of Albuminuria and Retinopathy - (12/09/08)
     
  1622. Statins and primary prevention of cardiovascular events- Editorials - (12/09/08)
     
  1623. ddi + hydroxyurea making comeback - (12/09/08)
     
  1624. Hepatitis Virus Coinfection in the Strategic Management of Antiretroviral Therapy (SMART) Study: A Marker for Nonliver, Non-Opportunistic Disease Mortality - (12/09/08)
     
  1625. Nut-Enriched Mediterranean Diet Helps Reverse Metabolic Syndrome - (12/09/08)
     
  1626. Webcasts from the 10th Intl Workshop on Adverse Drug Reactions & Lipodystrophy
     
  1627. 9th Interntl Drug Thrpy HIV: Adherence with Lopinavir/ritonavir (LPV/r) Tablet and Soft-Gel Capsule (SGC)-Based Antiretroviral Regimens and Predictors of Early Treatment Compliance - (12/08/08)
     
  1628. 9th Interntl Drug Thrpy HIV: Metabolic Evaluation of Study M05-730 through Week (Wk) 48: Phase 3, Randomized, Open-Label Study of Lopinavir/ritonavir (LPV/r) Tablets Once Daily (QD) versus Twice Daily (BID), Co-Administered with Tenofovir DF (TDF) + Emtricitabine (FTC) in Antiretroviral-Naï ve (ARV) HIV-1 Infected Subjects - (12/08/08)
     
  1629. 9th Interntl Drug Thrpy HIV: Topics from the Drug Therapy in HIV Infection Meeting - written by Stephen Becker, MD - (12/08/08)
     
  1630. ICAAC: DOUBLING THE DOSE OF RALTEGRAVIR (RAL) DOES NOT INCREASE TROUGH LEVELS IN THE PRESENCE OF RIFAMPIN (RIF) (12/08/08)
     
  1631. ICAAC: Omeprazole Increases Plasma Levels of Raltegravir (RAL) in Healthy Subjects (12/08/08)
     
  1632. ICAAC: Raltegravir (RAL) Pharmacokinetics in Individuals with UGT1A1*1/*1 and UGT1A1*28/*28 Genotypes (12/08/08)
     
  1633. ICAAC: Pharmacokinetic (PK) Evaluation of Darunavir/Ritonavir (DRV/r) and Raltegravir (RAL) in Healthy Subjects (12/08/08)
     
  1634. ICAAC: Analysis of Resistance to the HIV-1 Integrase Inhibitor Raltegravir: Results from BENCHMRK-1 and -2 (12/08/08)
     
  1635. Pfizer's Novel HIV/AIDS Treatment SELZENTRY(TM) Becomes the Latest Fully Approved Antiretrovial for Treatment-Experienced HIV Patients - (12/03/08)
     
  1636. Vitamin K Linked to Insulin Resistance in Older Men - (12/03/08)
     
  1637. "elevations in inflammatory markers seen in insulin resistance, metabolic syndrome, and diabetes are not causative but a consequence of these abnormalities." - (12/02/08)
     
  1638. Metabolic Syndrome Predicts New Onset of Chronic Kidney Disease in 5,829 Patients With Type 2 Diabetes - (12/02/08)
     
  1639. Endothelial Activation Markers Are Linked to HIV Status and Are Independent of Antiretroviral Therapy and Lipoatrophy - (12/02/08)
     
  1640. Inflammation May Be Associated with AIDS Progression - (12/02/08)
     
  1641. Uric Acid Levels Increase Risk for New-Onset Kidney Disease - Editorial - (12/02/08)
     
  1642. ICAAC: Performance Characteristics and Validation of the PhenoSense® Integrase Assay (12/02/08)
     
  1643. ICAAC: Raltegravir Pharmacokinetics and Safety in Adolescents: Preliminary Results from IMPAACT P1066 (12/02/08)
     
  1644. ICAAC: Validation of an Enhanced Sensitivity Trofile™ HIV-1 Co-receptor Tropism Assay (12/02/08)
     
  1645. ICAAC: Use of Tenofovir Disoproxil Fumarate (TDF) in Pregnancy: Findings from the Antiretroviral Pregnancy Registry (APR) (12/02/08)
     
  1646. ICAAC: Chronic Hepatitis B Virus (HBV) Infection in the HIV Outpatient Study (HOPS), 1996-2006: Prevalence in the Era of Evolving Interventions (12/02/08)
     
  1647. Cancer Rates Doubled in HIV+ - (11/24/08)
     
  1648. ICAAC: Continuous Antiretroviral Therapy Decreases Bone Mineral Density: Results from the SMART Study (11/24/08)
     
  1649. ICAAC: Bone Loss in SMART Study - Written by Mark Mascolini - (10/30/08)
     
  1650. 9th Interntl Drug Thrpy HIV: Switching from enfuvirtide to etravirine - efficacy results from the etravirine early access programme - (11/24/08)
     
  1651. 9th Interntl Drug Thrpy HIV: Etravirine protects the activity of darunavir in the DUET trials - (11/24/08)
     
  1652. 9th Interntl Drug Thrpy HIV: Antiretroviral treatment use and HIV RNA suppression rates for 941 European patients in the etravirine early access programme - (11/24/08)
     
  1653. 9th Interntl Drug Thrpy HIV: Safety and tolerability of etravirine in hepatitis B and/or C co-infected patients in DUET-1 and DUET-2: pooled 48-week results - (11/24/08)
     
  1654. 9th Interntl Drug Thrpy HIV: Atazanavir Is Safe and Efficacious in HBV and HCV Coinfected Patients: Results of AI424138 (CASTLE) - (11/24/08)
     
  1655. CD4 Cell Counts of 800 Cells/mm3 or Greater After 7 Years of Highly Active Antiretroviral Therapy Are Feasible in Most Patients Starting With 350 Cells/mm3 or Greater - (11/21/08)
     
  1656. Statin induced myopathy - (11/21/08)
     
  1657. Physicians Reluctant to Follow CDC Call for Routine HIV Testing - (11/21/08)
     
  1658. 9th Interntl Drug Thrpy HIV: The pharmacokinetic interaction between omeprazole and TMC278, an investigational NNRTI - (11/21/08)
     
  1659. 9th Interntl Drug Thrpy HIV: Activity of etravirine on different HIV-1 subtypes: Week 48 data of the pooled DUET trials and in-vitro susceptibility in treatment-naïve patients - (11/21/08)
     
  1660. 9th Interntl Drug Thrpy HIV: Simplification of Antiretroviral Therapy with Efavirenz/Emtricitabine/Tenofovir DF Single Tablet Regimen vs. Continued Antiretroviral Therapy in Suppressed, HIV-1-Infected Patients - (11/20/08)
     
  1661. 9th Interntl Drug Thrpy HIV: Incidence of Infections in Treatment-experienced Patients Infected with R5 HIV-1 in the MOTIVATE Studies of Maraviroc in Combination with Optimized Background Therapy - (11/20/08)
     
  1662. 9th Interntl Drug Thrpy HIV: Phase III TITAN Week 96 final analysis: efficacy/safety of darunavir/ritonavir versus lopinavir/ritonavir in lopinavir/ritonavir-naïve, treatment-experienced patients - (11/20/08)
     
  1663. 10th Intl Workshp Adverse Drug Reactions & Lipo: Effect of HAART on insulin sensitivity, autonomic nervous system function and beta-adrenergic mediated lipolysis (11/20/08)
     
  1664. 10th Intl Workshp Adverse Drug Reactions & Lipo: Efavirenz induces alterations in lipid metabolism through AMPK activation (11/20/08)
     
  1665. 10th Intl Workshp Adverse Drug Reactions & Lipo: COMPARISON OF THE EFFECTS OF LOPINAVIR/RITONAVIR AND EFAVIRENZ ON GENE EXPRESSION AND DIFFERENTIATION OF HUMAN ADIPOCYTES (11/20/08)
     
  1666. Failure of bone marrow transplantation to eradicate HIV reservoir despite efficient HAART - (11/19/08)
     
  1667. Longitudinal evaluation of cardiovascular disease-associated biomarkers in relation to abacavir therapy - (11/19/08)
     
  1668. HIV TAT Protein Infects Brain Shortly After HIV-Infection and Disrupts Brain Normal Activity, Affects Mitochondria-- Pretreatment with the RyR antagonist, dantrolene mediated these pathologic effects.....dantrolene has side effects but these findings could lead to research for therapy to block this mechanism of action "RyR may be a crucial target for neuroprotection in HIV-associated neurologic disease" - (11/19/08)
     
  1669. Statin (Crestor) Prevents Heart Disease, Lowers LDL and Inflammation in Healthy with Normal Lipids - (11/18/08)
     
  1670. Statin Therapy for Prevention? EDITORIAL Expanding the Orbit of Primary Prevention - Moving beyond JUPITER - (11/18/08)
     
  1671. JUPITER hits New Orleans: Landmark study shows statins benefit healthy individuals with high CRP levels - (11/18/08)
     
  1672. Crestor Study Will Boost Statin Demand - (11/18/08)
     
  1673. The role of HIV in serious diseases (non-AIDS diseases) other than AIDS - (11/18/08)
     
  1674. Silent cardiac dysfunction and exercise intolerance in HIV+ men receiving combined antiretroviral therapies - (11/18/08)
     
  1675. Higher frequency of dementia in older HIV-1 individuals The Hawaii Aging with HIV-1 Cohort - (11/18/08)
     
  1676. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis - (11/18/08)
     
  1677. Proinflammatory Markers, Insulin Sensitivity, and Cardiometabolic Risk Factors in Treated HIV Infection - (11/18/08)
     
  1678. 9th Interntl Drug Thrpy HIV: Patient Reported Outcomes after Simplification to a Single Tablet Regimen of Efavirenz (EFV) / Emtricitabine (FTC) / Tenofovir DF (TDF) - (11/17/08)
     
  1679. 9th Interntl Drug Thrpy HIV: Two HAART Interruption Studies Presented at Glasgow HIV Conference Nov 10 2008 - (11/17/08)
     
  1680. The relationship between an adverse effect of cART and underlying risk illustrated by number needed to treat to harm (NNTH) - Risk of myocardial infarction and abacavir use - (11/13/08)
     
  1681. Evolution and Predictors of Change in Total Bone Mineral Density Over Time in HIV-Infected Men and Women in the Nutrition for Healthy Living Study - (11/13/08)
     
  1682. 9th Interntl Drug Thrpy HIV: Raltegravir Clinical Efficacy Against B Subtype and Non-B Subtype HIV-1 is Similar - (11/17/08)
     
  1683. 9th Interntl Drug Thrpy HIV: Efficacy and Safety (malignancies) of Maraviroc in Treatment-Experienced (TE) Patients Infected with R5 HIV-1: 96-week Combined Analysis of the MOTIVATE 1 & 2 Studies - (11/17/08)
     
  1684. 9th Interntl Drug Thrpy HIV: Better CD4 Gains on Antiretrovirals Linked to Clearance of Cancer-Causing HPV - Written by Mark Mascolini - (11/17/08)
     
  1685. 9th Interntl Drug Thrpy HIV: Risks and Benefits of 5 Days On/2 Days Off in the FOTO Study - Written by Mark Mascolini - (11/17/08)
     
  1686. 9th Interntl Drug Thrpy HIV: No Evidence of Virologic Benefit With Higher Lopinavir Dose for Children - Written by Mark Mascolini - (11/17/08)
     
  1687. 9th Interntl Drug Thrpy HIV: More Time With Sub-500 Load on First Regimen Cuts Risk of Second-Line Failure - Written by Mark Mascolini - (11/17/08)
     
  1688. 9th Interntl Drug Thrpy HIV: Lipid effects in the ARTEMIS and TITAN trials: effects of demographics, HIV disease stage, treatment arm and lipid-lowering drugs - (11/17/08)
     
  1689. 9th Interntl Drug Thrpy HIV: OI and Death Rates With Low CD4s and High vs Low Viral Load - Undetectable Viral Load Matters - Written by Mark Mascolini - (11/13/08)
     
  1690. 9th Interntl Drug Thrpy HIV: Failure Rate Twice Higher With Second-Line Versus First-Line HAART - Written by Mark Mascolini - (11/13/08)
     
  1691. 9th Interntl Drug Thrpy HIV: Lower Failure and Resistance Rates With Darunavir Than Lopinavir at 96 Weeks of TITAN - Written by Mark Mascolini - (11/13/08)
     
  1692. 9th Interntl Drug Thrpy HIV: Slow CD4 Gain With HAART Raises AIDS Rate 5 Times in Virologic Responders - Written by Mark Mascolini - (11/13/08)
     
  1693. 9th Interntl Drug Thrpy HIV: Cardiovascular disease; HIV, ART, immunodeficiency, pro-inflammation and other factors - (11/13/08)
     
  1694. 9th Interntl Drug Thrpy HIV: Efficacy and safety of TMC278 in treatment-naïve, HIV-infected patients: Week 96 data from TMC278-C204 - (11/13/08)
     
  1695. 9th Interntl Drug Thrpy HIV: Efficacy and Safety by Baseline HIV RNA and CD4 Count in Treatment-Naïve Patients Treated With Atazanavir/RTV and Lopinavir/RTV in the CASTLE Study - (11/13/08)
     
  1696. 9th Interntl Drug Thrpy HIV: Efficacy and safety of switching from Lopinavir/r to Atazanavir/r in suppressed patients receiving a LPV/r containing HAART: ATAZIP 96 weeks results - (11/13/08)
     
  1697. ICAAC: Earlier Chance at HIV Diagnosis Probably Often Missed in Prison written by Mark Mascolini (11/12/08)
     
  1698. ICAAC: Pharmacology at ICAAC-IDSA - The Maraviroc and Raltegravir Interaction: Do We Know How to Dose When Using These Two Important Agents? Written by Stephen Becker, MD (11/12/08)
     
  1699. ICAAC: Summary from ICAAC/IDSA for Treatment Naïve patients written by Joseph J. Eron Jr. MD (11/12/08)
     
  1700. ICAAC: HIV drug resistance at IDSA/ICAAC written by David Margolis, MD (11/12/08)
     
  1701. 9th Interntl Drug Thrpy HIV: High HIV Load Stymies Calcium Deposition in Bone-Forming Cells - Written by Mark Mascolini - (11/12/08)
     
  1702. 9th Interntl Drug Thrpy HIV: Response Rate, Resistance, and Side Effects After 96 Weeks of TMC278 - Written by Mark Mascolini - (11/12/08)
     
  1703. 9th Interntl Drug Thrpy HIV: D:A:D Cohort Group Offers Tool to Predict Short-Term Diabetes With HIV - Written by Mark Mascolini - (11/12/08)
     
  1704. 9th Interntl Drug Thrpy HIV: Will Etravirine Work Once Daily--With Once-Daily Darunavir? - Written by Mark Mascolini - (11/12/08)
     
  1705. 9th Interntl Drug Thrpy HIV: Salvage With Raltegravir, Etravirine, and Darunavir Works Fast in Small Case Series - Written by Mark Mascolini - (11/12/08)
     
  1706. 9th Interntl Drug Thrpy HIV: Potent Multidrug Salvage Without PIs or NRTIs: Raltegravir + Maraviroc + Etravirine - Written by Mark Mascolini - (11/12/08)
     
  1707. 9th Interntl Drug Thrpy HIV: CD4 Gains During Suppressive Therapy Differ by Pretreatment T-Cell Count - Written by Mark Mascolini - (11/12/08)
     
  1708. 9th Interntl Drug Thrpy HIV: Three Cohorts See No RNA Disadvantage With Abacavir/Lamivudine - Written by Mark Mascolini - (11/12/08)
     
  1709. 9th Interntl Drug Thrpy HIV: Renal Tubule Damage With Tenofovir Despite Normal Glomerular Function - Written by Mark Mascolini - (11/12/08)
     
  1710. 9th Interntl Drug Thrpy HIV: Inflammation and Coagulation Markers Askew in Children With Higher HIV RNA - Written by Mark Mascolini - (11/12/08)
     
  1711. 10th Intl Wrkshp Drug Reactions & Lipo: Impact of body changes on the quality of life of HIV-positive treatment experienced patients An online community-based survey (11/10/08)
     
  1712. 10th Intl Wrkshp Drug Reactions & Lipo: Skeletal muscle mitochondrial proteins discordantly regulated by insulin in HIV+ with insulin resistance: a mass spectrometry-based muscle proteomics study (11/10/08)
     
  1713. 10th Intl Wrkshp Drug Reactions & Lipo: Association between Peripheral Lipoatrophy and Bone Demineralisation in Treated HIV-positive Males (11/10/08)
     
  1714. 10th Intl Wrkshp Drug Reactions & Lipo: Effect of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor (GRF) Analogue, on Visceral Adipose Tissue (VAT) in HIV-Infected Patients with Excess Abdominal Fat: Impact of Antiretroviral Therapy Regimen (11/10/08)
     
  1715. 10th Intl Wrkshp Drug Reactions & Lipo: CD4 and Undetectable Viral Load Predict Non-AIDS Cancers: "AIDS and non-AIDS defining malignancies in HIV-infected patients - The 2006 ONCOVIH French study" (11/10/08)
     
  1716. 10th Intl Wrkshp Drug Reactions & Lipo: Comparison of Directly Measured and Estimated Glomerular Filtration Rates in Virologically Suppressed Patients Switching to Tenofovir or Continuing Zidovudine (11/10/08)
     
  1717. ICAAC: Complications of HIV infection. A summary form the IDSA/ICAAC conference in Washington DC. written by Pablo Tebas (11/07/08)
     
  1718. ICAAC: An enhanced assay to refine the use of CCR5 inhibitors - Written by David Margolis, MD (11/07/08)
     
  1719. Revised Guidelines for the Use of AntiretroviralAgents in HIV-1-Infected Adults and Adolescents - abacavir - (11/06/08)
     
  1720. ICAAC: HbA1c Underestimates Plasma Glucose in People Taking Antiretrovirals - Written by Mark Mascolini - (11/06/08)
     
  1721. ICAAC: Longer Antiretroviral Therapy Means Bigger Coronary Plaques - Written by Mark Mascolini - (11/03/08)
     
  1722. ICAAC: KS, NHL, and Encephalopathy Getting Diagnosed at Higher CD4 Counts in US Cohort - Written by Mark Mascolini - (11/03/08)
     
  1723. ICAAC: Nonalcoholic Fatty Liver in One Third of Naval Center Patients With HIV - Written by Mark Mascolini - (11/03/08)
     
  1724. ICAAC: Body Fat and Bone Changes After 96 Weeks of Fosamprenavir/Ritonavir - Written by Mark Mascolini - (11/03/08)
     
  1725. ICAAC: Antiretrovirals at CD4 Counts Above 350 May Quell HCV-Related Liver Inflammation - Written by Mark Mascolini - (11/03/08)
     
  1726. ICAAC: Limb and Trunk Fat Changes by Total Body DEXA After 96 Weeks of Treatment with Once-Daily (QD) Fosamprenavir Boosted with Either 100 mg or 200 mg of Ritonavir (/r) plus Abacavir (ABC)/lamivudine (3TC): COL100758 - (11/03/08)
     
  1727. ICAAC: Comparative Analysis of HIV+ and HIV- Interaction with Testosterone on Bone Mineral Density - (11/03/08)
     
  1728. ICAAC: HIV Infection and the Risk of Diabetes Mellitus - (11/03/08)
     
  1729. HIV CRISIS: AIDS is the leading cause of death for African-American women ages 25-34 today - (10/31/08)
     
  1730. HIV Doctors May Treat All Infected, Adding Thousands: When To Start HAART Debate - (10/31/08)
     
  1731. ICAAC: CD4+ Cell Increases at 48 Weeks in the Maraviroc Treatment-naive MERIT Trial - (10/31/08)
     
  1732. ICAAC: Adverse Event Profile of Maraviroc in Treatment-experienced Patients Infected with R5 HIV-1 - (10/31/08)
     
  1733. ICAAC: Unremitting Kaposi Sarcoma in HIV infected patients with viral suppression on antiretrovirals - (10/31/08)
     
  1734. ICAAC: Should Vitamin D Be Prescribed with Tenofovir/FTC? - (10/31/08)
     
  1735. ICAAC: Substitution of Nevirapine (NVP) for Efavirenz (EFV) Toxicity in ACTG A5095 - (10/31/08)
     
  1736. ICAAC: Pharmacokinetic interaction between darunavir in combination with low-dose ritonavir and rifabutin - (10/31/08)
     
  1737. ICAAC: Treatment Response among HIV Patients Co-enrolled in the Etravirine (ETR) and Raltegravir (RAL) Expanded Access Programs (EAPs) at Kaiser Permanente - (10/31/08)
     
  1738. ICAAC: Pharmacokinetics and pharmacodynamics of etravirine in treatment-experienced HIV-1-infected patients: pooled 48-week results of DUET-1 and DUET-2 - (10/31/08)
     
  1739. ICAAC: Renal Function after Use of Tenofovir as Part of the Initial ART Regimen - (10/31/08)
     
  1740. ICAAC: Prevalence and Risk Factors of Chronic Kidney Disease in an HIV Infected Minority Urban Population - (10/31/08)
     
  1741. ICAAC: A Phase II Safety and Efficacy Study of Bevirimat in Heavily Treatment-Experienced HIV+ Patients Identifies the Target Phase III Study Profile - (10/30/08)
     
  1742. ICAAC: Low Vitamin D Tied to High Bone Marker Levels in Men Taking Tenofovir - Written by Mark Mascolini - (10/30/08)
     
  1743. ICAAC: Bone Loss in SMART Study - Written by Mark Mascolini - (10/30/08)
     
  1744. ICAAC: Pulmonary Hypertension Rate 5.5% in Antiretroviral-Treated US Navy Group - Written by Mark Mascolini - (10/30/08)
     
  1745. ICAAC: Darunavir or Raltegravir in Rescue Regimen Raises Chance of Success 3 to 4 Times - Written by Mark Mascolini - (10/30/08)
     
  1746. ICAAC: High Rash Rate in Healthy Volunteers Combining Raltegravir and Darunavir - Written by Mark Mascolini - (10/30/08)
     
  1747. ICAAC: Did HIV Become More Virulent in First Decade of US Epidemic? - Written by Mark Mascolini - (10/30/08)
     
  1748. ICAAC: Hospital Admission Rate Stays Higher for First 90 Days of HAART - Written by Mark Mascolini - (10/30/08)
     
  1749. ICAAC: Doubled Risk of Failure After 1 Year Under 50 Copies in Women and Steady Blippers - Written by Mark Mascolini - (10/30/08)
     
  1750. ICAAC: Long-Term Safety of Vicriviroc: out to 4 yrs (10/29/08)
     
  1751. ICAAC: A Pharmacokinetic Study to Evaluate an Interaction between Maraviroc and Raltegravir in Healthy Adults (10/29/08)
     
  1752. ICAAC: Pharmacokinetic (PK) Evaluation of Darunavir/Ritonavir (DRV/r) and Raltegravir (RAL) in Healthy Subjects (10/29/08)
     
  1753. ICAAC: Three-year Efficacy of Lopinavir/ritonavir Monotherapy in the OK04 Trial (10/29/08)
     
  1754. ICAAC: Single Agent Therapy with Lopinavir/Ritonavir Suppresses HIV-1 Viral Replication in ARV Naive Patients: IMANI II - 96 Week Final Results (10/29/08)
     
  1755. ICAAC: Darunavir Makes HIV Undetectable in Half of Heavily Pretreated Children - Written by Mark Mascolini - (10/28/08)
     
  1756. ICAAC: Phase 2 Trial Confirms Baseline Mutation Risk With Maturation Inhibitor - Written by Mark Mascolini - (10/28/08)
     
  1757. ICAAC: Lower CD4 Count With HIV Ups Risk of Anal Cancer in Case-Control Study - Written by Mark Mascolini - (10/28/08)
     
  1758. ICAAC: Antiretroviral Therapy Lowers MRSA Risk 84% in US Cohort Study - Written by Mark Mascolini - (10/28/08)
     
  1759. ICAAC: Antiretroviral Trial Strictures Make Outcomes Harder to Interpret in Clinic: HIV trials need patients with 'major illnesses or more advanced HIV disease' - Written by Mark Mascolini - (10/28/08)
     
  1760. ICAAC: Lower Risk of Diabetes With HIV in US Veterans Affairs Cohort - Written by Mark Mascolini - (10/28/08)
     
  1761. ICAAC: Characterization of Virologic Failure Over 96 Weeks by Drug Resistance and Antiviral Response in ART Naïve Patients Receiving Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC) Each with Lopinavir/Ritonavir QD in the HEAT Study (10/28/08)
     
  1762. ICAAC: The Impact of Tenofovir on Insulin Sensitivity and Lipids in Healthy Volunteers (10/28/08)
     
  1763. ICAAC: Resistance to RDEA806 Requires Multiple Mutations Which Have Limited Cross-Resistance to Other NNRTIs (10/28/08)
     
  1764. ICAAC: RDEA806, a Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor, Shows Positive Outcome in Treatment of Naive HIV Patients (10/28/08)
     
  1765. ICAAC: Elvucitabine Phase II 48 Week Interim Results Show Safety and Efficacy Profiles Similar to Lamivudine in Treatment Naive HIV-1 Infected Patients with a Unique Pharmacokinetic Profile (10/28/08)
     
  1766. ICAAC: Safety and Efficacy of Raltegravir-Based Versus Efavirenz-Based Combination Therapy in Treatment-Naive HIV-1 Infected Patients (10/28/08)
     
  1767. ICAAC: 96-Week Data From CASTLE Study Continue to Show Similar Efficacy Between Once-Daily REYATAZ® (atazanavir sulfate)/Ritonavir and Twice-Daily Lopinavir/Ritonavir In Previously Untreated HIV-1 Infected Adult Patients - BMS Press Release (10/28/08)
     
  1768. ICAAC: Reanalysis of the MERIT Study with the Enhanced Trofile Assay (MERIT-ES) (10/28/08)
     
  1769. ICAAC: Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naïve Adults, Tibotec press release (10/27/08)
     
  1770. ICAAC: Efficacy and safety of darunavir/ritonavir 800/100mg once-daily versus lopinavir/ritonavir in treatment-naïve, HIV-1-infected patients at 96 weeks: ARTEMIS (TMC114-C211) (10/27/08)
     
  1771. ICAAC: Response to Vicriviroc in HIV-Infected Treatment-Experienced Subjects using an Enhanced Version of the Trofile HIV Co-receptor Tropism Assay: Reanalysis of ACTG 5211 Results (10/27/08)
     
  1772. ICAAC: ATRIPLA: Simplification of Antiretroviral Therapy with Efavirenz/Emtricitabine/Tenofovir DF Single Tablet Regimen vs. Continued Unmodified Antiretroviral Therapy in Virologically-Suppressed, HIV-1-Infected Patients (10/27/08)
     
  1773. ATRIPLA: The 48-Week Efficacy and Safety of Switching to Fixed-Dose Efavirenz/Emtricitabine/Tenofovir DF in HIV-1-Infected Patients Receiving HAART (11/18/08)
     
  1774. ICAAC: Atazanavir/Ritonavir vs Lopinavir/Ritonavir in Antiretroviral-Naive HIV-1-Infected Patients: CASTLE 96 Week Efficacy and Safety (10/27/08)
     
  1775. ICAAC: Atazanavir/Ritonavir (ATV/r) + Abacavir/Lamivudine (ABC/3TC) in Antiretroviral (ART)-Naïve, HIV-1 Infected, HLA-B*5701 Negative Subjects Demonstrates Efficacy and Safety: the ARIES Trial (10/27/08)
     
  1776. ICAAC: Effects of NRTI backbone on efficacy of first-line boosted PI based HAART: meta-analysis comparing TDF to ABC (10/27/08)
     
  1777. ICAAC: Steady Evolution of Integrase Mutations After Raltegravir Fails - Written by Mark Mascolini - (10/27/08)
     
  1778. ICAAC: Results on First-Line ABC/3TC With RNA Above 100,000: ARIES Study of abacavir/3TC plus atazanavir/r - Written by Mark Mascolini - (10/27/08)
     
  1779. ICAAC: Independent Analysis Suggests TDF/FTC Outdoes ABC/3TC With First-Line PIs - Written by Mark Mascolini - (10/27/08)
     
  1780. ICAAC: Enhanced Trofile Assays Shifts Results of ACTG 5211 Vicriviroc Trial - Written by Mark Mascolini - (10/27/08)
     
  1781. ICAAC: First-Line Raltegravir Controls HIV as Well as Efavirenz for 48 Weeks - Written by Mark Mascolini - (10/27/08)
     
  1782. ICAAC: Risk of Death 70% Higher When Delaying ART With CD4s at 351 to 500 - Written by Mark Mascolini - (10/27/08)
     
  1783. ICAAC: Black Women in US Less Likely to Get Antiretrovirals, Regardless of Insurance - Written by Mark Mascolini - (10/27/08)
     
  1784. ICAAC: In-Hospital Death Risk 4 Times Higher in Blacks Than Whites With HIV - Written by Mark Mascolini - (10/27/08)
     
  1785. ICAAC: Frequent Sexual Activity by Brooklyn Teens Infected With HIV at Birth - Written by Mark Mascolini - (10/27/08)
     
  1786. ICAAC: Greater Lipodystrophy Risk in Older US Children With Low Viral Load - Written by Mark Mascolini - (10/27/08)
     
  1787. ICAAC: Half of Black US Women Switch HIV Clinicians Because of Communication Problems - Written by Mark Mascolini - (10/27/08)
     
  1788. Mechanisms of Neuronal Injury and Death in HIV-1 Associated Dementia - (10/24/08)
     
  1789. Risk for Opportunistic Disease and Death after Reinitiating Continuous Antiretroviral Therapy in Patients with HIV Previously Receiving Episodic Therapy SMART - (10/24/08)
     
  1790. EMEA Extends Prezista Indication (darunavir) - (10/24/08)
     
  1791. The CNS HIV Antiretroviral Therapy Effects Research (CHARTER) study - (10/23/08)
     
  1792. Variable Cognitive Function Response to HAART: HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients - (10/23/08)
     
  1793. Neurotoxic effect of HIV: HIV-1 RNA concentration and cognitive performance in a cohort of HIV-positive people - (10/23/08)
     
  1794. U.S. Food and Drug Administration (FDA) Approves PREZISTA Once-Daily as Part of Combination Therapy for Treatment-Naive Adults with HIV-1 - (10/22/08)
     
  1795. Diabetes in D.A.D. Study - (10/21/08)
     
  1796. Non-AIDS Deaths In HIV Positive Patients Linked To Inflammation And Coagulation Markers...and ART interruption - (10/21/08)
     
  1797. Nadir CD4 Cell Count Predicts Neurocognitive Impairment in HIV-Infected Patients - (10/21/08)
     
  1798. Association of White Blood Cell Subfraction Concentration with Fitness and Fatness - (10/17/08)
     
  1799. B Vitamins for Prevention of Cognitive Decline - Editorial - (10/16/08)
     
  1800. Emergence and Persistence of CXCR4-Tropic HIV-1 in a Population of Men from the Multicenter AIDS Cohort Study - (10/15/08)
     
  1801. HIV-1 Tropism, Disease Progression, and Clinical Management - (10/15/08)
     
  1802. Phase II Study of Vicriviroc versus Efavirenz (both with Zidovudine/Lamivudine) in Treatment-Naive Subjects with HIV-1 Infection - (10/15/08)
     
  1803. Aging with HIV Increases Risk for Comorbidities: Do Patterns of Comorbidity Vary by HIV Status, Age, and HIV Severity? - (10/14/08)
     
  1804. Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen - (10/14/08)
     
  1805. Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes - (10/10/08)
     
  1806. Baseline Serum 25-Hydroxy Vitamin D Is Predictive of Future Glycemic Status and Insulin Resistance - (10/10/08)
     
  1807. Discrimination, Distrust, and Racial/Ethnic Disparities in Antiretroviral Therapy Adherence Among a National Sample of HIV-Infected Patients - (10/10/08)
     
  1808. Prospective Study of Dietary Fiber, Whole Grain Foods, and Small Intestinal Cancer - (10/09/08)
     
  1809. Mitochondria and Aging - (10/09/08)
     
  1810. New Genetic Model For Parkinson's Disease: mitochondrial damage - (10/09/08)
     
  1811. Mitochondria Damage & Aging - (10/09/08)
     
  1812. The Effect of Strength and Endurance Training on Insulin Sensitivity and Fat Distribution in Human Immunodeficiency Virus-Infected Patients with Lipodystrophy - (10/08/08)
     
  1813. Link Between Circumcision and HIV Risk Unclear in MSM - (10/08/08)
     
  1814. Circumcision for MSM May Be Effective: New Debate Over Circumcision, HIV Reduction - (10/08/08)
     
  1815. Incidence of cancer in children perinatally exposed to nucleoside reverse transcriptase inhibitors - (10/08/08)
     
  1816. Home use of vegetable oils, markers of systemic inflammation, and endothelial dysfunction among women - (10/08/08)
     
  1817. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients - (10/08/08)
     
  1818. Researchers to Evaluate a Once-Daily Investigational Dose of Raltegravir, Merck's Integrase Inhibitor, in an Investigational Population, Patients Previously Untreated for HIV-1 - (10/08/08)
     
  1819. CD4 Predicts Death: HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies - (10/08/08)
     
  1820. Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression - (10/08/08)
     
  1821. HAART Did Not Appear To Fully Correct the Adverse Effect of HIV on HCV Progression - (10/07/08)
     
  1822. New Inhibitor of HIV gp120: N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery - (10/07/08)
     
  1823. Reports of KS in Aging SF Patients - (10/06/08)
     
  1824. Can We Cure Aging? - (10/06/08)
     
  1825. New HIV Targets Discovered - (10/06/08)
     
  1826. New CDC HIV Prevalence Estimates -- United States, 2006 - (10/06/08)
     
  1827. Assessment of a hypothetical HIV chemoprophylaxis program among men who have sex with men in NYC - (10/06/08)
     
  1828. Prevalence of Human Papillomavirus (HPV) Genotypes in HIV-1 Infected Women in Seattle, WA and Nairobi, Kenya - (10/06/08) -
     
  1829. Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection - (10/03/08)
     
  1830. Maraviroc for Previously Treated Patients with R5 HIV-1 Infection - (10/03/08)
     
  1831. HIV Existed 100 Years Ago Study Reports, Urbanization of Africa Spread HIV (3 Nature articles below) - (10/03/08)
     
  1832. U.S. Food & Drug Administration Approved the use of REYATAZ(R) (atazanavir sulfate) Boosted with Ritonavir, in Combination Therapy, for Previously Untreated HIV-1 Infected Adult Patients - (10/03/08)
     
  1833. Antiviral Activity of Single-Dose PRO 140, a CCR5 Monoclonal Antibody, in HIV-Infected Adults - (10/03/08)
     
  1834. Progenics (PRO 140) Announces Progress and Presentations in HIV Therapy Program - (10/03/08)
     
  1835. Central obesity and increased risk of dementia more than three decades later - (10/03/08)
     
  1836. Impaired insulin secretion increases the risk of Alzheimer disease - (10/03/08)
     
  1837. Visceral Adiposity & Insulin Impairment & Dementia/Alzheimer's - (10/03/08)
     
  1838. Big Pharma, Pfizer, GSK Refocus, Big Pharma prunes R&D as times get tough - (10/03/08)
     
  1839. Drug-Susceptible HIV-1 Infection Despite Intermittent Fixed-Dose Combination Tenofovir/Emtricitabine as Prophylaxis Is Associated With Low-Level Viremia, Delayed Seroconversion, and an Attenuated Clinical Course [Rapid Communication] - (09/29/08)
     
  1840. HIV Serosorting in Men Who Have Sex With Men: Is It Safe? - (09/29/08)
     
  1841. Estimating GFR Using Cystatin Alone & in Combination with Creatinine: analysis of 3,418 with CKD - (09/26/08)
     
  1842. Chronic Kidney Disease Prevalence Higher in the USA: related to hypertension, diabetes, aging - (09/26/08)
     
  1843. CKD in the Elderly-Old Questions and New Challenges: CKD in the elderly as a new challenge for research, clinical practice, and public health. - (09/26/08)
     
  1844. A paradox of immunodeficiency and inflammation in human aging: lessons learned from apoptosis - (09/26/08)
     
  1845. DDI Delayed Release Generic Approved - (09/26/08)
     
  1846. Cancers in HIV: immunity/ART - (09/26/08)
     
  1847. Switch HAART Quickly After Viral Rebound-- Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study - (09/26/08)
     
  1848. A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle - (09/23/08)
     
  1849. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV - (09/23/08)
     
  1850. Genital levels of soluble immune factors with anti-HIV activity may correlate with increased HIV susceptibility - (09/23/08)
     
  1851. The Gut (Microbial translocation) is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy [Research Letters] - (09/23/08)
     
  1852. Lipoatrophy and lipohypertrophy are independently associated with hypertension (FRAM): the effect of lipoatrophy but not lipohypertrophy on hypertension is independent of obesity - (09/22/08)
     
  1853. IAS: In Mexico City Viva Metabolics! - David Alain Wohl, MD - The University of North Carolina - (09/22/08) -
     
  1854. Breast milk purged of HIV virus by Nipple Shield+Chemical - (09/22/08)
     
  1855. Elevated Uric Acid Increases the Risk for Kidney Disease - (09/22/08)
     
  1856. HAART Reduced Comoditities - (09/22/08)
     
  1857. 2 New Osteoporosis Drugs in the Works: Biologic Osteoporosis Drugs Denosumab and Odanacatib Show Promise in Clinical Trials - (09/22/08)
     
  1858. Update in Osteoporosis and Metabolic Bone Disorders - (09/22/08)
     
  1859. Denosumab Osteoporosis Trial Finds Patients Transitioned from Alendronate (Fosamax(R)) to Denosumab Achieved Significantly Greater Gains in Bone Mineral Density versus Those Continuing on Alendronate - (09/22/08)
     
  1860. Odanacatib, Merck's Investigational Cathepsin K Inhibitor, Increased BMD Over Two Years at Key Fracture Sites in Phase IIB Study - (09/22/08)
     
  1861. Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women: phase 3 results - (09/22/08)
     
  1862. Subclinical Glucose Abnormalities & Undiagnosed Diabetes Noted in HCV+ - (09/18/08)
     
  1863. Inaugural Conference of the BHIVA Hepatitis Working Group (BHWG) - Oct 8 2008 London - (09/18/08)
     
  1864. Pharmacologic Treatment of Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical Practice Guideline from the American College of Physicians - (09/18/08)
     
  1865. HAART, Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Cote d'Ivoire - (09/18/08)
     
  1866. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy - (09/18/08)
     
  1867. Myriad Genetics Announces Topline Results of Phase 1 Trial of Vivecon for HIV Trial Indicates Favorable Safety and Pharmacokinetics Profiles - (09/18/08)
     
  1868. Myriad Genetics Submits IND on Vivecon New HIV Maturation Inhibitor - (09/18/08)
     
  1869. New HIV Maturation Inhibitor MPC-9055 - (09/18/08)
     
  1870. (Increased) Fracture Risk in Type 2 Diabetes: Update of a Population-Based Study - (09/17/08)
     
  1871. HCV/HIV Coinfection Progressed More Quickly than HCV Despite HAART - (09/17/08)
     
  1872. Adherence to Mediterranean diet and health status (reduces mortality): meta-analysis - (09/17/08)
     
  1873. Cystatin C Level as a Marker of Kidney Function in Human Immunodeficiency Virus Infection - (09/17/08)
     
  1874. FDA Issues (generic drugs) Warning Letters to Ranbaxy Laboratories Ltd., and an Import Alert for Drugs from Two Ranbaxy Plants in India - (09/17/08)
     
  1875. Racivir - New HIV Drug - (09/17/08)
     
  1876. Depression in the United States Household Population, 2005-2006 - (09/16/08)
     
  1877. Acyclovir Could Help Control HIV, Study Finds - (09/16/08)
     
  1878. tentative approval of abacavir sulfate 60 mgscored tablet for pediatric dosing - (09/16/08)
     
  1879. HIV-associated Alzheimer's disease in the Future? - (09/16/08)
     
  1880. Statins for Slowing Kidney Disease Progression: An as yet Unproven Indication - (09/16/08)
     
  1881. Trimeris 2nd Generation Fusion Inhibitor TRI-1144 Update - (09/16/08)
     
  1882. Frailty Defined in Older Adults Evidence for a Phenotype - (09/16/08)
     
  1883. Physical Frailty Could Predict Alzheimer's Disease - (09/16/08)
     
  1884. CDC MMWR Analysis Provides New Details on HIV Incidence in U.S. Populations: highest in MSM-African-Americans, Latinos and Black Women - (09/16/08)
     
  1885. TNF-α and TLR agonists increase susceptibility to HIV-1 transmission by human Langerhans cells ex vivo - (09/16/08)
     
  1886. Alzheimer's Disease Risk Factors: exercise, metabolics, lifestyle, genetics - (09/16/08)
     
  1887. Intensive Blood Glucose Control Has Positive Outcomes in ADVANCE Study - (09/12/08)
     
  1888. Trimeris Reports Financial Results for the Second Quarter 2008 and Top-Line Results from Its Phase 1 Clinical Study of TRI-1144 - (09/12/08)
     
  1889. ACTG Bone Study Group Established; More Bone Issues Need Attention - (09/12/08)
     
  1890. Influence of HAART on the Clinical Course of HIV-1-Infected Patients With Progressive Multifocal Leukoencephalopathy: Results of an Observational Multicenter Study - (09/12/08)
     
  1891. Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis - (09/12/08)
     
  1892. Analysis of Nevirapine (NVP) Resistance in Ugandan Infants Who Were HIV Infected Despite Receiving Single-Dose (SD) NVP versus SD NVP Plus Daily NVP Up to 6 Weeks of Age to Prevent HIV Vertical Transmission - (09/8/08)
     
  1893. Approach to the Patient with Prediabetes - (09/8/08)
     
  1894. HIV and prostate cancer: a systematic review of the literature - (09/8/08)
     
  1895. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients - (09/5/08)
     
  1896. Risk factors for decreased bone density and effects of HIV on bone in the elderly - (09/3/08)
     
  1897. The near absence of osteoporosis treatment in older men with fractures - (09/3/08)
     
  1898. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection [EPIDEMIOLOGY AND SOCIAL] - (09/3/08)
     
  1899. HIV Infection and Bone Mineral Density in Middle-Aged Women - (09/3/08)
     
  1900. BMD Is Reduced in HIV-Infected Men Irrespective of ART Treatment - (09/3/08)
     
  1901. Bone and Mineral Metabolism in Human Immunodeficiency Virus Infection - (09/2/08)
     
  1902. Inflammatory Markers and Incident Fracture Risk in Older Men and Women: The Health Aging and Body Composition Study - (09/2/08)
     
  1903. Running slows the aging clock, Stanford researchers find - (09/2/08)
     
  1904. Sexual transmission- MSM & Natural Pregnancy: blood & semen viral load associated, and Herpes-2 with HIV transmission; Persistent differences in the antiviral effects of highly active antiretroviral therapy in the blood and male genital tract - (09/2/08)
     
  1905. FDA Update on Norvir Label Change QT/QTc Interval & PR Interval Prolongation - (09/2/08)
     
  1906. HCV Coinfection Increases Risk for HIV-Related Kidney Disease - (08/29/08)
     
  1907. IAS: ddI/FTC/ATV QD vs AZT/3TC bid+Efavrienz QD - Mark Mascolini - (08/29/08) -
     
  1908. Long-term use of bisphosphonates in the treatment of HIV-related bone pain in perinatally infected pediatric patients [Correspondence] - (08/29/08)
     
  1909. INTELENCE (etravirine) Receives Marketing Authorisation In The European Union For HIV Combination Therapy - (08/29/08)
     
  1910. Genetics Influence Lipodystrophy - (08/29/08)
     
  1911. Long-term safety (52 weeks) and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation [BASIC SCIENCE] - (08/29/08)
     
  1912. Clinical impact of patient racial/ethnic population differences and genomic variation in efavirenz therapy [EDITORIAL REVIEW] - (08/29/08)
     
  1913. Aging with HIV; Early Cognitive Decline - (08/28/08)
     
  1914. IAS: The Inflammatory Debate: Is it the Virus, the Drugs, or the Host? Reviewed by Charles Hicks, MD; Duke University Medical Center - (08/28/08) -
     
  1915. IAS: Highly-sensitive C-reactive protein (hsCRP) is associated with body mass index (BMI) and serum lipids in HIV-infected patients with low cardiovascular disease (CVD) risk and virologic suppression on antiretroviral therapy (ART) - (08/28/08) -
     
  1916. IAS: Clinicians Fail to Routinely Provide Reproductive Counseling to HIV-Infected Women in the United States - (08/27/08) -
     
  1917. IAS: Societal Stigma of Pregnant HIV-Infected Women in the United States - (08/27/08) -
     
  1918. Changes in Causes of Death Among Adults Infected by HIV Between 2000 and 2005: The Mortalite 2000 and 2005 Surveys (ANRS EN19 and Mortavic) [Epidemiology and Social Science] - (08/27/08)
     
  1919. Effect of Treatment With Efavirenz on Neuropsychiatric Adverse Events of Interferon in HIV/HCV-Coinfected Patients [Brief Report: Clinical Science] - (08/27/08)
     
  1920. Decrease in Cardiovascular risk on HAART - Coronary Artery Calcification on Electron Beam Computed Tomography: A 6-Year Follow-Up Study of HIV-Infected Patients [Letters to the Editor] - (08/27/08)
     
  1921. Genotyping of Human Papillomavirus DNA in Anal Biopsies and Anal Swabs Collected From HIV-Seropositive Men With Anal Dysplasia [Clinical Science] - (08/27/08)
     
  1922. Characteristics of HIV Infection Among Hispanics, United States 2003-2006 [Epidemiology and Social Science] - (08/27/08)
     
  1923. Earlier HAART Suggested for African-Americans At-Risk for Kidney Disease - (08/27/08)
     
  1924. IAS: IAC Mexico City 2008 Summary Report - Written by Mark Wainberg - (08/26/08) -
     
  1925. IAS: Efavirenz Stops HIV Better Than Lopinavir When Starting With Few CD4s - Mark Mascolini - (08/26/08) -
     
  1926. IAS: IDX899, Novel HIV-1 NNRTI with High Barrier to Resistance, Provides Suppression of HIV Viral Load in Treatment-Naïve HIV-1-Infected Subjects - (08/26/08) -
     
  1927. IAS: Efficacy and safety profile of APTIVUS oral solution or capsules co-administered with low dose ritonavir (APTIVUS/r) in treatment experienced children and teenagers after two years of treatment (Phase I/IIa study) - (08/25/08) -
     
  1928. FDA: Important updates to the Reyataz (atazanvir) label - (08/25/08)
     
  1929. Genetic Variation Linked to Body Changes & Abnormal Lipids: Genetic analysis implicates resistin in HIV lipodystrophy [BASIC SCIENCE] - (08/25/08)
     
  1930. Herpes simplex virus 2 serostatus and viral loads of HIV-1 in blood and semen as risk factors for HIV transmission among men who have sex with men [EPIDEMIOLOGY AND SOCIAL: CONCISE COMMUNICATIONS] - (08/25/08)
     
  1931. First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America [Research Letters] - (08/25/08)
     
  1932. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma [Research Letters] - (08/25/08)
     
  1933. 650 Cd4s 55% Better Than 500, less death/AIDS: Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count [BASIC SCIENCE] - (08/25/08)
     
  1934. Poor Initial CD4+ Recovery With Antiretroviral Therapy Prolongs Immune Depletion and Increases Risk for AIDS and Non-AIDS Diseases [Clinical Science] - (08/25/08)
     
  1935. In Vitro Characterization of Multidrug-Resistant HIV-1 Isolates From a Recently Infected Patient (NYC 2005 Case) Associated With Dual Tropism and Rapid Disease Progression [Basic Science] - (08/25/08)
     
  1936. Muscular Strength & Mortality in Men - (08/25/08)
     
  1937. Increased cardiovascular risk in HIV infection: drugs, virus and immunity, EDITORIAL COMMENTS - (08/22/08)
     
  1938. Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men - (08/22/08)
     
  1939. Subclinical coronary atherosclerosis, HIV infection and antiretroviral therapy: Multicenter AIDS Cohort Study - (08/22/08)
     
  1940. Chemical liberated (LPS) by leaky gut may allow HIV to infect the brain, Einstein scientists find - (08/20/08)
     
  1941. Medical Policy Guideline for Trofile(TM) Established By Wellpoint, Inc: insurer says Trofile is only assay for testing tropism - (08/20/08)
     
  1942. Routine reporting of estimated glomerular filtration rate: not ready for prime time - (08/20/08)
     
  1943. IAS: Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients: Results of a Large Retrospective Database Study - (08/20/08) -
     
  1944. IAS: Coagulation factor levels are not affected by tipranavir (TPV/r) capsules or Vitamin E-containing solution formulations nor by comparator protease inhibitors (PI) - (08/20/08) -
     
  1945. IAS: Gender-Based Differences in ART-Naives in CASTLE Study: viral response, lipids, adverse events; and Other Gender-Based Studies at IAC - (08/19/08) -
     
  1946. IAS: CD4+ T-cell Counts < 350 cells/mm3 Are a Risk Factor for Cardiovascular Disease in the HIV Outpatient Study (HOPS) - (08/19/08) -
     
  1947. IAS: (NCEP)-based IDSA/ACTG Guidelines for Management of Cardiovascular Risk in the HIV Outpatient Study (HOPS) - (08/19/08) -
     
  1948. IAS: At IAC Meeting on AIDS, Focus Shifts to Long Haul - (08/19/08) -
     
  1949. IAS: Women's Rights Equals Women's Lives - from Mexico - (08/19/08) -
     
  1950. IAS: HIV Crosses the Gender Divide - (08/19/08) -
     
  1951. IAS: Impact of Baseline Antiretroviral Resistance Status on Efficacy Outcomes Among Patients Receiving Maraviroc Plus an Optimized Background Therapy (OBT) Versus Placebo Plus OBT in the MOTIVATE 1 and 2 Trials - (08/19/08) -
     
  1952. IAS: Switching to Fosamprenavir (FPV) Led to Similar Efficacy and Safety in HIV-1-infected Subjects on their First PI Regimen: a Prospective, Open-label, Multicenter, Randomized Trial (ESS100290) - (08/18/08) -
     
  1953. IAS: HLA-B*5701 Screening Reduces Abacavir Hypersensitivity Reactions (ABC HSR); Multiple Lines of Evidence to Establish a New Standard of Care - (08/18/08) -
     
  1954. IAS: HIV-1 viral load in cerebrospinal fluid (CSF) of successfully treated patients on long-term HAART - (08/18/08) -
     
  1955. IAS: Baseline evaluation in CSF and neuropsycho-logical testing in patients starting Monotherapy - (08/18/08) -
     
  1956. IAS: Cognitive Disorders Despite Undetectable Viremia: Low Scores in The HIV Dementia Scale (HDS) - (08/18/08) -
     
  1957. Transmission of HIV-1 from a Patient Who Developed AIDS to an Elite Suppressor: CD8 T-cell reponse in elite suppressor appears to prevent HIV replication - (08/15/08)
     
  1958. IAS: The Safety and Efficacy of Tenofovir DF (TDF) in Combination with Lamivudine (3TC) and Efavirenz (EFV) in Antiretroviral-Naive Patients Through Seven Years - (08/15/08) -
     
  1959. IAS: TMC278 long acting - a parenteral nanosuspension formulation that provides sustained clinically relevant plasma concentrations in HIV-negative volunteers - (08/15/08) -
     
  1960. IAS: Dose selection and pharmacokinetics-pharmacodynamics of darunavir coadministered with low-dose ritonavir in the DELPHI (TMC114-C212) trial in treatment-experienced, HIV-1-infected children and adolescents - (08/15/08) -
     
  1961. IAS: HCV Increased Risk for MI and Stroke in HIV+, Study Reported at IAC - (08/13/08) -
     
  1962. IAS: Renal Safety Profile of Tenofovir DF (TDF)-containing vs. Thymidine Analog-containing Regimens Through 144 Weeks in Antiretroviral-naive Patients - (08/13/08) -
     
  1963. IAS: The Safety and Efficacy of Switching Stavudine to Tenofovir DF in Combination with Lamivudine and Efavirenz in HIV-1-Infected Patients: A Four-Year Follow-up - (08/13/08) -
     
  1964. IAS: Combination with Lamivudine (3TC) and Efavirenz (EFV) in Antiretroviral-Naive Patients Through Seven Years - (08/13/08) -
     
  1965. IAS: Efficacy, Safety and Tolerability of Etravirine With and Without Darunavir and/or Raltegravir in Treatment-Experienced Patients: Preliminary Analysis of TMC125-C214 Early Access Program (EAP) in the US - (08/13/08) -
     
  1966. IAS: Impact of Gender on Response to Lopinavir/ritonavir (LPV/r) Tablets Dosed QD or BID Administered with Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC) in Antiretroviral-naive (ARV) Subjects: Results from Study M05-730 - (08/12/08) -
     
  1967. IAS: Long-Term Impact of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analogue, on Body Image Parameters in HIV-Infected Patients with Abdominal Fat Accumulation - (08/12/08) -
     
  1968. IAS: Results from the 26-week Confirmatory, Phase 3 Trial of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analogue, in HIV Patients with Excess Abdominal Fat: A Multicenter, Double-blind, Placebo-controlled Study with 404 Randomized Patients - (08/12/08) -
     
  1969. IAS: Week-96 end of trial analysis of antiretroviral-naive patients randomized to the lopinavir/ritonavir single drug arm in the MONARK trial - (08/12/08) -
     
  1970. IAS: Maraviroc Exposure-efficacy (<50 copies/mL) Analysis in HIV-1-infected Treatment-naive Subjects - ITT Population (MERIT Study) - (08/12/08) -
     
  1971. IAS: ARTEMIS: lipid tolerability and safety of darunavir and lopinavir in antiretroviral-naive patients - (08/12/08) -
     
  1972. IAS: Switching NRTI Backbone to Tenofovir Plus Emtricitabine (Truvada, TVD) Promptly Improves Triglycerides and LDL-cholesterol Levels in Dyslipidemic HIV-1 Infected Patients: The TOTEM Randomised Trial - (08/12/08) -
     
  1973. IAS: Metabolic Outcomes from Prospective, Randomized Clinical Trials of Tenofovir DF (TDF) Compared to Thymidine Analog-containing Efavirenz-based Regimens in Antiretroviral-Naive Patients - (08/12/08) -
     
  1974. IAS: Lopinavir/ritonavir (LPV/r) in Pregnancy: ART Pregnancy Registry - (08/12/08) -
     
  1975. IAS: CCR5 Monoclonal Antibody PRO 140 Inhibited HIV-1 Resistant to Maraviroc, a Small Molecule CCR5 Antagonist - (08/12/08) -
     
  1976. IAS: A Comparison of the Single Dose Bioavailability of a Ritonavir Tablet Formulation Relative to the Ritonavir Soft Gelatin Capsule in Healthy Adult Subjects - (08/12/08) -
     
  1977. Reduced Disability and Mortality Among Aging Runners - (08/12/08)
     
  1978. IAS: Lopinavir-ritonavir plus Nevirapine as a Strategy to Improve Nucleoside-Related Mitochondrial Toxicity in Chronically Treated HIV-Infected Patients: 48 Week Follow-Up of MULTINEKA Study - (08/12/08) -
     
  1979. IAS:IAS: Maraviroc Exposure-safety Biomarker (Transaminases and Creatine Kinase) Analyses in MOTIVATE 1 and 2 Studies in HIV-1-infected Treatment-experienced Subjects - (08/12/08) -
     
  1980. IAS:CD4+ Cell Restoration after 48 Weeks in the Maraviroc Treatment-experienced Trials MOTIVATE 1 and 2 - (08/12/08) -
     
  1981. IAS: Clinical Predictors of Tenofovir-Associated Nephrotoxicity - written by Mark Mascolini - (08/11/08)
     
  1982. IAS: Twelve-Study Analysis Implicates Certain PIs and NRTIs in Lipid Jumps - written by Mark Mascolini - (08/11/08)
     
  1983. IAS: Cohort Studies Disagree on Tenofovir Role in Kidney Trouble - written by Mark Mascolini - (08/11/08)
     
  1984. IAS: Heart Marker (hsCRP) Tied to Lipids and Weight in People With Tight HIV Control - written by Mark Mascolini - (08/11/08)
     
  1985. IAS: Responding to Darunavir/Etravirine For Patients With Resistance - written by Mark Mascolini - (08/11/08)
     
  1986. IAS: Nevirapine Is Best Semen Penetrator in Study of Six PIs and Nonnucleosides - written by Mark Mascolini - (08/11/08)
     
  1987. IAS: Similarity in Efficacy and Safety of Abacavir/Lamivudine (ABC/3TC) Compared to Tenofovir/Emtricitabine (TDF/FTC) in Combination with QD Lopinavir/Ritonavir (LPV/r) Over 96 Weeks in the HEAT Study - (08/11/08) -
     
  1988. IAS: New Norvir Tablet Bioequivalence - (08/11/08) -
     
  1989. IAS: NATAP Summary of IAC 2008 Clinical Late Breaker Abstracts - written by Andrew Zolopa, MD Stanford University - (08/11/08) -
     
  1990. IAS: RAL-KAL: PHARMACOKINETICS OF COADMINISTERED RALTEGRAVIR AND LOPINAVIR-RITONAVIR IN HEALTHY ADULTS - (08/11/08) -
     
  1991. IAS: High Rate of Bone Thinning in Healthy Gay Men Without HIV - written by Mark Mascolini - (08/08/08)
     
  1992. IAS: HCV Emerging as New Sexually Transmitted Disease in MSM With HIV - written by Mark Mascolini - (08/08/08)
     
  1993. IAS: Studies Disagree on Faster Failure With First-Line Abacavir/Lamivudine ACTG 5202 - (08/08/08)
     
  1994. IAS: Abacavir and Heart Disease - written by Mark Mascolini - (08/08/08)
     
  1995. IAS: Safety, Tolerability and Efficacy of Darunavir/Ritonavir in Treatment-Experienced Women With HIV Infection: 24-Week Interim Analysis of GRACE (Gender, Race, And Clinical Experience) - (08/07/08)
     
  1996. IAS: Study Suggests HIV Itself Unleashes Body-Fat-Change Cascade, Gene Study Suggests - written by Mark Mascolini - (08/07/08)
     
  1997. IAS: Dangerous Liver Problem Seen After Switch to Raltegravir With Tipranavir - written by Mark Mascolini - (08/07/08)
     
  1998. IAS: Response in Etravirine Expanded Access With Diverse Background Regimens - written by Mark Mascolini - (08/07/08)
     
  1999. IAS: The incidence of rash observed with the NNRTI etravirine in the Phase III DUET trials using pooled 48-week data - (08/07/08)
     
  2000. IAS: Incidence and severity of nervous system and psychiatric events are similar with etravirine versus placebo: pooled 48-week data from the Phase III DUET studies - (08/07/08)
     
  2001. IAS: Pharmacokinetics of etravirine are not affected by sex, age, race, treatment duration or use of enfuvirtide in HIV-1-infected subjects - (08/07/08)
     
  2002. IAS: Efficacy and Safety By Racial Group in ARV-Naive Subjects Treated With Atazanavir/Ritonavir or Lopinavir/Ritonavir: 48-Week Results for the CASTLE Study - (08/07/08)
     
  2003. IAS: TMC278 (rilpivirine), an investigational next-generation NNRTI, demonstrates long-term efficacy and tolerability in ARV-naive patients: 96-week results of study C204 - (08/06/08)
     
  2004. IAS: Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines - (08/06/08)
     
  2005. IAS: Raltegravir 96 Weeks data from Phase II Study in Treatment-Naive - (08/06/08)
     
  2006. IAS: Combined darunavir and etravirine resistance analysis of the pooled DUET trials: when can we spare the other new classes? - (08/06/08)
     
  2007. IAS: Compelling 96-Week Findings on Raltegravir as First-Line Option - written by Mark Mascolini - (08/06/08)
     
  2008. IAS: Nonnucleoside TMC-278 Slated for First-Line Use Looks Good Through 96 Weeks - written by Mark Mascolini - (08/06/08)
     
  2009. IAS: Lower CD4 Count Despite Undetectable Load Raises Risks of AIDS and Death - written by Mark Mascolini - (08/06/08)
     
  2010. Abbott Prepares to Submit Heat-Stable Norvir Tablet for Registration by End of Year - (08/05/08)
     
  2011. Hepatitis C Virus Coinfection Does Not Affect CD4 Restoration in HIV-Infected Patients after Initiation of Antiretroviral Therapy - (08/05/08)
     
  2012. Lack of Effectiveness of Microbicide Cellulose Sulfate Gel for the Prevention of Vaginal HIV Transmission - (08/05/08)
     
  2013. Enhancement of HIV Infection by Cellulose Sulfate - (08/05/08)
     
  2014. Visceral fat predicts liver inflammation: A key mediator of steatohepatitis in metabolic liver disease; metabolic syndrome - (08/05/08)
     
  2015. Bush signs PEPFAR, expansion of U.S. global AIDS programs - (08/05/08)
     
  2016. CASTLE Study: Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results - (08/05/08)
     
  2017. HIV Incidence, New HIV Infections: CDC Announcement - (08/05/08)
     
  2018. Injection Drug Users Respond As Well To HAART - (08/05/08)
     
  2019. Low-Dose Physiological Growth Hormone in Patients With HIV and Abdominal Fat Accumulation - (08/05/08)
     
  2020. IAS: Switch to Atazanavir/Ritonavir Does Not Trim Trunk Fat in 48 Weeks - written by Mark Mascolini - (08/05/08)
     
  2021. IAS: Resistance Test Before ART Erases Risk of Poor Viral Response - written by Mark Mascolini - (08/05/08)
     
  2022. IAS: Mental Development Equivalent in ARV-Exposed and Unexposed Kids Without HIV - written by Mark Mascolini - (08/05/08)
     
  2023. IAS: CDC underestimated new HIV cases by 40 percent - (08/02/08)
     
  2024. IAS: Africa the worst hit by AIDS, by far - (08/02/08)
     
  2025. IAS: PrEP for Prevention Has Arrived-Researchers Look to Daily Pill to Avert H.I.V. - (08/02/08)
     
  2026. IAS: New Antiretroviral Treatment of Adult HIV Infection: 2008 Recommendations of the International AIDS Society-USA Panel; Earlier HAART Recommended - (08/02/08)
     
  2027. IAS: Africa the worst hit by AIDS, by far - (08/02/08)
     
  2028. IAS: CDC Reports Higher Rates of New HIV Cases, Causes Controversy - (08/02/08)
     
  2029. IAS: AIDS hitting Asian gays at high rates - UN - (08/02/08)
     
  2030. 3rd Intl Wrkshp HIV Transmission: WHO Updates List of Transmitted Mutations for Surveillance Studies - written by Mark Mascolini - (08/04/08)
     
  2031. 3rd Intl Wrkshp HIV Transmission: Recently HIV-Infected Quebec Residents Cause More Than Half of New Cases - written by Mark Mascolini (08/04/08)
     
  2032. 3rd Intl Wrkshp HIV Transmission: Intermittent Truvada PrEP Offers Monkeys Some Protection - written by Mark Mascolini (08/04/08)
     
  2033. 3rd Intl Wrkshp HIV Transmission: Tenofovir/Emtricitabine Gel Protects Female Monkeys From SHIV - written by Mark Mascolini (08/04/08)
     
  2034. 3rd Intl Wrkshp HIV Transmission: Are T-Cell-Based HIV Vaccines "Hanging by a Thread"? - written by Mark Mascolini (08/04/08)
     
  2035. 3rd Intl Wrkshp HIV Transmission: Common Estimate of Heterosexual HIV Transmission Risk Sometimes Far Too Low - written by Mark Mascolini (08/04/08)
     
  2036. 3rd Intl Wrkshp HIV Transmission: Syphilis and Other STIs May Drive HIV Spread in German Gays - written by Mark Mascolini (08/04/08)
     
  2037. 3rd Intl Wrkshp HIV Transmission: German Gays - written by Mark Mascolini (08/04/08)
     
  2038. Routine HIV Screening Recommended for All Women, Regardless of Individual Risk Factors; ACOG Pushes Routine Prenatal HIV Testing - American College of Obstetricians and Gynecologists - (08/01/08)
     
  2039. Merck Freezes Integrase Isentress (raltegravir) Price - (08/01/08)
     
  2040. GILEAD SCIENCES AND MERCK & CO., INC. ENTER INTO AN AGREEMENT TO REGISTER AND DISTRIBUTE HIV MEDICATION ATRIPLA (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) IN TWELVE COUNTRIES, INCLUDING IN LATIN AMERICA AND THE ASIA-PACIFIC REGION - (08/01/08)
     
  2041. Enhancement of HIV Infection by Cellulose Sulfate - (07/31/08)
     
  2042. Lack of Effectiveness of Microbicide Cellulose Sulfate Gel for the Prevention of Vaginal HIV Transmission - (07/31/08)
     
  2043. Drinking Alcohol That Exceeded US Dietary Guidelines (>1 drink per drinking day for men & >2 drinks per drinking day for men) Increased Risk of Metabolic Syndrome by 60%; binge drinking >/=once per week increased risk by 51% - (07/31/08)
     
  2044. Liver Fibrosis during an Outbreak of Acute Hepatitis C Virus Infection in HIV-Infected Men: A Prospective Cohort Study - (07/30/08)
     
  2045. Managing Metabolic Changes in Protease Inhibitor-Naive Patients Treated for 1 Year With Lopinavir/Ritonavir - (07/30/08)
     
  2046. MDR HIV Can Have High-Level Replication and Virulence - (07/30/08)
     
  2047. APOBEC3G, hA3G expression affects the establishment of the viral set point and may therefore function as a host determinant in the pathogenesis of HIV-1 infection, developing AIDS more quickly - (07/30/08)
     
  2048. Life Expectancy Increases Due to HAART: study estimates extended life of 43 yrs for 20 yr old and 32 yrs for 35 yr old starting HAART, and this doesn't include new and future advances - (07/29/08)
     
  2049. Many Gays Don't Tell Doctors Their Sexuality, Study Finds - (07/29/08)
     
  2050. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1- discordant couples in Rakai, Uganda - (07/29/08)
     
  2051. Risk of HIV transmission in discordant couples - (07/29/08)
     
  2052. Poor Initial CD4+ Recovery With Antiretroviral Therapy Prolongs Immune Depletion and Increases Risk for AIDS and Non-AIDS Diseases; Earlier HAART (>350 CD4s) Prevents AIDS/NonAIDS Events - (07/29/08)
     
  2053. Fish-Heavy Diet May Slow Hardening of Arteries: - (07/29/08)
     
  2054. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study - (07/29/08)
     
  2055. HIV Infection and the Gut: Scarred for Life? EDITORIAL COMMENTARY - (07/28/08)
     
  2056. HIV Infection and the Gut: Scarred for Life; Should HAART Be Started Early? EDITORIAL COMMENTARY - (07/28/08)
     
  2057. Does HIV/AIDS still require an exceptional response? - (07/28/08)
     
  2058. Discordant Heterosexual Couples: condom use required or New HIV Cases Will Double Over 10 Years - (07/28/08)
     
  2059. 3 New GSK Integrase Inhibitors in Studies - (07/25/08)
     
  2060. Viagra for Women with Antidepressant-Associated Sex Dysfunction - (07/25/08)
     
  2061. AGING AND INFECTIOUS DISEASES- NIH-NIAID Workshop on HIV Infection and Aging: What Is Known and Future Research Directions - (07/25/08)
     
  2062. NNRTIs & mtDNA Toxicity: Lymphocyte Mitochondrial Depolarization and Apoptosis in HIV-1-Infected HAART Patients - (07/25/08)
     
  2063. Efavirenz in Human Breast Milk, Mothers', and Newborns' Plasma - (07/25/08)
     
  2064. HIV Vaccine Research: The Way Forward - (07/25/08)
     
  2065. Whither or Wither Microbicides? Commentary - (07/25/08)
     
  2066. Chronic Kidney Disease Prevalence and Risk Factors Among HIV-Infected Patients In Spain - (07/24/08)
     
  2067. TIBOTEC RECRUITING FOR TWO PIVOTAL PHASE III CLINICAL TRIALS STUDYING TMC278 IN TREATMENT-NAIVE ADULTS WITH HIV - (07/24/08)
     
  2068. No Impairment of Endothelial Dysfunction or Insulin Sensitivity with 4 Weeks of Reyataz or Kaletra in Healthy Subjects - (07/24/08)
     
  2069. No Impairment of Endothelial Dysfunction or Insulin Sensitivity with 4 Weeks of Reyataz or Kaletra in Healthy Subjects - (07/24/08)
     
  2070. HbA1c 6.5% or greater should be accepted as a criterion for diagnosing diabetes - (07/24/08)
     
  2071. GILEAD INITIATES PHASE III CLINICAL TRIAL OF ELVITEGRAVIR, AN INVESTIGATIONAL INTEGRASE INHIBITOR FOR HIV - (07/24/08)
     
  2072. FDA Approves Updated Labeling for ZIAGEN - (07/24/08)
     
  2073. Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection - (07/24/08)
     
  2074. Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection - (07/24/08)
     
  2075. Efffects of 3 Diets: Mediterranean, Low-Fat, & Low-Carb on Weight Loss, Lipids, Glucose, Metabolics - (07/17/08)
     
  2076. High-Dose HBV Vaccination Rechallenge - (07/16/08)
     
  2077. HIV and Kidney Disease - (07/16/08)
     
  2078. Incidence and Epidemiology of Anal Cancer in the Multicenter AIDS Cohort Study - (07/16/08)
     
  2079. HAART Prevents AIDS-Cancers & Non-Cancer AIDS - (07/16/08)
     
  2080. Incidence and Epidemiology of Anal Cancer in the Multicenter AIDS Cohort Study - (07/16/08)
     
  2081. FRAX Bone Treatment Algorithm: A Revised Clinician's Guide to the Prevention and Treatment of Osteoporosis- commentary - (07/15/08)
     
  2082. Serial Assessment of Serum Bone Metabolism Markers Identifies Women with the Highest Rate of Bone Loss and Osteoporosis Risk - (07/15/08)
     
  2083. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen [Research Letters] - (07/15/08)
     
  2084. Toxic lopinavir concentrations in an HIV-1 infected patient taking herbal medications [Correspondence] - (07/15/08)
     
  2085. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir - (07/15/08)
     
  2086. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells - (07/15/08)
     
  2087. Liver ultrastructural morphology and mitochondrial DNA levels in HIV/hepatitis C virus coinfection: no evidence of mitochondrial damage with highly active antiretroviral therapy [Research Letters] - (07/15/08)
     
  2088. Roche Limits HIV R&D But Emphasizes HCV Research - commentary - (07/14/08)
     
  2089. The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics: risk for HIV drug resistance - (07/11/08)
     
  2090. ARTEMIS Study: Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48 - (07/11/08)
     
  2091. Revised 2008 PhRMA CODE ON INTERACTIONS WITH HEALTHCARE PROFESSIONALS - (07/11/08)
     
  2092. Detection of Nonnucleoside Reverse-Transcriptase Inhibitor-Resistant HIV-1 after Discontinuation (Interruption) of Virologically Suppressive Antiretroviral Therapy - (07/09/08)
     
  2093. CLINICIAN'S GUIDE TO PREVENTION AND TREATMENT OF OSTEOPOROSIS (National Osteoporosis Foundation Guidelines) - (07/07/08)
     
  2094. Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture - (07/04/08)
     
  2095. Use of Antidepressants and Rates of Hip Bone Loss in Older Women - (07/04/08)
     
  2096. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis (increased 13% risk): A systematic review - (07/02/08)
     
  2097. Changes in the Risk of Death After HIV Seroconversion Compared With Mortality in the General Population: high rates of improved mortality among HIV diagnosed - (07/02/08)
     
  2098. Fracture Prevalence Among HIV-Infected versus Non HIV-Infected Patients in a Large U.S. Healthcare System - (07/02/08)
     
  2099. Overproduction of Very Low-Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome - (07/01/08)
     
  2100. Low HDL Cholesterol Is a Risk Factor for Deficit and Decline in Memory in Midlife. The Whitehall II Study - (07/01/08)
     
  2101. Low Levels Of Good Cholesterol Linked To Memory Loss, Dementia Risk - (07/01/08)
     
  2102. Important FDA Label changes to Viramune (nevirapine) oral solution and tablets - (06/30/08)
     
  2103. Antiretroviral Therapy is Associated With an Atherogenic Lipoprotein Phenotype Among HIV-1-Infected Men in the Multicenter AIDS Cohort Study - (06/27/08)
     
  2104. Prevalence and Predictors of Metabolic Syndrome Among HIV-Infected and HIV-Uninfected Women in the Women's Interagency HIV Study: metabolic syndrome 50% in HIV+ women - (06/27/08)
     
  2105. Kidney and Bladder Cancers Among People With AIDS in the United States - (06/27/08)
     
  2106. Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes - (06/27/08)
     
  2107. New pediatric dosing information for Kaletra, patients 14 days to 6 months and 12-18 years of age and update information on coadministration with midazolam - (06/24/08)
     
  2108. European Commission Approves REYATAZ(R) (Atazanavir Sulfate 100mg, 150mg, 200mg, 300mg), in Combination With Other Antiretroviral Medicinal Products, for use in Treatment Naive HIV-1 Infected Adults - (06/24/08)
     
  2109. CVD is a "Major Killer" in HIV+ Patients, but Underrecognized by Doctors. Complicated interplay between risks from anti-HIV drugs, risks from virus itself, and traditional risk factors which tend to be prevalent among HIV-infected - (06/24/08)
     
  2110. ResisWksp: Low frequency K103N mutations are strongly associated with inadequate virologic responses to NNRTI-based therapy. sdNVP & K103N - (06/26/08)
     
  2111. ResisWksp: Identifying Low-Level CXCR4 Virus with Roche 454 Life Sciences Sensitive Assay - (06/25/08)
     
  2112. ResisWksp: Comparable in-vitro susceptibility and virological outcome to darunavir in patients infected with subtype B and non-subtype B HIV isolates participating in the ARTEMIS Phase III trial - (06/25/08)
     
  2113. ResisWksp: Detection of Low Abundance Drug Resistant HIV Variants in Treatment Experienced Subjects by Ultra Deep Sequencing (454 Life Sciences/Roche Test) - (06/25/08)
     
  2114. ResisWksp: NNRTI Resistance in Naives 16%. Changes in Regional Prevalence, Clade and Epidemiology of HIV-1 Drug Resistance Mutations and Clade among Antiviral Therapy-Naive Patients in the United States (US) from 2000 to 2007 - (06/25/08)
     
  2115. Weight Gain Increases Risk for Kidney Disease - (06/24/08)
     
  2116. ResisWksp: HIV-1 resistance in Mozambican infants following prophylaxis with single-dose nevirapine (sdNVP) - (06/24/08)
     
  2117. ResisWksp: Report on the XV11 International Drug Resistance Workshop, June 10-14, 2008, Sitges, Spain - Written by Mark A Wainberg - (06/24/08)
     
  2118. ResisWksp: Virological evolution in HIV treatment-experienced patients with raltegravir-based salvage regimens - (06/24/08)
     
  2119. ResisWksp: Antiretroviral Intensification Does Not Reduce HIV-1 Viremia in Patients Suppressed on Standard Combination Therapy - (06/24/08)
     
  2120. ResisWksp: No effect of subtype on susceptibility and virologic response to TPV/r for treatment experienced patients - (06/24/08)
     
  2121. ResisWksp: Mutations 24I, 50L/V, 54L, and 76V, selected by other protease inhibitors, predict durable response to tipranavir in treatment experienced patients when two or more are present - (06/24/08)
     
  2122. ResisWksp: Dynamics of emergence of CXCR4-using HIV in clinical samples as detected by Trofile and MT-2 assays - (06/23/08)
     
  2123. ResisWksp: Technical Validation of an Enhanced Sensitivity Trofile HIV Co-receptor Tropism Assay for Selecting Patients for Therapy with Entry Inhibitors Targeting CCR5 - (06/23/08)
     
  2124. ResisWksp: Virological Response and Resistance in Multi-Experienced Patients Treated with Raltegravir - (06/20/08)
     
  2125. ResisWksp: Slightly Revised Darunavir Resistance Profile from Tibotec - (06/20/08)
     
  2126. ResisWksp: Virologic and Immunologic Outcomes in a Cohort of Subjects Failing Integrase Inhibitors - (06/20/08)
     
  2127. ResisWksp: Tibotec Analysis: Nucleoside-associated mutations cause hypersusceptibility to etravirine (ETR) - (06/20/08)
     
  2128. ResisWksp: Monogram Analysis: Loss of Raltegravir Susceptibility in Treated Patients is Conferred by Multiple Non-overlapping Genetic Pathways - (06/20/08)
     
  2129. ResisWksp: Minority quasispecies of drug-resistant HIV-1 leading to early therapy failure in treatment-naive and adherent patients - (06/20/08)
     
  2130. ResisWksp: Tibotec Etravirine Weighted Genotype Score to Predict Response - (06/20/08)
     
  2131. ResisWksp: Resistance Mutations in HIV-1 Integrase Selected with Raltegravir or Elvitegravir Confer Reduced Susceptibility to a Diverse Panel of Integrase Inhibitors - (06/19/08)
     
  2132. ResisWksp: Integrase Inhibitor Resistance (elvitegravir/raltegravir) Involves Complex Interactions Among Primary and Secondary Resistance Mutations: A Novel Mutation L68V/I Associates with E92Q and Increases Resistance - (06/19/08)
     
  2133. THERATECHNOLOGIES REPORTS POSITIVE 26-WEEK RESULTS FOR ITS SECOND TESAMORELIN PHASE 3 TRIAL - (06/19/08)
     
  2134. ResisWksp: Increased Phenotypic Susceptibility to Etravirine in HIV-1 with NRTI Resistance - (06/19/08)
     
  2135. ResisWksp: HIV DNA Viral Load Evolution under a Raltegravir-based Therapy: modest decline, authors say "these findings suggest raltegravir may be protective from infection to newly CD4 cells generated during treatment" - (06/19/08)
     
  2136. ResisWksp: Increased Phenotypic Susceptibility to Etravirine in HIV-1 with NRTI Resistance - (06/18/08)
     
  2137. ResisWksp: Virco Etravirine Clinical Cutoffs - (06/18/08)
     
  2138. ResisWksp: Monogram HIV-1 Genotype Algorithms for Prediction of Etravirine Susceptibility: Novel Mutations and Weighting Factors Identified Through Correlations to Phenotype - (06/18/08)
     
  2139. ResisWksp: Merck's Longitudinal Analysis of Resistance to the HIV-1 Integrase Inhibitor Raltegravir: Results from P005 a Phase 2 Study in Treatment Experienced Patients - (06/18/08)
     
  2140. ResisWksp: Mechanism by which the HIV Integrase Active Site Mutation N155H Confers Resistance to Raltegravir - (06/18/08)
     
  2141. ResisWksp: Determination of phenotypic clinical cut-offs for etravirine (ETR): pooled Week 24 results of the DUET-1 and DUET-2 trials - (06/17/08)
     
  2142. ResisWksp: Biological and Clinical Cutoff Analyses for Etravirine in the PhenoSense HIV Assay - (06/17/08)
     
  2143. ResisWksp: Monogram Devises Weighted Genotypic Score to Predict Etravirine Response - Written by Mark Mascolini - (06/17/08)
     
  2144. ResisWksp: Low-End Clinical Cutoff Proposed for Etravirine - Written by Mark Mascolini - (06/17/08)
     
  2145. ResisWksp: Early Hints on Potency and Cross-Resistance With New NNRTI - Written by Mark Mascolini - (06/16/08)
     
  2146. ResisWksp: Low-Level Pretreatment NNRTI Mutation May Imperil Virologic Response - Written by Mark Mascolini - (06/16/08)
     
  2147. ResisWksp: Impact of Raltegravir on HIV DNA--and Fitness of Raltegravir-Resistant Virus - Written by Mark Mascolini - (06/16/08)
     
  2148. ResisWksp: Gene-Based Tools Getting Better at Predicting Coreceptor Use - Written by Mark Mascolini - (06/16/08)
     
  2149. ResisWksp: Multidrug Resistance in Antiretroviral Therapy-Experienced Patients in North America: 2000-2005 - (06/16/08)
     
  2150. ResisWksp: Early Clues From Raltegravir Failure in Clinical Practice; Diverse Patterns of Resistance Mutations - Written by Mark Mascolini - (06/16/08)
     
  2151. ResisWksp: HIV-1 Gag Polymorphisms Determine Treatment Response to Bevirimat (PA-457) (06/16/08)
     
  2152. ResisWksp: Response to Vicriviroc in HIV-Infected Treatment-Experienced Subjects using an Enhanced Version of the Trofile HIV Co-receptor Tropism Assay: Reanalysis of ACTG5211 Results. Using Enhanced Tropism Assay Improves Outcomes. (06/16/08)
     
  2153. ResisWksp: Early Hints on Potency and Cross-Resistance With New NNRTI - Written by Mark Mascolini - (06/13/08)
     
  2154. ResisWksp: Hexadecyloxypropyltenofovir (CMX157) has enhanced potency in vitro against NRTI-resistant HIV relative to tenofovir and a favorable preclinical profile - (06/13/08)
     
  2155. ResisWksp: Hexadecyloxypropyl Tenofovir (CMX157) Has Enhanced Potency in Vitro against NRTI Resistant HIV Relative to Tenofovir and a Favorable Preclinical Profile (06/13/08)
     
  2156. ResisWksp: Hexadecyloxpropyl Tenofovir (CMX157) Has Enhanced Potency In Vitro Against NRTI Resistant HIV Relative to Tenofovir and a Favorable Preclinical Profile (06/13/08)
     
  2157. ResisWksp: New Trofile Assay Would Have Improved Vicriviroc Response in ACTG 5211 - Written by Mark Mascolini - (06/13/08)
     
  2158. ResisWksp: Cumulative Resistance Catalog Gives Clearer Picture of Salvage Picks - Written by Mark Mascolini - (06/13/08)
     
  2159. ResisWksp: Supersensitive Genotyping Spots More Mutations in Lopinavir Monotherapy Trial - Written by Mark Mascolini - (06/13/08)
     
  2160. ResisWksp: Intensifying Standard Regimens Does Not Lower Residual Plasma HIV RNA - Written by Mark Mascolini - (06/11/08)
     
  2161. ResisWksp: Triple-Class Resistance Halved in Catalonia From 2002 to 2005 - Written by Mark Mascolini - (06/11/08)
     
  2162. ResisWksp: Resistance Mutation Rate Rising in Treatment-Naive US Trial Enrollees - Written by Mark Mascolini - (06/11/08)
     
  2163. ResisWksp: Resistance Risk Higher in Injecting Drug Users, Regardless of Adherence - Written by Mark Mascolini - (06/11/08)
     
  2164. ResisWksp: Multiclass Resistance Rate--But Not All-Class Resistance--Falls in US and Canada - Written by Mark Mascolini - (06/11/08)
     
  2165. ResisWksp: Novel Integrase Mutation Boosts Resistance to Elvitegravir and Raltegravir - Written by Mark Mascolini - (06/11/08)
     
  2166. ResisWksp: Five Mutations Tied to Better Tipranavir Response at 48 Weeks - Written by Mark Mascolini - (06/11/08)
     
  2167. ResisWksp: NNRTI Mutation Rates With Failing EFV vs NVP in EuroSIDA - Written by Mark Mascolini - (06/11/08)
     
  2168. ResisWksp: In Vitro Cross-Resistance Profile for a Next-Generation NNRT I: IDX899 (06/11/08)
     
  2169. ResisWksp: Antiviral Activity, Safety and Pharmacokinetics of IDX899, a Novel HIV-1 NNRTI with High Barrier to Resistance, in Treatment-Naïve HIV-1-Infected Subjects (06/11/08)
     
  2170. ResisWksp: In Vitro Cross-Resistance Profile, Antiviral Activity, Safety and Pharmacokinetics in HIV-1 Infected Subjects of IDX899, a Novel HIV-1 NNRTI with High Barrier to Resistance (06/11/08)
     
  2171. ResisWksp: Mutually Exclusive Resistance Paths Seen With Raltegravir Failure - Written by Mark Mascolini - (06/11/08)
     
  2172. ResisWksp: Q148 Mutations Emerge as Primary Raltegravir Resistance Pathway - Written by Mark Mascolini - (06/11/08)
     
  2173. ResisWksp: Routes to Cross-Resistance With Raltegravir and Elvitegravir - Written by Mark Mascolini - (06/11/08)
     
  2174. Effects of Early, Abrupt Weaning for HIV-free Survival of Children in Zambia - (06/11/08)
     
  2175. Breast-Feeding, Antiretroviral Prophylaxis, and HIV - (06/11/08)
     
  2176. Heroin Use Higher Among Hispanic Students: drugs, sex, life-style among students and ethnic disparities - (06/11/08)
     
  2177. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy - (06/11/08)
     
  2178. Intensive Glycemic Control in the ACCORD and ADVANCE Trials EDITORIAL - (06/11/08)
     
  2179. Glycemic Targets and Cardiovascular Disease EDITORIAL - (06/11/08)
     
  2180. Effects of Intensive Glucose Lowering in Type 2 Diabetes - (06/11/08)
     
  2181. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes - (06/11/08)
     
  2182. Delayed Immune-Mediated Adverse Effects of Polyalkylimide Dermal Fillers - (06/09/08)
     
  2183. Monogram Biosciences Announces Immediate Availability of Enhanced Sensitivity Trofile(TM) HIV Tropism Assay - (06/09/08)
     
  2184. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies - (06/09/08)
     
  2185. Brain chemical serotonin helps us tolerate foul play and appears to cause aggressive angry behavior response - (06/09/08)
     
  2186. Regional Brain Abnormalities Associated With Long-term Heavy Cannabis Use - (06/04/08)
     
  2187. Prevalence of and Risk Factors for Anal Human Papillomavirus Infection in Heterosexual Men - (06/04/08)
     
  2188. BRIEF REPORT Atazanavir Modestly Increases Plasma Levels of Raltegravir in Healthy Subjects - (06/04/08)
     
  2189. Regional Brain Abnormalities Associated With Long-term Heavy Cannabis Use - (06/03/08)
     
  2190. Resurgent HIV Among Men Who Have Sex With Men: What is to be done? Microbicides and Pre-Exposure Prophylaxis is the Only Answer - (06/03/08)
     
  2191. Increased Risk of CKD among Type 2 Diabetics with Nonalcoholic Fatty Liver Disease - (06/02/08)
     
  2192. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus - (06/02/08)
     
  2193. Regional Adipose Tissue and Elevations in Serum Aminotransferases in HIV-Infected Individuals - (05/30/08)
     
  2194. Periodontal disease, tooth loss, and cancer risk in male health professionals: a prospective cohort study - (05/29/08)
     
  2195. A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy in The Netherlands - (05/29/08)
     
  2196. 41% of HIV+ MSM in UK Unaware of Status: Sexual risk behaviour and knowledge of HIV status among community samples of gay men in the UK - (05/29/08)
     
  2197. New Option for HIV Testing Now Available - (05/29/08)
     
  2198. Sustained Benefits in Vascular Function Through Flavanol-Containing Cocoa in Medicated Diabetic Patients - (05/29/08)
     
  2199. Determination of Clinically Relevant Cutoffs for HIV-1 Phenotypic Resistance Estimates Through a Combined Analysis of Clinical Trial and Cohort Data - (05/28/08)
     
  2200. Incidence of Types of Cancer among HIV-Infected Persons Compared with the General Population in the United States, 1992-2003 - (05/28/08)
     
  2201. Early Intensive Insulin Therapy for Newly Diagnosed Diabetes - (05/28/08)
     
  2202. Inflammation, Lipids and Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies - (05/28/08)
     
  2203. New HIV Vaccine Research Funding, Where is Money for USA Needs - (05/28/08)
     
  2204. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study - (05/28/08)
     
  2205. Lifestyle intervention, diabetes, and cardiovascular disease EDITORIAL - (05/28/08)
     
  2206. The global challenge of diabetes, Editorial - (05/28/08)
     
  2207. Diabetes care for south Asian patients: a special case, EDITORIAL - (05/28/08)
     
  2208. Flavanol-Rich Cocoa: A Promising New Dietary Intervention to Reduce Cardiovascular Risk in Type 2 Diabetes? EDITORIAL COMMENT - (05/28/08)
     
  2209. Sustained Benefits in Vascular Function Through Flavanol-Containing Cocoa in Medicated Diabetic Patients - (05/28/08)
     
  2210. Periodontal disease, tooth loss, and cancer risk in male health professionals: a prospective cohort study - (05/28/08)
     
  2211. A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy in The Netherlands - (05/28/08)
     
  2212. Pioglitazone in chronic hepatitis C with Insulin Resistance not responding to pegylated interferon-β and ribavirin - (05/27/08)
     
  2213. Liver and heart: A new link? - ALT Predicts Heart Disease - (05/27/08)
     
  2214. Bioavailability of Generic Ritonavir and Lopinavir/ritonavir Tablet Products in a Dog Model - (05/27/08)
     
  2215. Controversies in Hypertension: diet, exercise Weight Loss and Blood Pressure Control (Pro) - (05/27/08)
     
  2216. Sex, drugs, and HIV/AIDS in China - (05/27/08)
     
  2217. Association of Pioglitazone Treatment with Decreased Bone Mineral Density in Obese Premenopausal Patients with Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial - (05/22/08)
     
  2218. Acute Meningoencephalitis in Chronic HIV Infection: Clinical Resolution with Lopinavir-Ritonavir-Containing Therapy - (05/21/08)
     
  2219. Insulin Resistance and Risk of Chronic Kidney Disease in Nondiabetic US Adults - (05/21/08)
     
  2220. Metabolic Syndrome and the Risk for Chronic Kidney Disease among Nondiabetic Adults - (05/21/08)
     
  2221. Metabolic Syndrome, Proteinuria, and the Risk of Progressive CKD in Hypertensive African Americans - (05/21/08)
     
  2222. Use of Multiple Biomarkers to Improve the Prediction of Death from Cardiovascular Causes - (05/19/08)
     
  2223. Biomarkers in Heart Failure EDITORIAL - (05/19/08)
     
  2224. Class-Sparing Regimens for Initial Treatment of HIV-1 Infection. ACTG 5142 Efavirenz v Kaletra v Efavirenz+Kaletra - (05/19/08)
     
  2225. ACTG 5142, Efavirenz v Kaletra v Kaletra+Efavirenz Class Sparing Study. Initial Treatment for HIV Infection - An Embarrassment of Riches EDITORIAL - (05/19/08)
     
  2226. Chronic Kidney Disease Incidence, and Progression to End-Stage Renal Disease, in HIV-Infected Individuals: A Tale of Two Races - (05/19/08)
     
  2227. HIV and the Kidney: A Spotlight on Racial Disparities EDITORIAL COMMENTARY - (05/19/08)
     
  2228. FDA Approves Generic Nevirapine - (05/19/08)
     
  2229. New Darunavir 600 mg Tablet Available - (05/19/08)
     
  2230. Viracept Use in Pregnancy- Important News - (05/19/08)
     
  2231. GSK Response Letters to Abacavir Article in the The Independent - (05/15/08)
     
  2232. Guidelines Recommend Screening for Men at Increased Risk for Ostoeporosis. - (05/10/08)
     
  2233. Comparative Efficacy between therapies for bone disease: What We Know, What We Need to Know, and How We Can Get There EDITORIAL - (05/10/08)
     
  2234. Guidelines Recommend Screening for Men at Increased Risk for Ostoeporosis. "Screening for Osteoporosis in Men: A Clinical Practice Guideline from the American College of Physicians" - (05/10/08)
     
  2235. Is there a role for etravirine in patients with Nonnucleoside reverse transcriptase inhibitor resistance? [RESEARCH LETTERS] - (05/07/08)
     
  2236. HAART Can Eliminate HIV Mother-To-Child Transmission (MTCT). Properly Timed Effective Use of HAART Can Prevent MTCT - (05/07/08)
     
  2237. Bone health & Antiepileptic Drugs - (05/02/08)
     
  2238. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy - (05/02/08)
     
  2239. Changes Over Time in Risk Factors for Cardiovascular Disease and Use of Lipid-Lowering Drugs in HIV-Infected Individuals and Impact on Myocardial Infarction - (05/02/08)
     
  2240. EASL: NAFLD AND NASH Linked to Metabolic Syndrome and Cardiovascular Disease - (05/02/08)
     
  2241. Use of Alendronate and Risk of Incident Atrial Fibrillation in Women - (05/01/08)
     
  2242. Diabetes drugs (glitazones) double fracture risk: Swiss study - (05/01/08)
     
  2243. EASL: NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS ASSOCIATED WITH HIGHER OVERALL MORTALITY AND LIVER RELATED MORTALITY - (04/25/08)
     
  2244. EASL: NEW HCV DRUGS at EASL Apr 23-27, 2008 Milan - (04/23/08)
     
  2245. EASL: Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008 - (04/23/08)
     
  2246. EASL: HCV Drug Resistance - (04/23/08)
     
  2247. The 3rd International Workshop on Clinical Pharmacology of Hepatitis Therapy - Written by Jennifer J. Kiser, Pharm.D. - (04/22/08)
     
  2248. 9th International Workshop on Clinical Pharmacology of HIV Therapy - Written by Jennifer J. Kiser, Pharm.D. and Courtney V. Fletcher, Pharm.D. (04/22/08)
     
  2249. Insulin Resistance Confounds Heart Disease Studies in HIV: Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy - (04/22/08)
     
  2250. CD4 Count & Viral Load Predict non-AIDS & AIDS diseases: CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection - (04/22/08)
     
  2251. Major Clinical Outcomes in Antiretroviral Therapy (ART)-Naive Participants and in Those Not Receiving ART at Baseline in the SMART Study - (04/21/08)
     
  2252. Inferior Clinical Outcome of the CD4+ Cell Count-Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV RNA Levels during Follow-up - (04/21/08)
     
  2253. Hepatic steatosis in HIV/HCV co-infected patients: Correlates, efficacy and outcomes of anti-HCV therapy: A paired liver biopsy study - (04/21/08)
     
  2254. CROI: Women, Younger Age & Black Race Associated with Shorter Time to Viral Failure: Effect of Baseline Characteristics on Treatment Outcomes in ACTG 5142: A Prospective, Randomized, Phase III Trial of NRTI-, PI-, and NNRTI-sparing Regimens for Initial Treatment of HIV-1 Infection - (04/21/08)
     
  2255. DASH Diet Reduces Heart Disease Risk by 24% - (04/18/08)
     
  2256. The Impact of HIV Tropism on Decreases in CD4 Cell Count, Clinical Progression, and Subsequent Response to a First Antiretroviral Therapy Regimen. - (04/18/08)
     
  2257. Gut (liver), inflammation and osteoporosis: basic and clinical concepts - (04/16/08)
     
  2258. SCHERING-PLOUGH INITIATES PHASE II STUDY WITH VICRIVIROC IN TREATMENT-NAIVE HIV-INFECTED PATIENTS: Novel Nucleoside-Sparing Regimen Designed to Avoid Risk of Toxicity Associated with Nucleoside Class of HIV Drugs - (04/15/08)
     
  2259. TMC125 safety and tolerability in treatment-experienced hepatitis B or C coinfected patients in DUET-1 and DUET-2 - (04/15/08)
     
  2260. 9th Int Wrkshp Pharm HIV: Safety, Tolerability and Activity of KP-1461 a Novel Viral Mutagen in HIV Infected Adults - (04/15/08)
     
  2261. Walking and primary prevention: a meta-analysis of prospective cohort studies - (04/14/08)
     
  2262. Maximal oxygen intake and independence in old age: aorobic exercise adds 12 years of life - (04/14/08)